Robert Califf

Q: What Schools Are Affiliated With Robert Califf

Robert Califf is affiliated with the following schools: University of Washington, University of Barcelona, University of Texas Southwestern Medical Center, Harvard University, University of Vermont, Boston University, Uppsala University, University of Sydney, University of Alberta, University of Michigan, Queen's University at Kingston, Baylor College of Medicine, University of Glasgow, University of Toronto, University of Copenhagen, Duke University, Monash University, Brown University, University of Florida, Stanford University, Case Western Reserve University

Robert Califf's AcademicInfluence.com Rankings

Robert Califf

Philosophy

#1653

World Rank

#2962

Historical Rank

#650

USA Rank

Logic

#288

World Rank

#586

Historical Rank

#123

USA Rank

philosophy Degrees

Download Badge

Philosophy

Robert Califf's Degrees

Doctorate Medicine Duke University

Why Is Robert Califf Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Robert McKinnon Califf is an American cardiologist who currently serves as the 25th Commissioner of the Food and Drug Administration. He was first nominated to be commissioner in September 2015 by President Barack Obama and he was confirmed by the U.S. Senate in February 2016, serving until January 20, 2017.

(See a Problem?)

Robert Califf's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. (2011) (5296)
ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction--summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the Management of Patients (2002) (3666)
An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. (1993) (3530)
Evaluating the yield of medical tests. (1982) (2621)
Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. (2003) (2366)
The effectiveness of right heart catheterization in the initial care of critically ill patients. SUPPORT Investigators. (1996) (2290)
ACC/AHA guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction--2002: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients (2002) (2245)
ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-Elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patie (2007) (1962)
Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. (2004) (1917)
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. (2015) (1787)
Regression modelling strategies for improved prognostic prediction. (1984) (1614)
1999 update: ACC/AHA guidelines for the management of patients with acute myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). (1996) (1525)
A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group. (1997) (1423)
A brief self-administered questionnaire to determine functional capacity (the Duke Activity Status Index). (1989) (1415)
Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. (2004) (1346)
ACC/AHA guidelines for the management of patients with acute myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). (1996) (1335)
Real-World Evidence - What Is It and What Can It Tell Us? (2016) (1197)
Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. (2002) (1096)
ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina). (2000) (1029)
Predictors of 30-day mortality in the era of reperfusion for acute myocardial infarction. Results from an international trial of 41,021 patients. GUSTO-I Investigators. (1995) (1025)
Relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes. (2004) (1024)
Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial (2018) (993)
Predictors of outcome in patients with acute coronary syndromes without persistent ST-segment elevation. Results from an international trial of 9461 patients. The PURSUIT Investigators. (2000) (970)
A randomized trial of immediate versus delayed elective angioplasty after intravenous tissue plasminogen activator in acute myocardial infarction. (1987) (955)
Relationship of depression to increased risk of mortality and rehospitalization in patients with congestive heart failure. (2001) (931)
Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. (2007) (926)
Sex, clinical presentation, and outcome in patients with acute coronary syndromes. Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes IIb Investigators. (1999) (897)
ACC/AHA 2002 guideline update for the management of patients with unstable angina and non–ST-segment elevation myocardial infarction—summary article (2002) (893)
Scientific evidence underlying the ACC/AHA clinical practice guidelines. (2009) (879)
Randomised trial of coronary intervention with antibody against platelet IIb/IIIa iritegrin for reduction of clinical restenosis: results at six months (1994) (844)
Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials (2002) (840)
Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. (2004) (833)
Prognostic value of a treadmill exercise score in outpatients with suspected coronary artery disease. (1991) (814)
Sudden death in patients with myocardial infarction and left ventricular dysfunction, heart failure, or both. (2005) (773)
1999 update: ACC/AHA Guidelines for the Management of Patients With Acute Myocardial Infarction: Executive Summary and Recommendations: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction) (1999) (737)
Cardiac Troponin T Levels for Risk Stratification in Acute Myocardial Ischemia (1996) (671)
A pharmacogenetic versus a clinical algorithm for warfarin dosing. (2013) (667)
Impact of the pulmonary artery catheter in critically ill patients: meta-analysis of randomized clinical trials. (2005) (655)
A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: The Flolan International Randomized Survival Trial (FIRST). (1997) (650)
Exercise treadmill score for predicting prognosis in coronary artery disease. (1987) (641)
Impact of bleeding severity on clinical outcomes among patients with acute coronary syndromes. (2005) (637)
Comparison of Omapatrilat and Enalapril in Patients With Chronic Heart Failure: The Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE) (2002) (630)
Risk factors, angiographic patterns, and outcomes in patients with ventricular septal defect complicating acute myocardial infarction. GUSTO-I (Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries) Trial Investigators. (2000) (630)
N‐Terminal Pro‐Brain Natriuretic Peptide and Other Risk Markers for the Separate Prediction of Mortality and Subsequent Myocardial Infarction in Patients With Unstable Coronary Artery Disease: A Global Utilization of Strategies To Open occluded arteries (GUSTO)‐IV Substudy (2003) (627)
Effect of valsartan on the incidence of diabetes and cardiovascular events. (2010) (626)
What clinicians should know about the QT interval. (2003) (617)
ACC/AHA guidelines for the management of patients with unstable angina and non‐ST segment elevation myocardial infarction: Executive summary and recommendations (2000) (606)
The ClinicalTrials.gov results database--update and key issues. (2011) (605)
2011 ACCF/AHA Focused Update Incorporated Into the ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines (2011) (595)
Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. (2011) (591)
2012 ACCF/AHA focused update incorporated into the ACCF/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. (2013) (590)
Evolution of adverse changes in stored RBCs (2007) (589)
Critical issues in peripheral arterial disease detection and management: a call to action. (2003) (578)
Relationship between delay in performing direct coronary angioplasty and early clinical outcome in patients with acute myocardial infarction: results from the global use of strategies to open occluded arteries in Acute Coronary Syndromes (GUSTO-IIb) trial. (1999) (574)
Myonecrosis after revascularization procedures. (1998) (572)
The SUPPORT Prognostic Model: Objective Estimates of Survival for Seriously Ill Hospitalized Adults (1995) (564)
Prognostic importance of social and economic resources among medically treated patients with angiographically documented coronary artery disease. (1992) (560)
Cardiorenal interactions: insights from the ESCAPE trial. (2008) (552)
Adenosine as an adjunct to thrombolytic therapy for acute myocardial infarction: results of a multicenter, randomized, placebo-controlled trial: the Acute Myocardial Infarction STudy of ADenosine (AMISTAD) trial. (1999) (552)
Prognostic value of the admission electrocardiogram in acute coronary syndromes. (1999) (540)
Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction. (1995) (534)
Depression and long-term mortality risk in patients with coronary artery disease. (1996) (526)
Racial variation in the use of coronary-revascularization procedures. Are the differences real? Do they matter? (1997) (523)
Value of the History and Physical in Identifying Patients at Increased Risk for Coronary Artery Disease (1993) (516)
Effect of nesiritide in patients with acute decompensated heart failure. (2011) (516)
Practice Standards for Electrocardiographic Monitoring in Hospital Settings: An American Heart Association Scientific Statement From the Councils on Cardiovascular Nursing, Clinical Cardiology, and Cardiovascular Disease in the Young (2004) (512)
Link between the angiographic substudy and mortality outcomes in a large randomized trial of myocardial reperfusion. Importance of early and complete infarct artery reperfusion. GUSTO-I Investigators. (1995) (507)
Electrocardiographic diagnosis of evolving acute myocardial infarction in the presence of left bundle-branch block. GUSTO-1 (Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries) Investigators. (1996) (499)
Heart failure etiology and response to milrinone in decompensated heart failure: results from the OPTIME-CHF study. (2003) (495)
Prognostic Implications of Abnormalities in Renal Function in Patients With Acute Coronary Syndromes (2002) (489)
Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure: insights from the Flolan International Randomized Survival Trial (FIRST). (1999) (489)
Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes. (2008) (487)
Metabolic syndrome: definition, pathophysiology, and mechanisms. (2005) (486)
Sex differences in mortality following acute coronary syndromes. (2009) (483)
2011 ACCF/AHA focused update incorporated into the ACC/AHA 2007 Guidelines for the Management of Patients with Unstable Angina/Non-ST-Elevation Myocardial Infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in c (2011) (474)
Lower Serum Sodium Is Associated With Increased Short-Term Mortality in Hospitalized Patients With Worsening Heart Failure: Results From the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) Study (2005) (469)
Prognostic value of a coronary artery jeopardy score. (1985) (464)
Launching PCORnet, a national patient-centered clinical research network (2014) (463)
Effect of Hypericum perforatum (St John's wort) in major depressive disorder: a randomized controlled trial. (2002) (448)
The Impact of Serious Illness on Patients' Families (1994) (444)
Biomarker definitions and their applications (2018) (442)
Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty. (1994) (440)
Effect of nateglinide on the incidence of diabetes and cardiovascular events. (2010) (440)
Time from symptom onset to treatment and outcomes after thrombolytic therapy. GUSTO-1 Investigators. (1996) (438)
Platelet Glycoprotein IIb/IIIa Inhibitors Reduce Mortality in Diabetic Patients With Non–ST-Segment-Elevation Acute Coronary Syndromes (2001) (429)
Continuing evolution of therapy for coronary artery disease. Initial results from the era of coronary angioplasty. (1994) (421)
Consequences of reocclusion after successful reperfusion therapy in acute myocardial infarction. TAMI Study Group. (1990) (414)
ACC/AHA guidelines for the management of patients with acute myocardial infarction: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). (1996) (409)
Relation between dose of loop diuretics and outcomes in a heart failure population: Results of the ESCAPE Trial (2007) (408)
Characteristics of clinical trials registered in ClinicalTrials.gov, 2007-2010. (2012) (407)
Early versus delayed, provisional eptifibatide in acute coronary syndromes. (2009) (406)
Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. Evaluation of Platelet IIb/IIIa Inhibition in Stenting Investigators. (1999) (399)
Long-Term Adherence to Evidence-Based Secondary Prevention Therapies in Coronary Artery Disease (2006) (393)
Influence of Diabetes Mellitus on Clinical Outcome in the Thrombolytic Era of Acute Myocardial Infarction (1997) (387)
Combined accelerated tissue-plasminogen activator and platelet glycoprotein IIb/IIIa integrin receptor blockade with Integrilin in acute myocardial infarction. Results of a randomized, placebo-controlled, dose-ranging trial. IMPACT-AMI Investigators. (1997) (387)
Factors affecting sensitivity and specificity of exercise electrocardiography. Multivariable analysis. (1984) (383)
Contemporary reperfusion therapy for cardiogenic shock: the GUSTO-I trial experience. The GUSTO-I Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. (1995) (376)
Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in ischemic heart disease. (1998) (367)
Estimating the likelihood of significant coronary artery disease. (1983) (366)
Atrial fibrillation in the setting of acute myocardial infarction: the GUSTO-I experience. Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries. (1997) (365)
Clinical determinants of mortality in patients with angiographically diagnosed ischemic or nonischemic cardiomyopathy. (1997) (360)
Use of medical resources and quality of life after acute myocardial infarction in Canada and the United States. (1994) (357)
Efficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in non-ST-Segment elevation acute coronary syndromes: a systematic overview. (2004) (353)
Long-term Protection From Myocardial Ischemic Events in a Randomized Trial of Brief Integrin β3 Blockade With Percutaneous Coronary Intervention (1997) (347)
Platelet/Endothelial Biomarkers in Depressed Patients Treated With the Selective Serotonin Reuptake Inhibitor Sertraline After Acute Coronary Events: The Sertraline AntiDepressant Heart Attack Randomized Trial (SADHART) Platelet Substudy (2003) (344)
Clinical trials of restenosis after coronary angioplasty. (1991) (341)
The evolution of medical and surgical therapy for coronary artery disease. A 15-year perspective. (1989) (336)
Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF (2012) (335)
Prognostic Value of Growth-Differentiation Factor-15 in Patients With Non–ST-Elevation Acute Coronary Syndrome (2007) (333)
Regional variation across the United States in the management of acute myocardial infarction. GUSTO-1 Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. (1995) (333)
Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: results from a multicentre randomised trial (1999) (330)
Risk stratification after hospitalization for decompensated heart failure. (2004) (325)
Profound inhibition of platelet aggregation with monoclonal antibody 7E3 Fab after thrombolytic therapy. Results of the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) 8 Pilot Study. (1993) (321)
A comparison of the clinical impact of bleeding measured by two different classifications among patients with acute coronary syndromes. (2006) (321)
Restenosis after coronary angioplasty: an overview. (1991) (321)
Effect of lipid-lowering therapy on early mortality after acute coronary syndromes: an observational study (2001) (318)
Efficacy and safety of edifoligide, an E2F transcription factor decoy, for prevention of vein graft failure following coronary artery bypass graft surgery: PREVENT IV: a randomized controlled trial. (2005) (315)
Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial. (1999) (311)
2011 ACCF/AHA focused update of the Guidelines for the Management of Patients with Unstable Angina/Non-ST-Elevation Myocardial Infarction (updating the 2007 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in (2011) (309)
Individual risk assessment for intracranial haemorrhage during thrombolytic therapy (1993) (307)
Evaluation of Combination Thrombolytic Therapy and Timing of Cardiac Catheterization in Acute Myocardial Infarction: Results of Thrombolysis and Angioplasty in Myocardial Infarction–Phase5 Randomized Trial (1991) (306)
Clinical Relevance of C-Reactive Protein During Follow-Up of Patients With Acute Coronary Syndromes in the Aggrastat-to-Zocor Trial (2006) (302)
Activated partial thromboplastin time and outcome after thrombolytic therapy for acute myocardial infarction: results from the GUSTO-I trial. (1996) (301)
Angiographic findings and outcome in diabetic patients treated with thrombolytic therapy for acute myocardial infarction: the GUSTO-I experience. (1996) (301)
Age and outcome with contemporary thrombolytic therapy. Results from the GUSTO-I trial. Global Utilization of Streptokinase and TPA for Occluded coronary arteries trial. (1996) (300)
Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes. (2008) (300)
Relationship between diabetes mellitus and long-term survival after coronary bypass and angioplasty. (1997) (300)
2012 ACCF/AHA Focused Update Incorporated Into the ACCF/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines (2013) (299)
Ethical and scientific implications of the globalization of clinical research. (2009) (294)
Troponin T levels in patients with acute coronary syndromes, with or without renal dysfunction. (2002) (294)
Value of serial troponin T measures for early and late risk stratification in patients with acute coronary syndromes. The GUSTO-IIa Investigators. (1998) (293)
Platelet glycoprotein IIb/IIIa receptor inhibition in non-ST-elevation acute coronary syndromes: early benefit during medical treatment only, with additional protection during percutaneous coronary intervention. (1999) (292)
Outcomes after cardioversion and atrial fibrillation ablation in patients treated with rivaroxaban and warfarin in the ROCKET AF trial. (2013) (286)
Outcome of patients with diabetes mellitus and acute myocardial infarction treated with thrombolytic agents. The Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) Study Group. (1993) (286)
Shifting the open-artery hypothesis downstream: the quest for optimal reperfusion. (2001) (284)
Cardiac rupture, mortality and the timing of thrombolytic therapy: a meta-analysis. (1990) (284)
Bleeding and blood transfusion issues in patients with non-ST-segment elevation acute coronary syndromes. (2007) (281)
Higher risk of death and stroke in patients with persistent vs. paroxysmal atrial fibrillation: results from the ROCKET-AF Trial (2014) (281)
Cardiac troponin T levels for risk stratification in acute myocardial ischemia. GUSTO IIA Investigators. (1996) (280)
Admission or Changes in Renal Function During Hospitalization for Worsening Heart Failure Predict Postdischarge Survival: Results From the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) (2008) (280)
Prognostic Value of Anxiety and Depression in Patients With Chronic Heart Failure (2004) (279)
Current prognosis of ischemic mitral regurgitation. Implications for future management. (1988) (276)
Endoscopic versus open vein-graft harvesting in coronary-artery bypass surgery. (2009) (276)
27th Bethesda Conference: matching the intensity of risk factor management with the hazard for coronary disease events. Task Force 5. Stratification of patients into high, medium and low risk subgroups for purposes of risk factor management. (1996) (274)
Comparisons of characteristics and outcomes among women and men with acute myocardial infarction treated with thrombolytic therapy. GUSTO-I investigators. (1996) (271)
Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the Platelet Integrin Glycoprotein IIb/IIIa Blocker Integrelin in Elective Coronary Intervention (1995) (271)
Baseline metabolomic profiles predict cardiovascular events in patients at risk for coronary artery disease. (2012) (269)
Long-term survival benefits of coronary artery bypass grafting and percutaneous transluminal angioplasty in patients with coronary artery disease. (1996) (265)
Troponin and C-reactive protein have different relations to subsequent mortality and myocardial infarction after acute coronary syndrome: a GUSTO-IV substudy. (2003) (265)
Factors Associated with Do-Not-Resuscitate Orders: Patients' Preferences, Prognoses, and Physicians' Judgments (1996) (261)
Gender differences in survival in advanced heart failure. Insights from the FIRST study. (1999) (261)
Outcome of patients sustaining acute ischemic mitral regurgitation during myocardial infarction. (1992) (259)
Resuscitation preferences among patients with severe congestive heart failure: results from the SUPPORT project. Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments. (1998) (256)
Long-term protection from myocardial ischemic events in a randomized trial of brief integrin beta3 blockade with percutaneous coronary intervention. EPIC Investigator Group. Evaluation of Platelet IIb/IIIa Inhibition for Prevention of Ischemic Complication. (1997) (255)
Changes in Ventricular Size and Function in Patients Treated With Valsartan, Captopril, or Both After Myocardial Infarction (2005) (254)
Coronary revascularization in diabetic patients: a comparison of the randomized and observational components of the Aypass Angioplasty Revascularization Investigation (BARI). (1999) (254)
Acute Coronary Syndromes in the GUSTO-IIb Trial Prognostic Insights and Impact of Recurrent Ischemia (1998) (252)
Comparison of sibrafiban with aspirin for prevention of cardiovascular events after acute coronary syndromes: a randomised trial (2000) (252)
Prognostic implications of angiographically normal and insignificantly narrowed coronary arteries. (1986) (248)
Direct thrombin inhibitors in acute coronary syndromes: principal results of a meta-analysis based on individual patients' data (2002) (246)
Relationship between depressive symptoms and long-term mortality in patients with heart failure. (2007) (245)
Use of Aortic Counterpulsation to Improve Sustained Coronary Artery Patency During Acute Myocardial Infarction: Results of a Randomized Trial (1994) (244)
Prognostic implications of left ventricular mass and geometry following myocardial infarction: the VALIANT (VALsartan In Acute myocardial iNfarcTion) Echocardiographic Study. (2008) (242)
Prognostic indicators from radionuclide angiography in medically treated patients with coronary artery disease. (1984) (235)
Chronic kidney disease, mortality, and treatment strategies among patients with clinically significant coronary artery disease. (2003) (233)
Benefit of Glycoprotein IIb/IIIa Inhibition in Patients With Acute Coronary Syndromes and Troponin T–Positive Status: The PARAGON-B Troponin T Substudy (2001) (233)
Impact of Global Geographic Region on Time in Therapeutic Range on Warfarin Anticoagulant Therapy: Data From the ROCKET AF Clinical Trial (2013) (231)
Guidelines and indications for coronary artery bypass graft surgery. A report of the American College of Cardiology/American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures (Subcommittee on Coronary Artery Bypass Graft Surgery). (1991) (230)
Newly Diagnosed and Previously Known Diabetes Mellitus and 1-Year Outcomes of Acute Myocardial Infarction: The Valsartan in Acute Myocardial Infarction (VALIANT) Trial (2004) (229)
Prognostic value of serial B-type natriuretic peptide testing during follow-up of patients with unstable coronary artery disease. (2005) (229)
Outcomes of Patients With Chronic Renal Insufficiency in the Bypass Angioplasty Revascularization Investigation (2002) (227)
Percutaneous revascularization of chronic coronary occlusions: an overview. (1995) (225)
Cardiogenic shock in patients with acute ischemic syndromes with and without ST-segment elevation. (1999) (224)
Coronary arterial thrombolysis with combined infusion of recombinant tissue-type plasminogen activator and urokinase in patients with acute myocardial infarction. (1988) (221)
Triage after hospitalization with advanced heart failure: the ESCAPE (Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness) risk model and discharge score. (2010) (221)
A Proactive Response to Prescription Opioid Abuse. (2016) (221)
Impact of an aggressive invasive catheterization and revascularization strategy on mortality in patients with cardiogenic shock in the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO-I) trial. An observational study. (1997) (220)
Effects of platelet glycoprotein IIb/IIIa receptor blockade by a chimeric monoclonal antibody (abciximab) on acute and six-month outcomes after percutaneous transluminal coronary angioplasty for acute myocardial infarction. EPIC investigators. (1996) (220)
The case for practical clinical trials in psychiatry. (2005) (219)
Clinical outcomes after detection of elevated cardiac enzymes in patients undergoing percutaneous intervention (1999) (218)
Prognostic value of radionuclide angiography in medically treated patients with coronary artery disease. A comparison with clinical and catheterization variables. (1990) (217)
New atrial fibrillation after acute myocardial infarction independently predicts death: the GUSTO-III experience. (2000) (215)
Factors associated with major bleeding events: insights from the ROCKET AF trial (rivaroxaban once-daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation). (2014) (215)
Pathogenesis of Sudden Unexpected Death in a Clinical Trial of Patients With Myocardial Infarction and Left Ventricular Dysfunction, Heart Failure, or Both (2010) (214)
Patients Who Want their Family and Physician to Make Resuscitation Decisions for Them: Observations from SUPPORT and HELP (2000) (214)
Value of Clinician Assessment of Hemodynamics in Advanced Heart Failure: The ESCAPE Trial (2008) (214)
2011 ACCF/AHA Focused Update Incorporated Into the ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction (2011) (214)
A Randomized Trial of Late Reperfusion Therapy for Acute Myocardial Infarction (1992) (213)
Failure of simple clinical measurements to predict perfusion status after intravenous thrombolysis. (1988) (212)
Facilitation of early percutaneous coronary intervention after reteplase with or without abciximab in acute myocardial infarction: results from the SPEED (GUSTO-4 Pilot) Trial. (2000) (211)
Differential survival after coronary revascularization procedures among patients with renal insufficiency. (2001) (210)
Multivessel coronary artery disease: a key predictor of short-term prognosis after reperfusion therapy for acute myocardial infarction. Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) Study Group. (1991) (208)
Long-Term Mortality of Patients Undergoing Cardiac Catheterization for ST-Elevation and Non–ST-Elevation Myocardial Infarction (2009) (208)
Safety and efficacy of enoxaparin vs unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin: a randomized controlled trial. (2004) (208)
Cardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetes (2014) (207)
Prognosis in cardiogenic shock after acute myocardial infarction in the interventional era. (1992) (205)
Health Insurance Portability and Accountability Act (HIPAA): must there be a trade-off between privacy and quality of health care, or can we advance both? (2003) (205)
Referral patterns for coronary artery disease treatment: gender bias or good clinical judgment? (1992) (205)
Sustained ventricular arrhythmias in patients receiving thrombolytic therapy: incidence and outcomes. The GUSTO Investigators. (1998) (204)
Evidence for prevention of death and myocardial infarction with platelet membrane glycoprotein IIb/IIIa receptor blockade by abciximab (c7E3 Fab) among patients with unstable angina undergoing percutaneous coronary revascularization. EPIC Investigators. Evaluation of 7E3 in Preventing Ischemic Compl (1997) (204)
Usefulness of right ventricular fractional area change to predict death, heart failure, and stroke following myocardial infarction (from the VALIANT ECHO Study). (2008) (200)
Outcome of acute myocardial infarction according to the specialty of the admitting physician. (1996) (199)
Influence of diabetes mellitus on clinical outcomes across the spectrum of acute coronary syndromes. Findings from the GUSTO-IIb Study (2000) (193)
Randomized, Double-Blind, Placebo-Controlled, International Trial of the Oral IIb/IIIa Antagonist Lotrafiban in Coronary and Cerebrovascular Disease (2003) (189)
Surrogate and Physician Understanding of Patients' Preferences for Living Permanently in a Nursing Home (1997) (189)
Effects of telmisartan, irbesartan, valsartan, candesartan, and losartan on cancers in 15 trials enrolling 138 769 individuals (2011) (189)
Clarifying Stem-Cell Therapy's Benefits and Risks. (2016) (189)
Relation between activated clotting time during angioplasty and abrupt closure. (1996) (188)
Selection of surgical or percutaneous coronary intervention provides differential longevity benefit. (2006) (188)
Compliance with results reporting at ClinicalTrials.gov. (2015) (188)
Association between change in daily ambulatory activity and cardiovascular events in people with impaired glucose tolerance (NAVIGATOR trial): a cohort analysis (2014) (187)
Intradialytic blood volume monitoring in ambulatory hemodialysis patients: a randomized trial. (2005) (187)
Valsartan in acute myocardial infarction trial (VALIANT): rationale and design. (2000) (186)
Incidence and Predictors of Bleeding After Contemporary Thrombolytic Therapy for Myocardial Infarction (1997) (186)
Prognostic significance of the initial electrocardiogram in patients with acute myocardial infarction. GUSTO-I Investigators. Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries. (1998) (186)
Comparison of predictions based on observational data with the results of randomized controlled clinical trials of coronary artery bypass surgery. (1988) (185)
Prognostic significance of elevated troponin I after percutaneous coronary intervention. (2002) (183)
The efficacy and safety of short- and long-term dual antiplatelet therapy in patients with mild or moderate chronic kidney disease: results from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial. (2008) (182)
A clinical comparison of mitral valve repair versus valve replacement in ischemic mitral regurgitation. (1988) (182)
Metaanalysis of five reported studies on the relation of early coronary patency grades with mortality and outcomes after acute myocardial infarction. (1996) (181)
Economic return of clinical trials performed under the pediatric exclusivity program. (2007) (180)
Influence of diabetes mellitus on clinical outcome in the thrombolytic era of acute myocardial infarction. GUSTO-I Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. (1997) (179)
Low Molecular Weight Heparin in Prevention of Restenosis After Angioplasty: Results of Enoxaparin Restenosis (ERA) Trial (1994) (179)
Clinical characteristics and outcomes with rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation but underlying native mitral and aortic valve disease participating in the ROCKET AF trial (2014) (177)
Recent trends in the care of patients with non-ST-segment elevation acute coronary syndromes: insights from the CRUSADE initiative. (2006) (176)
Economic assessment of low-molecular-weight heparin (enoxaparin) versus unfractionated heparin in acute coronary syndrome patients: results from the ESSENCE randomized trial. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q wave Coronary Events [unstable angina or non-Q-wave myocardial infarc (1998) (176)
Effect of age on outcome with primary angioplasty versus thrombolysis. (1999) (175)
Importance of clinical measures of ischemia in the prognosis of patients with documented coronary artery disease. (1988) (175)
Saphenous Vein Graft Failure After Coronary Artery Bypass Surgery: Insights From PREVENT IV (2014) (174)
Absence of sex bias in the referral of patients for cardiac catheterization. (1994) (174)
Clinical and therapeutic profile of patients presenting with acute coronary syndromes who do not have significant coronary artery disease.The Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) Trial Investigators. (2000) (174)
Continuously updated 12-lead ST-segment recovery analysis for myocardial infarct artery patency assessment and its correlation with multiple simultaneous early angiographic observations. (1993) (173)
Intracranial Hemorrhage Among Patients With Atrial Fibrillation Anticoagulated With Warfarin or Rivaroxaban: The Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (2014) (173)
Comparison of coronary artery bypass grafting versus medical therapy on long-term outcome in patients with ischemic cardiomyopathy (a 25-year experience from the Duke Cardiovascular Disease Databank). (2002) (172)
A multicenter, randomized trial of coronary angioplasty versus directional atherectomy for patients with saphenous vein bypass graft lesions. CAVEAT-II Investigators. (1995) (172)
Randomised trial of magnesium in in-hospital cardiac arrest (1997) (172)
A national survey of provisions in clinical-trial agreements between medical schools and industry sponsors. (2002) (172)
Use of intraaortic balloon counterpulsation in patients presenting with cardiogenic shock: observations from the GUSTO-I Study. Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries. (1997) (172)
Determinants of the use of coronary angiography and revascularization after thrombolysis for acute myocardial infarction. (1996) (171)
Cardiogenic shock complicating acute coronary syndromes (2000) (171)
Integrating quality into the cycle of therapeutic development. (2002) (171)
Prognostic usefulness of the six-minute walk in patients with advanced congestive heart failure secondary to ischemic or nonischemic cardiomyopathy. (2001) (170)
Extent, location, and clinical significance of non-infarct-related coronary artery disease among patients with ST-elevation myocardial infarction. (2014) (170)
Cardiogenic shock complicating acute myocardial infarction: predictors of death. GUSTO Investigators. Global Utilization of Streptokinase and Tissue-Plasminogen Activator for Occluded Coronary Arteries. (1999) (169)
Continuous 12‐Lead ST‐Segment Recovery Analysis in the TAMI 7 Study Performance of a Noninvasive Method for Real‐Time Detection of Failed Myocardial Reperfusion Detection of Failed Myocardial Reperfusion (1993) (168)
Recombinant hirudin for unstable angina pectoris. A multicenter, randomized angiographic trial. (1994) (168)
Myocardial infarction and stroke (1984) (167)
Serial measurement of monocyte chemoattractant protein-1 after acute coronary syndromes: results from the A to Z trial. (2007) (166)
The anticoagulant therapy with bivalirudin to assist in the performance of percutaneous coronary intervention in patients with heparin-induced thrombocytopenia (ATBAT) study: main results. (2003) (164)
Long-term mortality benefit with abciximab in patients undergoing percutaneous coronary intervention. (2001) (163)
Hemorrhagic complications associated with the use of intravenous tissue plasminogen activator in treatment of acute myocardial infarction. (1988) (163)
Characteristics and outcome of patients in whom reperfusion with intravenous tissue-type plasminogen activator fails: results of the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) I trial. (1988) (162)
Prognostic implications of ventricular arrhythmias during 24 hour ambulatory monitoring in patients undergoing cardiac catheterization for coronary artery disease. (1982) (162)
Sustained suppression of ischemic complications of coronary intervention by platelet GP IIb/IIIa blockade with abciximab: one-year outcome in the EPILOG trial. Evaluation in PTCA to Improve Long-term Outcome with abciximab GP IIb/IIIa blockade. (1999) (162)
Management of major bleeding events in patients treated with rivaroxaban vs. warfarin: results from the ROCKET AF trial. (2014) (162)
Rationale and design of the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure Trial (ASCEND-HF). (2009) (161)
Prognostic value of ST segment depression in acute coronary syndromes: insights from PARAGON-A applied to GUSTO-IIb. PARAGON-A and GUSTO IIb Investigators. Platelet IIb/IIIa Antagonism for the Reduction of Acute Global Organization Network. (2001) (161)
Surgical survival benefits for coronary disease patients with left ventricular dysfunction. (1988) (161)
Six‐Month Clinical and Angiographic Follow‐up After Direct Angioplasty for Acute Myocardial Infarction: Final Results From the Primary Angioplasty Registry (1994) (161)
Randomized trial of low molecular weight heparin (enoxaparin) versus unfractionated heparin for unstable coronary artery disease: one-year results of the ESSENCE Study. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q Wave Coronary Events. (2000) (160)
From myocardial salvage to patient salvage in acute myocardial infarction: the role of reperfusion therapy. (1989) (160)
Cardiovascular drug development: is it dead or just hibernating? (2015) (159)
Outcome in suspected acute myocardial infarction with normal or minimally abnormal admission electrocardiographic findings. (1987) (159)
Determinants of early versus late cardiac death in patients undergoing coronary artery bypass graft surgery. (1991) (159)
Predicting outcome in coronary disease. Statistical models versus expert clinicians. (1986) (159)
Choices of Seriously Ill Patients About Cardiopulmonary Resuscitation (1996) (158)
Atenolol use and clinical outcomes after thrombolysis for acute myocardial infarction: the GUSTO-I experience. Global Utilization of Streptokinase and TPA (alteplase) for Occluded Coronary Arteries. (1998) (158)
Electronic health records based phenotyping in next-generation clinical trials: a perspective from the NIH Health Care Systems Collaboratory. (2013) (158)
Prognostic implications of TIMI flow grade in the infarct related artery compared with continuous 12-lead ST-segment resolution analysis. Reexamining the "gold standard" for myocardial reperfusion assessment. (2000) (157)
Sensible approaches for reducing clinical trial costs (2008) (156)
Risk stratification with a point-of-care cardiac troponin T test in acute myocardial infarction. GUSTOIII Investigators. Global Use of Strategies To Open Occluded Coronary Arteries. (1999) (156)
End-systolic volume index at 90 to 180 minutes into reperfusion therapy for acute myocardial infarction is a strong predictor of early and late mortality. The Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO)-I Angiographic Investigators. (1997) (155)
Clinical significance of thrombocytopenia during a non-ST-elevation acute coronary syndrome. The platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial experience. (1999) (154)
The effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT). (2006) (154)
An international perspective on heart failure and left ventricular systolic dysfunction complicating myocardial infarction: the VALIANT registry. (2004) (154)
Occurrence and clinical significance of thrombocytopenia in a population undergoing high-risk percutaneous coronary revascularization. Evaluation of c7E3 for the Prevention of Ischemic Complications (EPIC) Study Group. (1998) (154)
Evolution of the coronary care unit: Clinical characteristics and temporal trends in healthcare delivery and outcomes* (2010) (153)
Relationship between antecedent angina pectoris and short-term prognosis after thrombolytic therapy for acute myocardial infarction. Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) Study Group. (1990) (152)
Risk Stratification after Myocardial Infarction (1997) (152)
Gender and acute myocardial infarction: is there a different response to thrombolysis? (1997) (151)
Characteristics and consequences of myocardial infarction after percutaneous coronary intervention: insights from the Coronary Angioplasty Versus Excisional Atherectomy Trial (CAVEAT). (1995) (150)
Relation of clinical and angiographic factors to functional capacity as measured by the Duke Activity Status Index. (1991) (150)
Peer-reviewed publication of clinical trials completed for pediatric exclusivity. (2006) (149)
Effect of platelet glycoprotein IIb/IIIa integrin blockade on activated clotting time during percutaneous transluminal coronary angioplasty or directional atherectomy (the EPIC trial). Evaluation of c7E3 Fab in the Prevention of Ischemic Complications trial. (1995) (149)
Cause of Death and Predictors of All‐Cause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation: Data From ROCKET AF (2016) (149)
Comparison of cefuroxime with or without intranasal fluticasone for the treatment of rhinosinusitis. The CAFFS Trial: a randomized controlled trial. (2001) (147)
Predictors of cardiogenic shock after thrombolytic therapy for acute myocardial infarction. (2000) (146)
The influence of risk status on guideline adherence for patients with non-ST-segment elevation acute coronary syndromes. (2006) (146)
Variations in Patient Management and Outcomes for Acute Myocardial Infarction in the United States and Other Countries: Results From the GUSTO Trial (1995) (146)
Multi-year follow-up of abciximab therapy in three randomized, placebo-controlled trials of percutaneous coronary revascularization. (2002) (145)
Prescription of QT-prolonging drugs in a cohort of about 5 million outpatients. (2003) (145)
Prediction of 1-year survival after thrombolysis for acute myocardial infarction in the global utilization of streptokinase and TPA for occluded coronary arteries trial. (2000) (145)
Characteristics of oncology clinical trials: insights from a systematic analysis of ClinicalTrials.gov. (2013) (145)
Cardiac repolarization: current knowledge, critical gaps, and new approaches to drug development and patient management. (2002) (144)
Sustained Ventricular Arrhythmias Among Patients With Acute Coronary Syndromes With No ST-Segment Elevation: Incidence, Predictors, and Outcomes (2002) (144)
Rivaroxaban for Stroke Prevention in East Asian Patients From the ROCKET AF Trial (2014) (144)
Economic assessment of platelet glycoprotein IIb/IIIa inhibition for prevention of ischemic complications of high-risk coronary angioplasty. EPIC Investigators. (1996) (144)
Reduction in complications of angioplasty with abciximab occurs largely independently of baseline lesion morphology. EPIC and EPILOG Investigators. Evaluation of 7E3 for the Prevention of Ischemic Complications. Evaluation of PTCA To Improve Long-term Outcome with abciximab GPIIb/IIIa Receptor Block (1998) (143)
Exploring the ethical and regulatory issues in pragmatic clinical trials (2015) (143)
Changing preferences for survival after hospitalization with advanced heart failure. (2008) (142)
Clinical benefit of glycoprotein IIb/IIIa blockade with Abciximab is independent of gender: pooled analysis from EPIC, EPILOG and EPISTENT trials. Evaluation of 7E3 for the Prevention of Ischemic Complications. Evaluation in Percutaneous Transluminal Coronary Angioplasty to Improve Long-Term Outcome (2000) (142)
The STARBRITE trial: a randomized, pilot study of B-type natriuretic peptide-guided therapy in patients with advanced heart failure. (2011) (142)
Troponin T levels and risk of 30-day outcomes in patients with the acute coronary syndrome: prospective verification in the GUSTO-IV trial. (2003) (142)
Cost effectiveness of early discharge after uncomplicated acute myocardial infarction. (2000) (141)
Persistence of delays in presentation and treatment for patients with acute myocardial infarction: The GUSTO-I and GUSTO-III experience. (2002) (141)
Previously known and newly diagnosed atrial fibrillation: A major risk indicator after a myocardial infarction complicated by heart failure or left ventricular dysfunction ☆ (2006) (140)
Outcomes of acute exacerbation of severe congestive heart failure: quality of life, resource use, and survival. SUPPORT Investigators. The Study to Understand Prognosis and Preferences for Outcomes and Risks of Treatments. (1998) (140)
Estimating the likelihood of severe coronary artery disease. (1991) (140)
Choices of seriously ill patients about cardiopulmonary resuscitation: correlates and outcomes. SUPPORT Investigators. Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments. (1996) (139)
Mortality Within 24 Hours of Thrombolysis for Myocardial Infarction: The Importance of Early Reperfusion (1994) (139)
Fate of patients with acute myocardial infarction with patency of the infarct-related vessel achieved with successful thrombolysis versus rescue angioplasty. (1990) (138)
Early discharge in the thrombolytic era: an analysis of criteria for uncomplicated infarction from the Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO) trial. (1996) (138)
Medical approaches to prevention of restenosis after coronary angioplasty. (1987) (138)
Assessment and treatment of depression in patients with cardiovascular disease: National heart, lung, and blood institute working group report (2006) (137)
Initiation of hormone replacement therapy after acute myocardial infarction is associated with more cardiac events during follow-up. (2001) (136)
Prognostic value of ventricular arrhythmias associated with treadmill exercise testing in patients studied with cardiac catheterization for suspected ischemic heart disease. (1983) (136)
Recurrent ischemia without warning. Analysis of risk factors for in-hospital ischemic events following successful thrombolysis with intravenous tissue plasminogen activator. (1989) (135)
Antidepressant use, depression, and survival in patients with heart failure. (2008) (135)
Rationale, design, and organization of a randomized, controlled Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) in patients with type 2 diabetes and established cardiovascular disease. (2013) (135)
Mortality at 1 year with combination platelet glycoprotein IIb/IIIa inhibition and reduced-dose fibrinolytic therapy vs conventional fibrinolytic therapy for acute myocardial infarction: GUSTO V randomized trial. (2002) (134)
The role of academic health science systems in the transformation of medicine (2010) (134)
Cardiac troponin T and cardiac troponin I: relative values in short-term risk stratification of patients with acute coronary syndromes (1998) (134)
Extended Mortality Benefit of Early Postinfarction Reperfusion (1998) (133)
Long-term efficacy of platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention. (2002) (132)
Clinical Outcomes of Palliative Surgery Including a Systemic-to-Pulmonary Artery Shunt in Infants With Cyanotic Congenital Heart Disease: Does Aspirin Make a Difference? (2007) (132)
Acute myocardial infarction and complete bundle branch block at hospital admission: clinical characteristics and outcome in the thrombolytic era. GUSTO-I Investigators. Global Utilization of Streptokinase and t-PA [tissue-type plasminogen activator] for Occluded Coronary Arteries. (1998) (132)
Standard versus low-dose weight-adjusted heparin in patients treated with the platelet glycoprotein IIb/IIIa receptor antibody fragment abciximab (c7E3 Fab) during percutaneous coronary revascularization. PROLOG Investigators. (1997) (131)
Platelet glycoprotein IIb/IIIa blockade and outcome of cardiogenic shock complicating acute coronary syndromes without persistent ST-segment elevation. (2000) (130)
Renal Dysfunction as a Predictor of Stroke and Systemic Embolism in Patients With Nonvalvular Atrial FibrillationClinical Perspective (2013) (130)
Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness (ESCAPE): design and rationale. (2001) (130)
Relationship Between Vein Graft Failure and Subsequent Clinical Outcomes After Coronary Artery Bypass Surgery (2012) (129)
Left ventricular ejection fraction may not be useful as an end point of thrombolytic therapy comparative trials. (1990) (128)
A metaanalysis of predischarge risk stratification after acute myocardial infarction with stress electrocardiographic, myocardial perfusion, and ventricular function imaging. (1996) (128)
Clinical characteristics and long-term survival of patients with variant angina. (1984) (127)
A nitric oxide processing defect of red blood cells created by hypoxia: deficiency of S-nitrosohemoglobin in pulmonary hypertension. (2005) (126)
Predictors of mortality and mortality from cardiac causes in the bypass angioplasty revascularization investigation (BARI) randomized trial and registry. For the BARI Investigators. (2000) (126)
Clinical and Economic Implications of the Multicenter Automatic Defibrillator Implantation Trial-II (2005) (125)
Randomized COMparison of Platelet Inhibition With Abciximab, TiRofiban and Eptifibatide During Percutaneous Coronary Intervention in Acute Coronary Syndromes: The COMPARE Trial (2002) (124)
Prior aspirin use predicts worse outcomes in patients with non-ST-elevation acute coronary syndromes. PURSUIT Investigators. Platelet IIb/IIIa in Unstable angina: Receptor Suppression Using Integrilin Therapy. (1999) (124)
Detection of restenosis after elective percutaneous transluminal coronary angioplasty using the exercise treadmill test. (1990) (123)
Early Intensive vs a Delayed Conservative Simvastatin Strategy in Patients With Acute Coronary Syndromes (2004) (123)
Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months. The EPIC Investigators. (1994) (123)
Cost-effectiveness of platelet glycoprotein IIb/IIIa inhibition with eptifibatide in patients with non-ST-elevation acute coronary syndromes. (2000) (123)
One-Year Results From the Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries (GUSTO-I) Trial (1996) (122)
Resource Use and Survival of Patients Hospitalized with Congestive Heart Failure: Differences in Care by Specialty of the Attending Physician (2000) (122)
Ethics and regulatory complexities for pragmatic clinical trials. (2014) (122)
Repeat percutaneous transluminal coronary angioplasty and predictors of recurrent restenosis. (1989) (122)
Bleeding complications in patients with acute coronary syndrome undergoing early invasive management can be reduced with radial access, smaller sheath sizes, and timely sheath removal (2007) (121)
Randomized trial of candesartan cilexetil in the treatment of patients with congestive heart failure and a history of intolerance to angiotensin-converting enzyme inhibitors. (2000) (121)
Inhaled ethyl nitrite gas for persistent pulmonary hypertension of the newborn (2002) (120)
Coronary artery bypass graft failure after on-pump and off-pump coronary artery bypass: findings from PREVENT IV. (2008) (120)
Long-term outcome and its predictors among patients with ST-segment elevation myocardial infarction complicated by shock: insights from the GUSTO-I trial. (2007) (120)
Job strain and the prevalence and outcome of coronary artery disease. (1995) (120)
Combining thrombolysis with the platelet glycoprotein IIb/IIIa inhibitor lamifiban: results of the Platelet Aggregation Receptor Antagonist Dose Investigation and Reperfusion Gain in Myocardial Infarction (PARADIGM) trial. (1998) (119)
Pharmacodynamics of thrombolysis with recombinant tissue-type plasminogen activator. Correlation with characteristics of and clinical outcomes in patients with acute myocardial infarction. The TAMI Study Group. (1989) (119)
Physician Understanding Of Patient Resuscitation Preferences: Insights and Clinical Implications (2000) (119)
The landscape of clinical trials in nephrology: a systematic review of Clinicaltrials.gov. (2014) (119)
Reducing the costs of phase III cardiovascular clinical trials. (2005) (118)
Association between minor elevations of creatine kinase-MB level and mortality in patients with acute coronary syndromes without ST-segment elevation. PURSUIT Steering Committee. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy. (2000) (118)
Relationships among Ventricular Arrhythmias, Coronary Artery Disease, and Angiographic and Electrocardiographic Indicators of Myocardial Fibrosis (1978) (118)
Pediatric Antihypertensive Trial Failures: Analysis of End Points and Dose Range (2008) (117)
Troponin-T and N-terminal pro-B-type natriuretic peptide predict mortality benefit from coronary revascularization in acute coronary syndromes: a GUSTO-IV substudy. (2006) (117)
The SUPPORT Prognostic Model (1995) (117)
Effect of cigarette smoking on outcome after thrombolytic therapy for myocardial infarction. (1995) (117)
Distinguishing between early and late responders to symptoms of acute myocardial infarction. (1995) (117)
Effect of platelet glycoprotein IIb/IIIa receptor inhibition on distal embolization during percutaneous revascularization of aortocoronary saphenous vein grafts. EPIC Investigators. Evaluation of IIb/IIIa platelet receptor antagonist 7E3 in Preventing Ischemic Complications. (1997) (116)
Comparative efficacy of dronedarone and amiodarone for the maintenance of sinus rhythm in patients with atrial fibrillation. (2009) (116)
Cine MR determination of left ventricular ejection fraction. (1987) (116)
Factors associated with change in resuscitation preference of seriously ill patients. The SUPPORT Investigators. Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments. (1996) (116)
Peripheral vascular complications in the Coronary Angioplasty Versus Excisional Atherectomy Trial (CAVEAT-I). (1995) (116)
Scorecard Cardiovascular Medicine: Its Impact and Future Directions (1994) (116)
Do Countries or Hospitals With Longer Hospital Stays for Acute Heart Failure Have Lower Readmission Rates?: Findings From ASCEND-HF (2013) (115)
Factors associated with change in resuscitation preference of seriously ill patients (1996) (115)
One-year follow-up in the Coronary Angioplasty Versus Excisional Atherectomy Trial (CAVEAT I) (1995) (114)
Meta-analysis of randomized trials of percutaneous transluminal coronary angioplasty versus atherectomy, cutting balloon atherotomy, or laser angioplasty. (2004) (114)
Improving Medication Adherence in Cardiometabolic Disease: Practical and Regulatory Implications. (2017) (113)
Thrombolytic therapy for women with myocardial infarction: is there a gender gap? Thrombolysis and Angioplasty in Myocardial Infarction Study Group. (1993) (113)
Occurrence and clinical significance of pseudothrombocytopenia during abciximab therapy. (2000) (113)
Effects of integrelin, a platelet glycoprotein IIb/IIIa receptor antagonist, in unstable angina. A randomized multicenter trial. (1996) (113)
Levels of Evidence Supporting American College of Cardiology/American Heart Association and European Society of Cardiology Guidelines, 2008-2018 (2019) (112)
Gastrointestinal bleeding in high risk survivors of myocardial infarction: the VALIANT Trial. (2009) (112)
Predictors and sequelae of distal embolization during saphenous vein graft intervention from the CAVEAT-II trial. Coronary Angioplasty Versus Excisional Atherectomy Trial. (1995) (112)
Outcome in One‐vessel Coronary Artery Disease (1983) (112)
Transforming Evidence Generation to Support Health and Health Care Decisions. (2016) (111)
Call to Action: Urgent Challenges in Cardiovascular Disease A Presidential Advisory From the American Heart Association (2019) (111)
Comparison of analytic models for estimating the effect of clinical factors on the cost of coronary artery bypass graft surgery. (1993) (111)
A Tale of Two Trials: A Comparison of the Post–Acute Coronary Syndrome Lipid-Lowering Trials A to Z and PROVE IT–TIMI 22 (2006) (110)
Prognostic implications and predictors of enhanced regional wall motion of the noninfarct zone after thrombolysis and angioplasty therapy of acute myocardial infarction. The TAMI Study Groups. (1989) (110)
Minimal myocardial damage during coronary intervention is associated with impaired outcome. (1999) (110)
Combination reperfusion therapy with eptifibatide and reduced-dose tenecteplase for ST-elevation myocardial infarction: results of the integrilin and tenecteplase in acute myocardial infarction (INTEGRITI) Phase II Angiographic Trial. (2003) (109)
Survival and cardiac event rates in the first year after emergency coronary angioplasty for acute myocardial infarction. (1988) (109)
Contemporary management of patients with left ventricular systolic dysfunction. Results from the Study of Patients Intolerant of Converting Enzyme Inhibitors (SPICE) Registry. (1999) (109)
Assessment and treatment of depression in patients with cardiovascular disease: National Heart, Lung, and Blood Institute Working Group Report. (2006) (108)
Improved clinical outcomes with abciximab therapy in acute myocardial infarction: a systematic overview of randomized clinical trials. (2004) (107)
Diabetes mellitus, glycoprotein IIb/IIIa blockade, and heparin: evidence for a complex interaction in a multicenter trial. EPILOG Investigators. (1998) (107)
Mortality and Morbidity Remain High Despite Captopril and/or Valsartan Therapy in Elderly Patients With Left Ventricular Systolic Dysfunction, Heart Failure, or Both After Acute Myocardial Infarction: Results From the Valsartan in Acute Myocardial Infarction Trial (VALIANT) (2005) (107)
Incidence, predictors, and outcomes of high-degree atrioventricular block complicating acute myocardial infarction treated with thrombolytic therapy. (2005) (106)
Difference in countries' use of resources and clinical outcome for patients with cardiogenic shock after myocardial infarction: results from the GUSTO trial (1997) (106)
Efficacy and Safety of Rivaroxaban in Patients With Heart Failure and Nonvalvular Atrial Fibrillation: Insights From ROCKET AF (2013) (106)
Racial Differences in Responses to Thrombolytic Therapy With Recombinant Tissue‐Type Plasminogen Activator: Increased Fibrin(ogen)olysis in Blacks (1991) (106)
Clinical characteristics and long-term outcome of patients in whom congestive heart failure develops after thrombolytic therapy for acute myocardial infarction: development of a predictive model. (1997) (106)
Stroke and acute myocardial infarction in the thrombolytic era: clinical correlates and long-term prognosis. (1990) (105)
AHA scientific statement: practice standards for electrocardiographic monitoring in hospital settings: an American Heart Association Scientific Statement from the Councils on Cardiovascular Nursing, Clinical Cardiology, and Cardiovascular Disease in the Young: endorsed by the International Society o (2005) (105)
Bleeding during thrombolytic therapy for acute myocardial infarction: mechanisms and management. (1989) (105)
Platelet glycoprotein IIb/IIIa receptor blockade in coronary artery disease. (2000) (104)
Increased left ventricular dysfunction in elderly patients despite successful thrombolysis: the GUSTO-I angiographic experience. (1996) (104)
Early percutaneous coronary intervention, platelet inhibition with eptifibatide, and clinical outcomes in patients with acute coronary syndromes. PURSUIT Investigators. (2000) (104)
Interventional cardiac catheterization at Duke Medical Center. (1988) (104)
Clinical outcomes of bivalirudin for ischemic heart disease. (1999) (104)
Prognostic significance of precordial ST-segment depression during inferior acute myocardial infarction. (1985) (103)
Cardiovascular Toxicity of Epoetin-Alfa in Patients with Chronic Kidney Disease (2013) (103)
One-year survival among patients with acute myocardial infarction complicated by cardiogenic shock, and its relation to early revascularization: results from the GUSTO-I trial. (1999) (103)
Troponin I in acute decompensated heart failure: insights from the ASCEND‐HF study (2011) (103)
Clinical characteristics and long-term outcomes of patients with heart failure and preserved systolic function. (2000) (103)
Techniques and benefits of multiple internal mammary artery bypass at 20 years of follow-up. (2007) (103)
Heart Failure With Preserved Ejection Fraction Expert Panel Report: Current Controversies and Implications for Clinical Trials. (2018) (101)
Thrombolysis-related intracranial hemorrhage: a radiographic analysis of 244 cases from the GUSTO-1 trial with clinical correlation. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. (1998) (101)
Lessons learned from recent cardiovascular clinical trials: Part I. (2002) (101)
Call to Action: Rural Health: A Presidential Advisory From the American Heart Association and American Stroke Association. (2020) (100)
Analyses of cancer data from three ezetimibe trials. (2008) (100)
EXTENT, LOCATION, AND CLINICAL SIGNIFICANCE OF NON-INFARCT RELATED CORONARY ARTERY DISEASE AMONG PATIENTS WITH ST-ELEVATION MYOCARDIAL INFARCTION (2014) (100)
Complete atrioventricular block complicating inferior wall acute myocardial infarction treated with reperfusion therapy (1991) (100)
Low-molecular-weight heparins in non–ST-segment elevation ischemia: the ESSENCE trial (1998) (99)
An update on the IMProved reduction of outcomes: Vytorin Efficacy International Trial (IMPROVE-IT) design. (2010) (99)
Meta-analysis of survival with platelet glycoprotein IIb/IIIa antagonists for percutaneous coronary interventions. (2003) (99)
Combined tissue-type plasminogen activator and prostacyclin therapy for acute myocardial infarction. Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) 4 Study Group. (1989) (99)
Relationship Between Time in Therapeutic Range and Comparative Treatment Effect of Rivaroxaban and Warfarin: Results From the ROCKET AF Trial (2014) (99)
Predictors of the first heart failure hospitalization in patients who are stable survivors of myocardial infarction complicated by pulmonary congestion and/or left ventricular dysfunction: a VALIANT study. (2008) (99)
Thrombolysis and Angioplasty in Myocardial Infarction (TAMI-1) trial: influence of infarct location on arterial patency, left ventricular function and mortality. (1989) (98)
Vascular access site complications after percutaneous coronary intervention with abciximab in the Evaluation of c7E3 for the Prevention of Ischemic Complications (EPIC) trial. (1998) (98)
Need for a National Evaluation System for Health Technology. (2016) (98)
Value of radionuclide angiography for predicting specific cardiac events after acute myocardial infarction. (1985) (98)
Effect of Cigarette Smoking on Outcome After Thrombolytic Therapy for Myocardial Infarction (1991) (97)
Anti-Platelet Factor 4/Heparin Antibodies: An Independent Predictor of 30-Day Myocardial Infarction After Acute Coronary Ischemic Syndromes (2003) (97)
Clinical risks of thrombolytic therapy. (1992) (97)
Randomized comparison of direct thrombin inhibition versus heparin in conjunction with fibrinolytic therapy for acute myocardial infarction: results from the GUSTO-IIb Trial. Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes (GUSTO-IIb) Investigators. (1998) (97)
Randomized clinical trials--removing unnecessary obstacles. (2013) (97)
Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: final baseline characteristics of the IMPROVE-IT study population. (2014) (96)
Comparison of time domain and frequency domain variables from the signal-averaged electrocardiogram: a multivariable analysis. (1988) (95)
Mechanical Dyssynchrony After Myocardial Infarction in Patients With Left Ventricular Dysfunction, Heart Failure, or Both (2010) (95)
The use of intraaortic balloon pumping as an adjunct to reperfusion therapy in acute myocardial infarction. The Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) Study Group. (1991) (95)
Quantitative analysis of right and left ventricular infarction in the presence of postinfarction ventricular septal defect. (1988) (95)
Biomarkers and Surrogate Endpoints: Developing Common Terminology and Definitions. (2016) (95)
Lessons learned from recent cardiovascular clinical trials: Part II. (2002) (94)
Troponin T and quantitative ST-segment depression offer complementary prognostic information in the risk stratification of acute coronary syndrome patients. (2003) (94)
A comparison of phenotype definitions for diabetes mellitus. (2013) (94)
Significance of a coronary artery with thrombolysis in myocardial infarction grade 2 flow "patency" (outcome in the thrombolysis and angioplasty in myocardial infarction trials). Thrombolysis and Angioplasty in Myocardial Infarction Study Group. (1995) (93)
Outcomes associated with the use of secondary prevention medications after coronary artery bypass graft surgery. (2007) (93)
Accuracy and interobserver variability of coronary cineangiography: a comparison with postmortem evaluation. (1984) (93)
Effects of profound platelet inhibition with c7E3 before coronary angioplasty on complications of coronary bypass surgery. EPIC Investigators. Evaluation Prevention of Ischemic Complications. (1994) (93)
Clinical data bases. Accomplishments and unrealized potential. (1985) (93)
Diabetes mellitus and outcome after primary coronary angioplasty for acute myocardial infarction: Lessons from the GUSTO-IIb Angioplasty Substudy (2000) (92)
The A-to-Z Trial: Methods and rationale for a single trial investigating combined use of low-molecular-weight heparin with the glycoprotein IIb/IIIa inhibitor tirofiban and defining the efficacy of early aggressive simvastatin therapy. (2001) (92)
Early Statin Initiation and Outcomes in Patients With Acute Coronary Syndromes (2002) (92)
Short- and long-term risk stratification in acute coronary syndromes: the added value of quantitative ST-segment depression and multiple biomarkers. (2006) (90)
Prevention of diabetes and cardiovascular disease in patients with impaired glucose tolerance: rationale and design of the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Trial. (2008) (90)
Relation between estrogen replacement therapy and restenosis after percutaneous coronary interventions. (1996) (90)
Feasibility of endovascular cooling as an adjunct to primary percutaneous coronary intervention (results of the LOWTEMP pilot study). (2004) (90)
Incidence and predictors of bleeding after contemporary thrombolytic therapy for myocardial infarction. The Global Utilization of Streptokinase and Tissue Plasminogen activator for Occluded coronary arteries (GUSTO) I Investigators. (1997) (90)
Clinical Guideline: Part II: Risk Stratification after Myocardial Infarction (1997) (90)
Conducting economic evaluations alongside multinational clinical trials: toward a research consensus. (2005) (90)
Efficacy and safety of enoxaparin compared with unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention in the Superior Yield of the New Strategy of Enoxaparin, Revascularization and Glycoprotein IIb/IIIa Inhibi (2006) (89)
Results from late-breaking clinical trials sessions at ACCIS 2000 and ACC 2000. American College of Cardiology. (2000) (89)
Intravenous Fluosol in the Treatment of Acute Myocardial Infarction: Results of the Thrombolysis and Angioplasty in Myocardial Infarction 9 Trial (1994) (88)
Progress toward the prevention and treatment of atrial fibrillation: A summary of the Heart Rhythm Society Research Forum on the Treatment and Prevention of Atrial Fibrillation, Washington, DC, December 9-10, 2013. (2015) (88)
Traversing the Valley of Death: A Guide to Assessing Prospects for Translational Success (2009) (88)
Saphenous Vein Grafts With Multiple Versus Single Distal Targets in Patients Undergoing Coronary Artery Bypass Surgery: One-Year Graft Failure and Five-Year Outcomes From the Project of Ex-Vivo Vein Graft Engineering via Transfection (PREVENT) IV Trial (2011) (88)
Patient-Specific Predictions of Outcomes in Myocardial Infarction for Real-Time Emergency Use: A Thrombolytic Predictive Instrument (1997) (88)
Overview of randomized trials of intravenous heparin in patients with acute myocardial infarction treated with thrombolytic therapy. (1996) (88)
Diabetic retinopathy should not be a contraindication to thrombolytic therapy for acute myocardial infarction: review of ocular hemorrhage incidence and location in the GUSTO-I trial. Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries. (1997) (88)
VALsartan In Acute myocardial iNfarcTion (VALIANT) trial: baseline characteristics in context (2003) (87)
Observational Comparison of Event‐Free Survival With Medical and Surgical Therapy in Patients With Coronary Artery Disease: 20 Years of Follow‐up (1992) (86)
Abciximab therapy and unplanned coronary stent deployment: favorable effects on stent use, clinical outcomes, and bleeding complications. EPILOG Trial Investigators. (1998) (86)
Abciximab and bleeding during coronary surgery: results from the EPILOG and EPISTENT trials. Improve Long-term Outcome with abciximab GP IIb/IIIa blockade. Evaluation of Platelet IIb/IIIa Inhibition in STENTing. (2000) (86)
Monitoring and ensuring safety during clinical research. (2001) (85)
Clinical correlates and course of thrombocytopenia during percutaneous coronary intervention in the era of abciximab platelet glycoprotein IIb/IIIa blockade. (2000) (85)
Digitizing clinical trials (2020) (85)
Thrombolytic therapy in patients requiring cardiopulmonary resuscitation. (1991) (85)
Impact of cardiovascular events on change in quality of life and utilities in patients after myocardial infarction: a VALIANT study (valsartan in acute myocardial infarction). (2014) (84)
The early glycoprotein IIb/IIIa inhibition in non-ST-segment elevation acute coronary syndrome (EARLY ACS) trial: a randomized placebo-controlled trial evaluating the clinical benefits of early front-loaded eptifibatide in the treatment of patients with non-ST-segment elevation acute coronary syndro (2005) (84)
Ischaemic cardiac outcomes in patients with atrial fibrillation treated with vitamin K antagonism or factor Xa inhibition: results from the ROCKET AF trial. (2014) (83)
Identification of Patients With Coronary Disease at High Risk for Loss of Employment: A Prospective Validation Study (1992) (83)
Patients with prolonged ischemic chest pain and presumed-new left bundle branch block have heterogeneous outcomes depending on the presence of ST-segment changes. (2005) (83)
Efficacy and safety of rivaroxaban compared with warfarin in patients with peripheral artery disease and non-valvular atrial fibrillation: insights from ROCKET AF. (2013) (83)
Effect of intensive lipid-lowering therapy on mortality after acute coronary syndrome (a patient-level analysis of the Aggrastat to Zocor and Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 trials). (2007) (82)
Disagreements between central clinical events committee and site investigator assessments of myocardial infarction endpoints in an international clinical trial: review of the PURSUIT study (2001) (82)
Selection of thrombolytic therapy for individual patients: development of a clinical model. GUSTO-I Investigators. (1997) (82)
Clinical trials bureaucracy: unintended consequences of well-intentioned policy (2006) (82)
Effects of nesiritide and predictors of urine output in acute decompensated heart failure: results from ASCEND-HF (acute study of clinical effectiveness of nesiritide and decompensated heart failure). (2013) (81)
Age and outcome after acute coronary syndromes without persistent ST-segment elevation. (2000) (81)
Depression and ischemic heart disease: what have we learned so far and what must we do in the future? (2005) (81)
Prognostic significance of ST segment shift early after resolution of ST elevation in patients with myocardial infarction treated with thrombolytic therapy: the GUSTO-I ST Segment Monitoring Substudy. (1998) (80)
Acute coronary syndromes in the GUSTO-IIb trial: prognostic insights and impact of recurrent ischemia. The GUSTO-IIb Investigators. (1998) (80)
Emerging Research Directions in Adult Congenital Heart Disease: A Report From an NHLBI/ACHA Working Group. (2016) (80)
ST2 and mortality in non-ST-segment elevation acute coronary syndrome. (2010) (80)
Resource use and cost of initial coronary revascularization. Coronary angioplasty versus coronary bypass surgery. (1990) (80)
Risk factors for in-hospital nonhemorrhagic stroke in patients with acute myocardial infarction treated with thrombolysis: results from GUSTO-I. (1998) (80)
Effectiveness of early coronary angioplasty and abciximab for failed thrombolysis (reteplase or alteplase) during acute myocardial infarction (results from the GUSTO-III trial). Global Use of Strategies To Open occluded coronary arteries. (1999) (80)
Stroke in patients with acute coronary syndromes: incidence and outcomes in the platelet glycoprotein IIb/IIIa in unstable angina. Receptor suppression using integrilin therapy (PURSUIT) trial. The PURSUIT Investigators. (1999) (79)
Extent of ST-segment depression and cardiac events in non-ST-segment elevation acute coronary syndromes. (2005) (79)
A subgroup analysis of the impact of prerandomization antithrombin therapy on outcomes in the SYNERGY trial: enoxaparin versus unfractionated heparin in non-ST-segment elevation acute coronary syndromes. (2006) (79)
Women's Ischemic Syndrome Evaluation: current status and future research directions: report of the National Heart, Lung and Blood Institute workshop: October 2-4, 2002: Section 3: diagnosis and treatment of acute cardiac ischemia: gender issues. (2004) (78)
Principles From Clinical Trials Relevant to Clinical Practice: Part II (2002) (78)
Role of diuretics, β blockers, and statins in increasing the risk of diabetes in patients with impaired glucose tolerance: reanalysis of data from the NAVIGATOR study (2013) (78)
Accelerated plasminogen activator dose regimens for coronary thrombolysis. The TAMI-7 Study Group. (1992) (78)
Localizing coronary artery obstructions with the exercise treadmill test. (1987) (77)
Noninvasive assessment of speed and stability of infarct-related artery reperfusion: results of the GUSTO ST segment monitoring study. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. (1995) (77)
Predicting outcome after thrombolysis in acute myocardial infarction according to ST-segment resolution at 90 minutes: a substudy of the GUSTO-III trial. Global Use of Strategies To Open occluded coronary arteries. (2002) (77)
Safety and antiplatelet effect of murine monoclonal antibody 7E3 Fab directed against platelet glycoprotein llb/llla in patients undergoing elective coronary angioplasty (1993) (76)
Intravenous recombinant tissue-type plasminogen activator in patients with unstable angina pectoris. Results of a placebo-controlled, randomized trial. (1990) (76)
Management of Patients With Acute Coronary Syndromes in the United States by Platelet Glycoprotein IIb/IIIa Inhibition: Insights From the Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) Trial (2000) (76)
Predictors and prognostic impact of recurrent myocardial infarction in patients with left ventricular dysfunction, heart failure, or both following a first myocardial infarction (2011) (76)
Early statin initiation and outcomes in patients with acute coronary syndromes. (2002) (76)
Prognostic significance of precordial ST segment depression during inferior myocardial infarction in the thrombolytic era: results in 16,521 patients. (1996) (76)
Clinical predictors of early infarct-related artery patency following thrombolytic therapy: importance of body weight, smoking history, infarct-related artery and choice of thrombolytic regimen: the GUSTO-I experience. Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries. (1998) (75)
Frequency and clinical outcome of cardiogenic shock during acute myocardial infarction among patients receiving reteplase or alteplase Results from GUSTO-III (1999) (75)
The cost of acute myocardial infarction in the new millennium: evidence from a multinational registry. (2006) (75)
Renal function, concomitant medication use and outcomes following acute coronary syndromes. (2005) (75)
International differences in evolution of early discharge after acute myocardial infarction (2004) (74)
Association between bleeding, blood transfusion, and costs among patients with non-ST-segment elevation acute coronary syndromes. (2008) (74)
Bivalirudin in patients with heparin-induced thrombocytopenia undergoing percutaneous coronary intervention. (2000) (74)
Comparison of cardiac troponin T versus creatine kinase-MB for risk stratification in a chest pain evaluation unit. (2000) (74)
A pooled analysis of coronary arterial patency and left ventricular function after intravenous thrombolysis for acute myocardial infarction. (1994) (74)
Painless exercise ST deviation on the treadmill: long-term prognosis. (1989) (74)
Implantable cardioverter defibrillators and cardiac resynchronization therapy in patients with left ventricular dysfunction: randomized trial evidence through 2004. (2005) (73)
Diagnostic and prognostic significance of minimally elevated creatine kinase-MB in suspected acute myocardial infarction. (1985) (73)
A secondary analysis of the CHOIR trial shows that comorbid conditions differentially affect outcomes during anemia treatment. (2010) (73)
Influence of diabetes mellitus on clinical outcomes across the spectrum of acute coronary syndromes. Findings from the GUSTO-IIb study. GUSTO IIb Investigators. (2000) (73)
Effect of Antecedent Hypertension and Follow-Up Blood Pressure on Outcomes After High-Risk Myocardial Infarction (2008) (73)
Thrombin generation, inhibition and clinical outcomes in patients with acute myocardial infarction treated with thrombolytic therapy and heparin: results from the GUSTO-I Trial. GUSTO-I Hemostasis Substudy Group. Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries. (1998) (73)
Modifiable Risk Factors for Vascular Access Site Complications in the IMPACT II Trial of Angioplasty With Versus Without Eptifibatide (1998) (73)
Cardiovascular disease and chronic kidney disease: insights and an update. (2004) (72)
Design of the blockade of the glycoprotein IIb/IIIa receptor to avoid vascular occlusion (BRAVO) trial. (2000) (72)
Long-Term Mortality of Patients With Acute Myocardial Infarction in the United States and Canada: Comparison of Patients Enrolled in Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO)-I (2004) (72)
Potential impact of evidence-based medicine in acute coronary syndromes: insights from GUSTO-IIb. Global Use of Strategies to Open Occluded Arteries in Acute Coronary Syndromes trial. (1998) (72)
Tying clinical research to patient care by use of an observational database. (1984) (71)
Comprehensive cardiovascular medicine (1998) (71)
Clinical pharmacology of higher dose eptifibatide in percutaneous coronary intervention (the PRIDE study). (2001) (71)
Coronary bypass surgery in chronic stable angina. (1989) (71)
ACCF / AHA Focused Update 2012 ACCF / AHA Focused Update of the Guideline for the Management of Patients With Unstable Angina / Non – ST-Elevation Myocardial Infarction ( Updating the 2007 Guideline and Replacing the 2011 Focused Update ) (2012) (71)
Precordial ST segment depression predicts a worse prognosis in inferior infarction despite reperfusion therapy. The Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) Study Group. (1990) (71)
Regional and practice variation in adherence to guideline recommendations for secondary and primary prevention among outpatients with atherothrombosis or risk factors in the United States: a report from the REACH Registry. (2009) (71)
ACCF/AHA Focused Update 2011 ACCF/AHA Focused Update of the Guidelines for the Management of Patients With Unstable Angina/ Non–ST-Elevation Myocardial Infarction (2011) (71)
Systematic adjudication of myocardial infarction end-points in an international clinical trial (2001) (70)
Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) trial. (1987) (70)
Changing the model of care for patients with acute coronary syndromes. (2003) (70)
Geographic health information systems: a platform to support the 'triple aim'. (2013) (70)
An independently derived and validated predictive model for selecting patients with myocardial infarction who are likely to benefit from tissue plasminogen activator compared with streptokinase. (2002) (70)
Diuretic response in acute heart failure-an analysis from ASCEND-HF. (2015) (70)
Survival Outcomes 1 Year After Reperfusion Therapy With Either Alteplase or Reteplase for Acute Myocardial Infarction: Results From the Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO) III Trial (2000) (70)
High-risk patients with acute coronary syndromes treated with low-molecular-weight or unfractionated heparin: outcomes at 6 months and 1 year in the SYNERGY trial. (2005) (69)
Hemodynamic profiles of advanced heart failure: association with clinical characteristics and long-term outcomes. (2001) (69)
Relation of temporal creatine kinase-MB release and outcome after thrombolytic therapy for acute myocardial infarction. TAMI Study Group. (2000) (69)
Reengineering the National Clinical and Translational Research Enterprise: The Strategic Plan of the National Clinical and Translational Science Awards Consortium (2010) (68)
Association of depression and survival in patients with chronic heart failure over 12 Years. (2012) (68)
Insights derived from the thrombolysis and angioplasty in myocardial infarction (TAMI) trials. (1988) (68)
A review of dyspnea in acute heart failure syndromes. (2010) (67)
Predicting the risk of abrupt vessel closure after angioplasty in an individual patient. (1994) (67)
Sustained ventricular arrhythmias and mortality among patients with acute myocardial infarction: results from the GUSTO-III trial. (2003) (67)
Medical, psychological and social correlates of work disability among men with coronary artery disease. (1986) (67)
Sustained Ventricular Tachycardia and Ventricular Fibrillation Complicating Non–ST-Segment–Elevation Acute Coronary Syndromes (2012) (66)
Clinical outcomes after detection of elevated cardiac enzymes in patients undergoing percutaneous intervention. IMPACT-II Investigators. Integrilin (eptifibatide) to Minimize Platelet Aggregation and Coronary Thrombosis-II. (1999) (66)
Support for the open-artery hypothesis in survivors of acute myocardial infarction: analysis of 11,228 patients treated with thrombolytic therapy. (1999) (66)
Is the Extrapolated Adult Dose of Fosinopril Safe and Effective in Treating Hypertensive Children? (2004) (66)
Prevalence, characteristics, and predictors of early termination of cardiovascular clinical trials due to low recruitment: insights from the ClinicalTrials.gov registry. (2014) (66)
Restenosis: the cost to society. (1995) (66)
Non-Q-wave versus Q-wave myocardial infarction after thrombolytic therapy: angiographic and prognostic insights from the global utilization of streptokinase and tissue plasminogen activator for occluded coronary arteries-I angiographic substudy. GUSTO-I Angiographic Investigators. (1998) (66)
Identification of Comatose Patients at High Risk for Death or Severe Disability (1995) (65)
Comparison of two dose regimens of intravenous tissue plasminogen activator for acute myocardial infarction. (1988) (65)
Correlation between Baseline Plasminogen Activator Inhibitor Levels and Clinical Outcome during Therapy with Tissue Plasminogen Activator for Acute Myocardial Infarction (1991) (65)
The prognosis for patients with new-onset angina who have undergone cardiac catheterization. (1983) (65)
Misreporting of myocardial infarction end points: results of adjudication by a central clinical events committee in the PARAGON-B trial. Second Platelet IIb/IIIa Antagonist for the Reduction of Acute Coronary Syndrome Events in a Global Organization Network Trial. (2002) (64)
Consistency of Financial Interest Disclosures in the Biomedical Literature: The Case of Coronary Stents (2008) (64)
Beyond randomized clinical trials: applying clinical experience in the treatment of patients with coronary artery disease. (1986) (64)
Vein graft preservation solutions, patency, and outcomes after coronary artery bypass graft surgery: follow-up from the PREVENT IV randomized clinical trial. (2014) (64)
Trends in physician management of uncomplicated acute myocardial infarction, 1970 to 1987. (1988) (64)
Atrial Fibrillation in the Setting of Acute Myocardial Infarction: The GUSTO-I Experience fn1 (1997) (64)
Underuse of aspirin in a referral population with documented coronary artery disease. (2002) (64)
Utility of Socioeconomic Status in Predicting 30-Day Outcomes After Heart Failure Hospitalization (2015) (63)
Effect of Simvastatin-Ezetimibe Compared With Simvastatin Monotherapy After Acute Coronary Syndrome Among Patients 75 Years or Older: A Secondary Analysis of a Randomized Clinical Trial. (2019) (63)
Early reinfarction after fibrinolysis: experience from the global utilization of streptokinase and tissue plasminogen activator (alteplase) for occluded coronary arteries (GUSTO I) and global use of strategies to open occluded coronary arteries (GUSTO III) trials. (2001) (63)
Identification of Acute Myocardial Infarction Patients Suitable for Early Hospital Discharge After Aggressive Interventional Therapy: Results From the Thrombolysis and Angioplasty in Acute Myocardial Infarction Registry (1991) (63)
Changing the diagnosis of acute myocardial infarction: implications for practice and clinical investigations. (2002) (63)
Enhanced Efficacy of Eptifibatide Administration in Patients With Acute Coronary Syndrome Requiring In-Hospital Coronary Artery Bypass Grafting (2000) (63)
Systolic Left Ventricular Function After Reperfusion Therapy for Acute Myocardial Infarction An Analysis of Determinants of Improvement (1993) (62)
Adoption of thrombolytic therapy in the management of acute myocardial infarction. (1988) (62)
Safety and transparency of pediatric drug trials. (2009) (62)
Increased risk of non-Q wave myocardial infarction after directional atherectomy is platelet dependent: evidence from the EPIC trial. Evaluation of c7E3 for the Prevention of Ischemic Complications. (1996) (61)
Clinical experience and predicting survival in coronary disease. (1989) (61)
Antiarrhythmic drug therapy for sustained ventricular arrhythmias complicating acute myocardial infarction* (2009) (61)
Geographic variability in outcomes within an international trial of glycoprotein IIb/IIIa inhibition in patients with acute coronary syndromes. Results from PURSUIT. (2000) (61)
Current use of aspirin and antithrombotic agents in the United States among outpatients with atherothrombotic disease (from the REduction of Atherothrombosis for Continued Health [REACH] Registry). (2010) (61)
Impact of perioperative myocardial infarction on angiographic and clinical outcomes following coronary artery bypass grafting (from PRoject of Ex-vivo Vein graft ENgineering via Transfection [PREVENT] IV). (2008) (61)
Clinical Outcomes With Rivaroxaban in Patients Transitioned From Vitamin K Antagonist Therapy (2013) (61)
The left bundle-branch block puzzle in the 2013 ST-elevation myocardial infarction guideline: from falsely declaring emergency to denying reperfusion in a high-risk population. Are the Sgarbossa Criteria ready for prime time? (2013) (60)
Economic impact of drug-eluting stents on hospital systems: a disease-state model. (2004) (60)
Effects of Coronary Angioplasty, Coronary Bypass Surgery, and Medical Therapy on Employment in Patients with Coronary Artery Disease: A Prospective Comparison Study (1994) (60)
Prophylactic lidocaine use in acute myocardial infarction: incidence and outcomes from two international trials. The GUSTO-I and GUSTO-IIb Investigators. (1999) (60)
Clinical importance of thrombocytopenia occurring in the hospital phase after administration of thrombolytic therapy for acute myocardial infarction. The Thrombolysis and Angioplasty in Myocardial Infarction Study Group. (1994) (60)
The changing survival benefits of coronary revascularization over time. (1987) (60)
Identification of the optimal electrocardiographic leads for detecting acute epicardial injury in acute myocardial infarction. (1987) (60)
A historical perspective on clinical trials innovation and leadership: where have the academics gone? (2011) (60)
Outcomes of Patients With Acute Coronary Syndromes and Prior Coronary Artery Bypass Grafting: Results From the Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) Trial (2002) (59)
Differences in the clinical features and outcomes in African Americans and whites with myocardial infarction. (2006) (59)
The prognostic value of creatine kinase elevations extends across the whole spectrum of acute coronary syndromes. (2002) (59)
Toward protecting the safety of participants in clinical trials. (2003) (59)
Outcomes among non-ST-segment elevation acute coronary syndromes patients with no angiographically obstructive coronary artery disease: observations from 37,101 patients (2014) (59)
Parenteral Anticoagulation with the Heparinoid Lomoparan (Org 10172) in Patients with Heparin Induced Thrombocytopenia and Thrombosis (1992) (59)
Pulmonary artery catheterization in acute coronary syndromes: Insights from the GUSTO IIb and GUSTO III trials (2005) (59)
Long‐Term Protection from Myocardial Ischemic Events in a Randomized Trial of Brief Integrin β3 Blockade with Percutaneous Coronary Intervention (1998) (58)
Long-term survival from acute myocardial infarction: salutary effect of an open coronary vessel. (1990) (58)
High mortality without ESCAPE: the registry of heart failure patients receiving pulmonary artery catheters without randomization. (2008) (58)
Elevated body mass index and intermediate-term clinical outcomes after acute coronary syndromes. (2005) (57)
Rationale and strategies for implementing community-based transfer protocols for primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction. (2004) (57)
Exercise treadmill testing is a poor predictor of anatomic restenosis after angioplasty for acute myocardial infarction. (1989) (57)
Prognostic value of the simplified Selvester QRS score in patients with coronary artery disease. (1988) (57)
Confronting the issues of patient safety and investigator conflict of interest in an international clinical trial of myocardial reperfusion. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO) Steering Committee. (1992) (57)
Prediction of 30-day mortality among patients with thrombolysis-related intracranial hemorrhage. (1998) (57)
Rural-Urban Differences in Cardiovascular Mortality in the US, 1999-2017. (2020) (57)
Time to Coronary Angiography and Outcomes Among Patients With High-Risk Non–ST-Segment–Elevation Acute Coronary Syndromes: Results From the SYNERGY Trial (2007) (57)
Impact of recovery of renal function on long-term mortality after coronary artery bypass grafting. (2010) (57)
Thrombolytic therapy for elderly patients. (1992) (57)
Risk of stroke associated with abciximab among patients undergoing percutaneous coronary intervention. (2001) (56)
High-sensitivity C-reactive protein in acute heart failure: insights from the ASCEND-HF trial. (2014) (56)
Patterns of transfer for patients with non-ST-segment elevation acute coronary syndrome from community to tertiary care hospitals. (2008) (56)
Prevalence, predictors, and impact of conservative medical management for patients with non-ST-segment elevation acute coronary syndromes who have angiographically documented significant coronary disease. (2008) (56)
A meta-analysis of randomized trials of calcium antagonists to reduce restenosis after coronary angioplasty. (1994) (56)
Attained Educational Level and Incident Atherothrombotic Events in Low- and Middle-Income Compared With High-Income Countries (2010) (56)
Relation of mortality to failure to prescribe beta blockers acutely in patients with sustained ventricular tachycardia and ventricular fibrillation following acute myocardial infarction (from the VALsartan In Acute myocardial iNfarcTion trial [VALIANT] Registry). (2008) (56)
Addressing barriers to optimal oral anticoagulation use and persistence among patients with atrial fibrillation: Proceedings, Washington, DC, December 3-4, 2012. (2014) (56)
Patients with acute coronary syndromes without persistent ST elevation undergoing percutaneous coronary intervention benefit most from early intervention with protection by a glycoprotein IIb/IIIa receptor blocker. (2002) (55)
Time-based risk assessment after myocardial infarction. Implications for timing of discharge and applications to medical decision-making. (2003) (55)
Canadian-American Differences in the Management of Acute Coronary Syndromes in the GUSTO IIb Trial: One-Year Follow-Up of Patients Without ST-Segment Elevation (2000) (55)
Helicopter transport of patients during acute myocardial infarction. (1988) (55)
Risk of intracranial haemorrhage with combined fibrinolytic and glycoprotein IIb/IIIa inhibitor therapy in acute myocardial infarction. Dichotomous response as a function of age in the GUSTO V trial. (2003) (55)
Antithrombotics in acute coronary syndromes. (2009) (55)
Improving the health of the community: Duke's experience with community engagement. (2008) (55)
Significance of atrial fibrillation during acute myocardial infarction, and its current management: insights from the GUSTO-3 trial. (2003) (55)
Association of diabetes mellitus and glycemic control strategies with clinical outcomes after acute coronary syndromes. (2004) (55)
Rethinking sensitivity and specificity. (1987) (54)
Low-molecular-weight heparins in non-ST-segment elevation ischemia: the ESSENCE trial. Efficacy and Safety of Subcutaneous Enoxaparin versus intravenous unfractionated heparin, in non-Q-wave Coronary Events. (1998) (54)
Multinational economic evaluation of valsartan in patients with chronic heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT). (2004) (54)
DIURETIC RESPONSE IN ACUTE HEART FAILURE: AN ANALYSIS FROM ASCEND-HF (2015) (54)
Comparison of continuous ST-segment recovery analysis with methods using static electrocardiograms for noninvasive patency assessment during acute myocardial infarction. Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) 7 Study Group. (1994) (54)
Testing new targets of therapy in advanced heart failure: the design and rationale of the Strategies for Tailoring Advanced Heart Failure Regimens in the Outpatient Setting: BRain NatrIuretic Peptide Versus the Clinical CongesTion ScorE (STARBRITE) trial. (2005) (54)
Dynamic prognostication in non-ST-elevation acute coronary syndromes: insights from GUSTO-IIb and PURSUIT. (2004) (53)
Predictors of clinical outcomes in acute decompensated heart failure: Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure outcome models. (2015) (53)
Prediction of One-Year Survival in High-Risk Patients with Acute Coronary Syndromes: Results from the SYNERGY Trial (2008) (53)
Relation of Increased Arterial Blood Pressure to Mortality and Stroke in the Context of Contemporary Thrombolytic Therapy for Acute Myocardial Infarction (1996) (53)
Perspectives on large-scale cardiovascular clinical trials for the new millennium. The Virtual Coordinating Center for Global Collaborative Cardiovascular Research (VIGOUR) Group. (1997) (53)
Sensible guidelines for the conduct of large randomized trials (2008) (53)
Enoxaparin versus unfractionated heparin in patients treated with tirofiban, aspirin and an early conservative initial management strategy: results from the A phase of the A-to-Z trial. (2004) (53)
Principles from clinical trials relevant to clinical practice: Part I. (2002) (52)
Dissociation between hemodynamic changes and symptom improvement in patients with advanced congestive heart failure (2002) (51)
Clinical and research issues regarding chronic advanced coronary artery disease part II: Trial design, outcomes, and regulatory issues. (2008) (51)
The inter‐relationship of diabetes and left ventricular systolic function on outcome after high‐risk myocardial infarction (2010) (51)
Aspirin dose and six-month outcome after an acute coronary syndrome. (2004) (51)
Myocardial infarction with minimal coronary atherosclerosis in the era of thrombolytic reperfusion. The Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) Study Group. (1991) (51)
Obesity in patients with non-ST-segment elevation acute coronary syndromes: results from the SYNERGY trial. (2010) (51)
The PRoject of Ex-vivo Vein graft ENgineering via Transfection IV (PREVENT IV) trial: study rationale, design, and baseline patient characteristics. (2005) (51)
Acute Coronary Care In The Thrombolytic Era (1995) (50)
Cardiogenic shock. (1994) (50)
Accelerating development of scientific evidence for medical products within the existing US regulatory framework (2017) (50)
Association Between Platelet Receptor Occupancy After Eptifibatide (Integrilin) Therapy and Patency, Myocardial Perfusion, and ST-Segment Resolution Among Patients With ST-Segment–Elevation Myocardial Infarction: An INTEGRITI (Integrilin and Tenecteplase in Acute Myocardial Infarction) Substudy (2004) (50)
Estimated glomerular filtration rate, inflammation, and cardiovascular events after an acute coronary syndrome. (2008) (50)
Preventing tomorrow's sudden cardiac death today: part I: Current data on risk stratification for sudden cardiac death. (2007) (50)
Major clinical trials of hypertension: what should be done next? (2005) (50)
Predictors of sudden cardiac death change with time after myocardial infarction: results from the VALIANT trial. (2008) (50)
A rapid troponin I assay is not optimal for determination of troponin status and prediction of subsequent cardiac events at suspicion of unstable coronary syndromes. (2004) (50)
Prognostic significance of isolated sinus tachycardia during first three days of acute myocardial infarction. (1984) (49)
Impact of Diabetes Mellitus on Percutaneous Revascularization (CAVEAT-I) (1997) (49)
Abstract 148: Efficacy and Safety of Rivaroxaban Compared with Warfarin Among Elderly Patients with Nonvalvular Atrial Fibrillation in the ROCKET-AF Trial (2012) (49)
Acute Coronary Care (1985) (49)
Metabolic syndrome: evaluation of pathological and therapeutic outcomes. (2005) (48)
Relationship of the Time Interval Between Cardiac Catheterization and Elective Coronary Artery Bypass Surgery With Postprocedural Acute Kidney Injury (2011) (48)
Cardiac tamponade in the fibrinolytic era: analysis of >100,000 patients with ST-segment elevation myocardial infarction. (2006) (48)
Redefining medical treatment in the management of unstable angina. (2011) (48)
Predictors of early dyspnoea relief in acute heart failure and the association with 30‐day outcomes: findings from ASCEND‐HF (2013) (48)
Lack of usefulness of prolonged bleeding times in predicting hemorrhagic events in patients receiving the 7E3 glycoprotein IIb/IIIa platelet antibody. The TAMI Study Group. (1993) (48)
Diets and clinical coronary events: the truth is out there. (2003) (48)
Lessons we have learned from the GUSTO trial. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries. (1995) (48)
Assessment of coronary reperfusion after thrombolysis with a model combining myoglobin, creatine kinase-MB, and clinical variables. TAMI-7 Study Group. Thrombolysis and Angioplasty in Myocardial Infarction-7. (1997) (48)
Statin Use and Sex-Specific Stroke Outcomes in Patients With Vascular Disease (2006) (48)
Promise of combined low-molecular-weight heparin and platelet glycoprotein IIb/IIIa inhibition: results from Platelet IIb/IIIa Antagonist for the Reduction of Acute coronary syndrome events in a Global Organization Network B (PARAGON B). (2002) (48)
Engaging Patients Across the Spectrum of Medical Product Development: View From the US Food and Drug Administration. (2015) (47)
Racial differences in the characteristics of patients admitted for acute decompensated heart failure and their relation to outcomes: results from the OPTIME-CHF trial. (2006) (47)
Clinical judgment and therapeutic decision making. (1990) (47)
Linking Scientific Discovery and Better Health for the Nation: The First Three Years of the NIH's Clinical and Translational Science Awards (2010) (47)
Patients with prior coronary artery bypass grafting have a poor outcome after myocardial infarction: an analysis of the VALsartan in acute myocardial iNfarcTion trial (VALIANT). (2009) (47)
Timing of and risk factors for myocardial ischemic events after percutaneous coronary intervention (IMPACT-II). Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis. (2000) (47)
Thrombolytic therapy for acute myocardial infarction. A review . (1992) (47)
Participation of Nurses in Decision Making for Seriously III Adults (1996) (46)
End of Study Transition From Study Drug to Open-Label Vitamin K Antagonist Therapy: The ROCKET AF Experience (2013) (46)
Problems and Advantages of an Observational Data Base Approach to Evaluating the Effect of Therapy on Outcome (1982) (46)
The impact of anthropomorphic indices on clinical outcomes in patients with acute ST-elevation myocardial infarction. (2007) (46)
Rationale and design of the OPTIME CHF trial: outcomes of a prospective trial of intravenous milrinone for exacerbations of chronic heart failure. (2000) (46)
Does intracoronary thrombus influence the outcome of high risk percutaneous transluminal coronary angioplasty? Clinical and angiographic outcomes in a large multicenter trial. EPIC Investigators. Evaluation of IIb/IIIa Platelet Receptor Antagonist 7E3 in Preventing Ischemic Complications. (1998) (46)
Atrioventricular and Intraventricular Conduction Disorders in Acute Myocardial Infarction: A Reappraisal in the Thrombolytic Era (1998) (46)
Ethnic differences in the prevalence and treatment of cardiovascular risk factors in US outpatients with peripheral arterial disease: insights from the reduction of atherothrombosis for continued health (REACH) registry. (2009) (46)
Outcomes in elderly patients with acute coronary syndromes randomized to enoxaparin vs. unfractionated heparin: results from the SYNERGY trial. (2008) (46)
Predictors of death and reinfarction at 30 days after primary angioplasty: the GUSTO IIb and RAPPORT trials. (2000) (46)
Sex differences in clinical characteristics and outcomes after myocardial infarction: insights from the Valsartan in Acute Myocardial Infarction Trial (VALIANT) (2015) (46)
Rivaroxaban, an oral direct factor Xa inhibitor. (2008) (46)
Transforming Psychiatry into Data-Driven Medicine with Digital Measurement Tools (2018) (46)
Functional status among survivors of in-hospital cardiopulmonary resuscitation. SUPPORT Investigators Study to Understand Progress and Preferences for Outcomes and Risks of Treatment. (1997) (46)
Chronic ischemic heart disease. (2000) (46)
Emergency coronary artery bypass surgery preserves global and regional left ventricular function after intravenous tissue plasminogen activator therapy for acute myocardial infarction. (1988) (46)
Rescuing clinical trials in the United States and beyond: a call for action. (2013) (45)
Effects of physical conditioning on left ventricular ejection fraction in patients with coronary artery disease. (1984) (45)
Management and outcome of patients with atrial fibrillation during acute myocardial infarction: the GUSTO-III experience (2002) (45)
Sex-specific differences in coronary artery disease risk factors, evaluation, and treatment: have they been adequately evaluated? (1996) (45)
Grade III Ischemia on Presentation with Acute Myocardial Infarction Predicts Rapid Progression of Necrosis and Less Myocardial Salvage with Thrombolysis (2002) (45)
Outcome of acute ST-segment elevation myocardial infarction in patients with prior coronary artery bypass surgery receiving thrombolytic therapy. (2001) (45)
Predictors of cardiovascular events in a contemporary population with impaired glucose tolerance: an observational analysis of the Nateglinide and Valsartan in impaired glucose tolerance outcomes research (NAVIGATOR) trial (2012) (45)
Refining clinical trial composite outcomes: an application to the Assessment of the Safety and Efficacy of a New Thrombolytic-3 (ASSENT-3) trial. (2011) (45)
The Child and Adolescent Psychiatry Trials Network (CAPTN). (2004) (45)
Extended mortality benefit of early postinfarction reperfusion. GUSTO-I Angiographic Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries Trial. (1998) (44)
Use and outcomes of antiarrhythmic therapy in patients with atrial fibrillation receiving oral anticoagulation: results from the ROCKET AF trial. (2014) (44)
Regional Patterns of Use of a Medical Management Strategy for Patients With Non–ST-Segment Elevation Acute Coronary Syndromes: Insights From the EARLY ACS Trial (2012) (44)
Upstream Clopidogrel Use and the Efficacy and Safety of Early Eptifibatide Treatment in Patients With Acute Coronary Syndrome: An Analysis From the Early Glycoprotein IIb/IIIa Inhibition in Patients With Non–ST-Segment Elevation Acute Coronary Syndrome (EARLY ACS) Trial (2011) (44)
Incremental prognostic power of single-photon emission computed tomographic myocardial perfusion imaging in patients with known or suspected coronary artery disease. (2005) (44)
Return of Research Results to Study Participants: Uncharted and Untested (2018) (44)
Coronary Revascularization in Diabetic Patients (1999) (44)
Initial Aspirin Dose and Outcome Among ST-Elevation Myocardial Infarction Patients Treated With Fibrinolytic Therapy (2008) (44)
Outcomes of patients in clinical trials with ST-segment elevation myocardial infarction among countries with different gross national incomes. (2006) (44)
Relationship of extent of revascularization with angina at one year in the Bypass Angioplasty Revascularization Investigation (BARI). (1999) (43)
Correlates of survival in patients with postinfarction ventricular septal defect (1989) (43)
Edifoligide and long-term outcomes after coronary artery bypass grafting: PRoject of Ex-vivo Vein graft ENgineering via Transfection IV (PREVENT IV) 5-year results. (2012) (43)
Feasibility and cost-saving potential of outpatient cardiac catheterization. (1990) (43)
Usefulness of biomarkers for predicting long-term mortality in patients with diabetes mellitus and non-ST-elevation acute coronary syndromes (a GUSTO IV substudy). (2006) (43)
International variation in the use of evidence-based medicines for acute coronary syndromes. (2003) (43)
Impediments to Clinical Research in the United States (2012) (43)
Performance measures have a major effect on cardiovascular outcomes: a review. (2007) (43)
Outpatient prescribing of antiarrhythmic drugs from 1995 to 2000. (2003) (42)
Clinical Characteristics and Current Management of Medically Refractory Unstable Angina (1984) (42)
Ethical and regulatory issues of pragmatic cluster randomized trials in contemporary health systems (2015) (42)
Early Reinfarction After Fibrinolysis: Experience From the Global Utilization of Streptokinase and Tissue Plasminogen Activator (Alteplase) for Occluded Coronary Arteries (GUSTO I) and Global Use of Strategies To Open Occluded Coronary Arteries (GUSTO III) Trials (2001) (42)
Clinical Trials in Peripheral Vascular Disease: Pipeline and Trial Designs An Evaluation of the ClinicalTrials.gov Database (2012) (42)
Secondary Prevention of Coronary Heart Disease (1982) (42)
Effect of hemoglobin target on progression of kidney disease: a secondary analysis of the CHOIR (Correction of Hemoglobin and Outcomes in Renal Insufficiency) trial. (2012) (42)
Hypotension During Hospitalization for Acute Heart Failure Is Independently Associated With 30-Day Mortality: Findings From ASCEND-HF (2014) (42)
Cardiac troponin after percutaneous coronary intervention and 1-year mortality in non-ST-segment elevation acute coronary syndrome using systematic evaluation of biomarker trends. (2013) (41)
Postmarket evaluation of breakthrough technologies. (2008) (41)
Holding GUSTO Up to the Light (1994) (41)
American industry and the U.S. Cardiovascular Clinical Research Enterprise an appropriate analogy? (2011) (41)
Patterns of management of atrial fibrillation complicating coronary artery bypass grafting: Results from the PRoject of Ex-vivo Vein graft ENgineering via Transfection IV (PREVENT-IV) Trial. (2009) (41)
Fatal myocardial rupture after acute myocardial infarction complicated by heart failure, left ventricular dysfunction, or both: the VALsartan In Acute myocardial iNfarcTion Trial (VALIANT). (2010) (41)
Rapid assay brain natriuretic peptide and troponin I in patients hospitalized with decompensated heart failure (from the Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness Trial). (2007) (41)
Outcomes and costs within a disease management program for advanced congestive heart failure. (1998) (41)
Neurosurgical evacuation of intracranial hemorrhage after thrombolytic therapy for acute myocardial infarction: experience from the GUSTO-I trial. Global Utilization of Streptokinase and tissue-plasminogen activator (tPA) for Occluded Coronary Arteries. (1999) (41)
A comparison of U.S. and Canadian cardiac catheterization practices in detecting severe coronary artery disease after myocardial infarction: efficiency, yield and long-term implications. (1999) (41)
High predictive accuracy of an unbiased proteomic profile for sustained virologic response in chronic hepatitis C patients (2011) (41)
Seeking the optimal aspirin dose in acute coronary syndromes. (2002) (41)
Usefulness of a pericardial friction rub after thrombolytic therapy during acute myocardial infarction in predicting amount of myocardial damage. The TAMI Study Group. (1990) (40)
The Determinants of Activated Partial Thromboplastin Time, Relation of Activated Partial Thromboplastin Time to Clinical Outcomes, and Optimal Dosing Regimens for Heparin Treated Patients with Acute Coronary Syndromes: A Review of GUSTO-IIb (2002) (40)
A simplified method to predict occurrence of complete heart block during acute myocardial infarction (1986) (40)
Economic effects of beta-blocker therapy in patients with heart failure. (2004) (40)
Clinical and Therapeutic Profile of Patients Presenting With Acute Coronary Syndromes Who Do Not Have Significant Coronary Artery Disease (2000) (40)
Regional, age and sex differences in baseline characteristics of patients enrolled in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) (2015) (40)
Dose-finding, safety, and tolerability study of an oral platelet glycoprotein IIb/IIIa inhibitor, lotrafiban, in patients with coronary or cerebral atherosclerotic disease. (2000) (40)
Is rhythm control superior to rate control in patients with atrial fibrillation and congestive heart failure? (2004) (40)
Variation in patient management and outcomes for acute coronary syndromes in Latin America and North America: results from the Platelet IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) trial. (2001) (40)
Atrial fibrillation and mortality among patients with acute coronary syndromes without ST-segment elevation: results from the PURSUIT trial. (2001) (40)
Diabetes mellitus and outcome after primary coronary angioplasty for acute myocardial infarction: lessons from the GUSTO-IIb Angioplasty Substudy. Global Use of Strategies to Open Occluded Arteries in Acute Coronary Syndromes. (2000) (40)
Need for Centers to Care for Patients With Acute Coronary Syndromes (2003) (40)
Lack of progress in cardiogenic shock: lessons from the GUSTO trials (2000) (40)
Thrombolysis and Q wave versus non-Q wave first acute myocardial infarction: a GUSTO-I substudy. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries Investigators. (1997) (40)
Abstract 19281: Outcomes Following Cardioversion and Atrial Fibrillation Ablation in Patients Treated with Rivaroxaban and Warfarin in the ROCKET AF Trial (2012) (40)
Comparison of outcomes of patients with myocardial infarction when living alone versus those not living alone. (2002) (40)
Safety Monitoring of Drugs Receiving Pediatric Marketing Exclusivity (2008) (40)
Association of mortality with years of education in patients with ST-segment elevation myocardial infarction treated with fibrinolysis. (2011) (39)
Randomized Trials Versus Common Sense and Clinical Observation (2020) (39)
Predictors of 90-day outcome in patients stabilized after acute coronary syndromes. (2003) (39)
Randomized trials of directional coronary atherectomy: implications for clinical practice and future investigation. (1994) (39)
Changing efficacy of coronary revascularization. Implications for patient selection. (1988) (39)
Operator-specific outcomes. A call to professional responsibility. (1996) (39)
Determining the most appropriate components for a composite clinical trial outcome. (2008) (38)
The failure of orally administered glycoprotein IIb/IIIa inhibitors to prevent recurrent cardiac events. (2002) (38)
Knowledge Deficits Related to the QT Interval Could Affect Patient Safety (2003) (38)
Racial Differences in Blood Pressure Response to Angiotensin‐Converting Enzyme Inhibitors in Children: A Meta‐Analysis (2008) (38)
Prediction of early recurrent myocardial ischemia and coronary reocclusion after successful thrombolysis: a qualitative and quantitative angiographic study. (1989) (38)
Technology-Enabled Clinical Trials: Transforming Medical Evidence Generation. (2019) (38)
Outcomes of patients with acute coronary syndrome and previous coronary artery bypass grafting (from the Pravastatin or Atorvastatin Evaluation and Infection Therapy [PROVE IT-TIMI 22] and the Aggrastat to Zocor [A to Z] trials). (2008) (38)
Native valve disease in patients with non-valvular atrial fibrillation on warfarin or rivaroxaban (2016) (38)
Comparative assessment of short-term adverse events in acute heart failure with cystatin C and other estimates of renal function: results from the ASCEND-HF trial. (2015) (38)
Anticipated Ethics and Regulatory Challenges in PCORnet: The National Patient-Centered Clinical Research Network (2016) (38)
Selection of reperfusion therapy for individual patients with evolving myocardial infarction. (1997) (38)
Worsening heart failure during hospitalization for acute heart failure: Insights from the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure (ASCEND-HF). (2015) (38)
Assessment of dyspnea in acute decompensated heart failure: insights from ASCEND-HF (Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure) on the contributions of peak expiratory flow. (2012) (38)
Nesiritide, Renal Function, and Associated Outcomes During Hospitalization for Acute Decompensated Heart Failure: Results From the Acute Study of Clinical Effectiveness of Nesiritide and Decompensated Heart Failure (ASCEND-HF) (2014) (38)
Hemodynamics as surrogate end points for survival in advanced heart failure: an analysis from FIRST. (2001) (38)
Predictors of recurrent ischemic events and death in unstable coronary artery disease after treatment with combination antithrombotic therapy. (2000) (37)
Acquisition, Analysis, and Sharing of Data in 2015 and Beyond: A Survey of the Landscape (2015) (37)
Differential Treatment Benefit of Platelet Glycoprotein IIb/IIIa Inhibition With Percutaneous Coronary Intervention Versus Medical Therapy for Acute Coronary Syndromes: Exploration of Methods (2004) (37)
An analysis of the cause of early mortality after administration of thrombolytic therapy (1993) (37)
Differential Influence of Diabetes Mellitus on Increased Jeopardized Myocardium After Initial Angioplasty or Bypass Surgery: Bypass Angioplasty Revascularization Investigation (2002) (37)
Upstream Use of Small-Molecule Glycoprotein IIb/IIIa Inhibitors in Patients With Non–ST-Segment Elevation Acute Coronary Syndromes: A Systematic Overview of Randomized Clinical Trials (2011) (37)
Placebo-Controls in Short-Term Clinical Trials of Hypertension (2001) (37)
A survey of health care practitioners’ knowledge of the QT interval (2005) (37)
Safety and efficacy of abciximab combined with dalteparin in treatment of acute coronary syndromes. (2002) (37)
International variation in invasive care of the elderly with acute coronary syndromes. (2006) (37)
Frequency, significance, and cost of recurrent ischemia after thrombolytic therapy for acute myocardial infarction. TAMI Study Group. (1995) (37)
Rivaroxaban, an oral direct factor Xa inhibitor (2008) (37)
Frequency of stent thrombosis after acute coronary syndromes (from the SYMPHONY and 2nd SYMPHONY trials). (2003) (36)
Glycoprotein IIb/IIIa blockade and thrombolytics: early lessons from the SPEED and GUSTO IV trials. (1999) (36)
Therapeutic value of eptifibatide at community hospitals transferring patients to tertiary referral centers early after admission for acute coronary syndromes. PURSUIT Investigators. (2001) (36)
Weighing the Benefits and Risks of Proliferating Observational Treatment Assessments: Observational Cacophony, Randomized Harmony. (2020) (36)
Impact of Regulatory Guidance on Evaluating Cardiovascular Risk of New Glucose-Lowering Therapies to Treat Type 2 Diabetes Mellitus (2020) (36)
Prognostic importance of concomitant heparin with eptifibatide in acute coronary syndromes. PURSUIT Investigators. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy. (2001) (36)
Outcome of acute ST-segment elevation myocardial infarction in diabetics treated with fibrinolytic or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: lessons from the GUSTO V trial. (2004) (36)
Incidence and Predictors of Sudden Cardiac Death in Patients with Diastolic Heart Failure (2007) (36)
High-risk myocardial infarction in the young: the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial. (2008) (36)
Rationale and clinical evidence for the use of GP IIb/IIIa inhibitors in acute coronary syndromes. (1998) (35)
Improving Heart Failure Therapeutics Development in the United States: The Heart Failure Collaboratory. (2018) (35)
International variation in the use of blood transfusion in patients with non-ST-segment elevation acute coronary syndromes. (2008) (35)
Standardizing care for acute decompensated heart failure in a large megatrial: the approach for the Acute Studies of Clinical Effectiveness of Nesiritide in Subjects with Decompensated Heart Failure (ASCEND-HF). (2009) (35)
A comparison of debulking versus dilatation of bifurcation coronary arterial narrowings (from the CAVEAT I Trial). Coronary Angioplasty Versus Excisional Atherectomy Trial-I. (1996) (35)
Time to reperfusion in acute myocardial infarction. It is time to reduce it! (2007) (35)
Curbing the cardiovascular disease epidemic: aligning industry, government, payers, and academics. (2007) (35)
The Clinical Trials Enterprise in the United States: A Call for Disruptive Innovation (2012) (35)
Mechanisms and predictors of mitral regurgitation after high-risk myocardial infarction. (2012) (35)
A simplified method to predict occurrence of complete heart block during acute myocardial infarction. (1987) (35)
Rationale and design of the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) (2009) (35)
Platelet glycoprotein IIb/IIIa receptor blockade with abciximab reduces ischemic complications in patients undergoing directional coronary atherectomy. EPILOG Investigators. Evaluation of PTCA to Improve Long-term Outcome by c7E3 GP IIb/IIIa Receptor Blockade. (1998) (35)
Beta-blocker therapy for heart failure: the evidence is in, now the work begins. (2000) (35)
Relationship between activated clotting time during percutaneous intervention and subsequent bleeding complications. (2002) (35)
An academic-health service partnership in nursing: lessons from the field. (2012) (34)
Technical feasibility , safety , and clinical outcome of stenting of unprotected left main coronary artery bifurcation narrowing (34)
Embedding cardiovascular research into practice. (2013) (34)
Smoking status and outcome after primary coronary angioplasty for acute myocardial infarction. (1999) (34)
Benefit of early sustained reperfusion in patients with prior myocardial infarction (the GUSTO-I trial). Global Utilization of Streptokinase and TPA for occluded arteries. (1998) (34)
Patient characteristics associated with care by a cardiologist among adults hospitalized with severe congestive heart failure. SUPPORT Investigators. Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments. (2000) (34)
Natural history of patients with single-vessel disease suitable for percutaneous transluminal coronary angioplasty. (1983) (34)
Aspirin Use Post-Acute Coronary Syndromes: Intolerance, Bleeding and Discontinuation (2003) (34)
Effect of abciximab on angiographic complications during percutaneous coronary stenting in the Evaluation of Platelet IIb/IIIa Inhibition in Stenting Trial (EPISTENT). (2002) (34)
Reducing Health Inequities in the U.S.: Recommendations From the NHLBI's Health Inequities Think Tank Meeting. (2016) (34)
Incidence of atrial fibrillation in a population with impaired glucose tolerance: the contribution of glucose metabolism and other risk factors. A post hoc analysis of the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research trial. (2013) (34)
Guided antithrombotic therapy: current status and future research direction: report on a National Heart, Lung and Blood Institute working group. (2012) (34)
Noninvasive detection of reperfusion after thrombolysis based on serum creatine kinase MB changes and clinical variables. TAMI 7 Study Group. Thrombolysis and Angioplasty in Myocardial Infarction. (1993) (33)
Reclassification of cardiovascular risk using integrated clinical and molecular biosignatures: Design of and rationale for the Measurement to Understand the Reclassification of Disease of Cabarrus and Kannapolis (MURDOCK) Horizon 1 Cardiovascular Disease Study. (2010) (33)
Early discharge after acute myocardial infarction. (1983) (33)
Acute decline in renal function, inflammation, and cardiovascular risk after an acute coronary syndrome. (2009) (33)
Predictors of Mortality and Mortality From Cardiac Causes in the Bypass Angioplasty Revascularization Investigation (BARI) Randomized Trial and Registry (2000) (33)
Developing systems for cost-effective auditing of clinical trials. (1997) (33)
The Project Baseline Health Study: a step towards a broader mission to map human health (2020) (33)
Defining the balance of risk and benefit in the era of genomics and proteomics. (2004) (33)
Amiodarone use after acute myocardial infarction complicated by heart failure and/or left ventricular dysfunction may be associated with excess mortality. (2008) (33)
Factors Associated with Do-Not-Resuscitate Orders (1996) (32)
Heart failure on admission and the risk of stroke following acute myocardial infarction: the VALIANT registry. (2005) (32)
An overview of the results of the EPIC trial. (1995) (32)
Long-Term Follow-Up of Gender-Specific Outcomes After Thrombolytic Therapy for Acute Myocardial Infarction from the GUSTO-I Trial (1997) (32)
Prognostic effect of bundle branch block related to coronary artery bypass grafting. (1987) (32)
Comparison of medicine alone, coronary angioplasty, and left internal mammary artery-coronary artery bypass for one-vessel proximal left anterior descending coronary artery disease. (2000) (32)
Comparison of benefits and complications of hirudin versus heparin for patients with acute coronary syndromes undergoing early percutaneous coronary intervention. (2001) (32)
Elevated creatine kinase-MB with normal creatine kinase predicts worse outcomes in patients with acute coronary syndromes: results from 4 large clinical trials. (2006) (32)
Impact of baseline physical activity and diet behavior on metabolic syndrome in a pharmaceutical trial: results from NAVIGATOR. (2014) (32)
Economic Assessment of Platelet Glycoprotein IIb/IIIa Receptor Blockade With Abciximab and Low-Dose Heparin During Percutaneous Coronary Revascularization: Results From the EPILOG Randomized Trial (2000) (32)
Frequency and clinical outcome of cardiogenic shock during acute myocardial infarction among patients receiving reteplase or alteplase. Results from GUSTO-III. Global Use of Strategies to Open Occluded Coronary Arteries. (1999) (32)
Cardiovascular disease on a global scale: defining the path forward for research and practice. (2007) (32)
Early angioplasty in acute coronary syndromes without persistent ST-segment elevation improves outcome but increases the need for six-month repeat revascularization: an analysis of the PURSUIT Trial. Platelet glycoprotein IIB/IIIA in Unstable angina: Receptor Suppression Using Integrilin Therapy. (2002) (32)
Treating menstruating women with thrombolytic therapy: insights from the global utilization of streptokinase and tissue plasminogen activator for occluded coronary arteries (GUSTO-I) trial. (1995) (32)
Race, resource use, and survival in seriously III hospitalized adults (1996) (31)
Advanced coronary artery disease: Appropriate end points for trials of novel therapies. (2001) (31)
Comparison of primary coronary angioplasty versus thrombolysis in patients with ST-segment elevation acute myocardial infarction and grade II and grade III myocardial ischemia on the enrollment electrocardiogram. (2001) (31)
Cough in Pediatric Patients Receiving Angiotensin‐Converting Enzyme Inhibitor Therapy or Angiotensin Receptor Blocker Therapy in Randomized Controlled Trials (2010) (31)
An improving prognosis over time in medically treated patients with coronary artery disease. (1983) (31)
Recurrent ischemia after thrombolysis: importance of associated clinical findings. GUSTO-I Investigators. Global Utilization of Streptokinase and t-PA [tissue-plasminogen activator] for Occluded Coronary Arteries. (1998) (31)
The future of cardiovascular clinical research: informatics, clinical investigators, and community engagement. (2012) (31)
Lack of progress in cardiogenic shock: lessons from the GUSTO trials. (2000) (30)
Comparative rates of resolution of QRS changes after operative and nonoperative acute myocardial infarcts. (1983) (30)
It is time to learn from patients like mine (2019) (30)
Clinical research sites--the underappreciated component of the clinical research system. (2009) (30)
The benefit of abciximab in percutaneous coronary revascularization is not device-specific. (2000) (30)
Resource use, costs, and quality of life among patients in the multinational Valsartan in Acute Myocardial Infarction Trial (VALIANT). (2005) (30)
Effects of stroke on medical resource use and costs in acute myocardial infarction. GUSTO I Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries Study. (1999) (30)
Check It, Change It: A Community-Based, Multifaceted Intervention to Improve Blood Pressure Control (2014) (30)
Race, resource use, and survival in seriously ill hospitalized adults. The SUPPORT Investigators. (1996) (30)
Heparin dosing and outcome in acute coronary syndromes: The GUSTO-IIb experience (2002) (30)
Comparison of the prognosis of spontaneous and percutaneous coronary intervention-related myocardial infarction. (2012) (30)
Race, Bleeding, and Outcomes in STEMI Patients Treated with Fibrinolytic Therapy. (2011) (30)
TIMI grade 3 flow and reocclusion after intravenous thrombolytic therapy: a pooled analysis. (1997) (29)
Premature release of data from clinical trials of ezetimibe. (2009) (29)
The economic returns of pediatric clinical trials of antihypertensive drugs. (2008) (29)
Usefulness of the Duke Sudden Cardiac Death risk score for predicting sudden cardiac death in patients with angiographic (>75% narrowing) coronary artery disease. (2009) (29)
Cardiac rehabilitation and survival in patients with left ventricular systolic dysfunction. (2001) (29)
Hemorrhagic complications of thrombolytic therapy in the treatment of myocardial infarction and venous thromboembolism. (1995) (29)
Long-term follow-up of gender-specific outcomes after thrombolytic therapy for acute myocardial infarction from the GUSTO-I trial. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. (1997) (29)
Mechanism of benefit of combination thrombolytic therapy for acute myocardial infarction: a quantitative angiographic and hematologic study. (1992) (29)
Impact of initial heart rate and systolic blood pressure on relation of age and mortality among fibrinolytic-treated patients with acute ST-elevation myocardial infarction presenting with cardiogenic shock. (2007) (29)
Characteristics of pediatric cardiovascular clinical trials registered on ClinicalTrials.gov. (2014) (29)
Liability issues for data monitoring committee members (2004) (29)
Unexplained international differences in clinical outcomes after acute myocardial infarction and fibrinolytic therapy: lessons from the Hirulog and Early Reperfusion or Occlusion (HERO)-2 trial. (2010) (28)
More on the GUSTO Trial (1994) (28)
Comparison of one-year outcomes following coronary artery stenting in diabetic versus nondiabetic patients (from the Enhanced Suppression of the Platelet IIb/IIIa Receptor With Integrilin Therapy [ESPRIT] Trial). (2002) (28)
Relationship of incorrect dosing of fibrinolytic therapy and clinical outcomes. (2005) (28)
Clinical value of coronary bypass graft evaluation with CT. (1983) (28)
Part I: Identifying holes in the safety net. (2004) (28)
One-year outcome after therapy with tissue plasminogen activator: report from the Thrombolysis and Angioplasty in Myocardial Infarction trial. (1990) (28)
Atrial fibrillation management strategies and early mortality after myocardial infarction: results from the Valsartan in Acute Myocardial Infarction (VALIANT) Trial (2010) (28)
Racial differences are seen in blood pressure response to fosinopril in hypertensive children. (2006) (28)
Correlates of survival in patients with postinfarction ventricular septal defect. (1989) (28)
What have we learned from the calcium channel blocker controversy? (1998) (28)
Methods and initial findings from the Durham Diabetes Coalition: Integrating geospatial health technology and community interventions to reduce death and disability (2015) (28)
Minimizing the risk of inappropriately administering thrombolytic therapy (Thrombolysis and Angioplasty in Myocardial Infarction [TAMI] study group). (1993) (28)
How much do we gain by reducing time to reperfusion therapy? (1996) (28)
Circumstances and Outcomes of Sudden Unexpected Death in Patients With High-Risk Myocardial Infarction: Implications for Prevention (2011) (28)
"Left main equivalent" coronary artery disease: its clinical presentation and prognostic significance with nonsurgical therapy. (1984) (28)
Simple principles of clinical trials remain powerful. (2005) (28)
Association of weight change with subsequent outcomes in patients hospitalized with acute decompensated heart failure. (2009) (27)
Clinical and prognostic implications of circulating pentraxin 3 levels in non ST-elevation acute coronary syndrome. (2013) (27)
Improving communication of drug risks to prevent patient injury: proceedings of a workshop (2003) (27)
Predictors of Incident Heart Failure Hospitalizations Among Patients With Impaired Glucose Tolerance: Insight From the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research Study (2013) (27)
Pericardial effusion after intravenous recombinant tissue-type plasminogen activator for acute myocardial infarction. (1991) (27)
The diagnosis of acute myocardial infarction. (1992) (27)
The relationship between periprocedural myocardial infarction and subsequent target vessel revascularization following percutaneous coronary revascularization: insights from the EPIC trial. Evaluation of IIb/IIIa platelet receptor antagonist 7E3 in Preventing Ischemic Complications. (1999) (27)
Negative T waves shortly after ST-elevation acute myocardial infarction are a powerful marker for improved survival rate. (2000) (27)
Stenting or surgery: an opportunity to do it right. (2005) (27)
Prognostic value of congestive heart failure history in patients undergoing percutaneous coronary interventions. (1998) (27)
A call to action for new global approaches to cardiovascular disease drug solutions. (2021) (27)
Clopidogrel use and clinical events after drug-eluting stent implantation: findings from the HealthCore Integrated Research Database. (2010) (27)
Digital clinical trials: creating a vision for the future (2019) (27)
The digital transformation of medicine can revitalize the patient-clinician relationship (2018) (27)
Incidence and Outcomes of Gastrointestinal Hemorrhage in Patients With Atrial Fibrillation Treated With Rivaroxaban or Warfarin: Results From the ROCKET AF Trial (2012) (27)
Long-term clinical and angiographic outcomes in patients with diabetes undergoing coronary artery bypass graft surgery: results from the Project of Ex-vivo Vein Graft Engineering via Transfection IV trial. (2015) (27)
Rural-Urban Disparity in Mortality in the US From 1999 to 2019. (2021) (27)
Clinical and electrocardiographic variables associated with increased risk of ventricular septal defect in acute anterior myocardial infarction. (2000) (27)
Risk factors for intracranial hemorrhage and nonhemorrhagic stroke after fibrinolytic therapy (from the GUSTO-i trial). (2004) (26)
Thrombolysis and angioplasty in acute myocardial infarction. (1988) (26)
Late ischemic events after clopidogrel cessation following drug-eluting stenting: should we be worried? (2006) (26)
Advanced congestive heart failure: What do patients want? (1998) (26)
Representativeness of a Heart Failure Trial by Race and Sex: Results From ASCEND-HF and GWTG-HF. (2019) (26)
Can We End the Salt Wars With a Randomized Clinical Trial in a Controlled Environment? (2018) (26)
Is Rhythm‐Control Superior to Rate‐Control in Patients with Atrial Fibrillation and Diastolic Heart Failure? (2010) (26)
Pulmonary artery catheterization in acute coronary syndromes: insights from the GUSTO IIb and GUSTO III trials. (2005) (26)
Future of Personalized Cardiovascular Medicine: JACC State-of-the-Art Review. (2018) (26)
Modifiable risk factors for vascular access site complications in the IMPACT II Trial of angioplasty with versus without eptifibatide. Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis. (1998) (26)
Slowing the progression of diabetic nephropathy and its cardiovascular consequences. (2004) (26)
Global Variation in Quality of Care Among Patients Hospitalized With Acute Heart Failure in an International Trial: Findings From the Acute Study Clinical Effectiveness of Nesiritide in Decompensated Heart Failure Trial (ASCEND-HF) (2013) (26)
Long-term outcome following successful reopening of abrupt closure after coronary angioplasty. (1993) (26)
Percutaneous transluminal coronary angioplasty in octogenarians as an effective therapy for angina pectoris. (1991) (26)
Reactivation of ischemic events in acute coronary syndromes: results from GUSTO-IIb. Gobal Use of Strategies To Open occluded arteries in acute coronary syndromes. (2001) (26)
Biomarkers and Clinical Cardiovascular Outcomes With Ezetimibe in the IMPROVE-IT Trial. (2019) (26)
Cardiac protection: evolving role of angiotensin receptor blockers. (2000) (26)
Digitizing clinical trials. (2020) (26)
The MURDOCK Study: a long-term initiative for disease reclassification through advanced biomarker discovery and integration with electronic health records. (2012) (25)
Patient race and decisions to withhold or withdraw life-sustaining treatments for seriously ill hospitalized adults. SUPPORT Investigators. Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments. (2000) (25)
The Measurement to Understand Reclassification of Disease of Cabarrus/Kannapolis (MURDOCK) Study Community Registry and Biorepository. (2012) (25)
The future of humans as model organisms (2018) (25)
Comparison of renal function and cardiovascular risk following acute myocardial infarction in patients with and without diabetes mellitus. (2008) (25)
Trends in the surgical treatment of ischemic mitral regurgitation: effects of mitral valve repair on hospital mortality. (1989) (25)
Isotretinoin and Staphylococcus aureus infection. A possible association. (1986) (25)
Pragmatic and mechanistic trials. (1997) (25)
Incidence and characteristics of stroke during 90-day follow-up in patients stabilized after an acute coronary syndrome. (2004) (25)
Abciximab survival advantage following percutaneous coronary intervention is predicted by clinical risk profile. (2002) (25)
Creatine kinase-MB elevation after percutaneous coronary intervention predicts adverse outcomes in patients with acute coronary syndromes. (2004) (24)
Relationship between renal function and outcomes in high-risk patients with non-ST-segment elevation acute coronary syndromes: results from SYNERGY. (2010) (24)
Benefit-Risk Assessments at the US Food and Drug Administration: Finding the Balance. (2017) (24)
Differences in treatment, outcomes, and quality of life among patients with heart failure in Canada and the United States. (2013) (24)
Abrupt closure: The CAVEAT I experience (1995) (24)
Issues facing clinical trials of the future (2003) (24)
Combination therapy for acute myocardial infarction: fibrinolytic therapy and glycoprotein IIb/IIIa inhibition. (2000) (24)
Negative trials in nephrology: what can we learn? (2008) (24)
Identification of comatose patients at high risk for death or severe disability. SUPPORT Investigators. Understand Prognoses and Preferences for Outcomes and Risks of Treatments. (1995) (24)
Rate-related left bundle branch block with chest pain and normal coronary arteriograms treated by exercise training. (1986) (24)
Impact of higher hemoglobin targets on blood pressure and clinical outcomes: a secondary analysis of CHOIR. (2012) (24)
Higher T-wave amplitude associated with better prognosis in patients receiving thrombolytic therapy for acute myocardial infarction (a GUSTO-I substudy). Global Utilization of Streptokinase and Tissue plasminogen Activator for Occluded Coronary Arteries. (1998) (24)
The Clinical Trials Transformation Initiative: innovation through collaboration (2014) (24)
Current Management of Mitral Valve Incompetence Associated with Coronary Artery Disease (1989) (23)
Cigarette smoking status and outcome among patients with acute coronary syndromes without persistent ST-segment elevation: effect of inhibition of platelet glycoprotein IIb/IIIa with eptifibatide. The PURSUIT trial investigators. (2000) (23)
Comparison of incidence of bleeding and mortality of men versus women with ST-elevation myocardial infarction treated with fibrinolysis. (2012) (23)
Randomized evaluation of coronary angioplasty for early TIMI 2 flow after thrombolytic therapy for the treatment of acute myocardial infarction: a new look at an old study (1994) (23)
Ten years of benefit from a one-hour intervention. (1998) (23)
Patient outcomes after fibrinolytic therapy for acute myocardial infarction at hospitals with and without coronary revascularization capability. (2002) (23)
Insulin resistance: a global epidemic in need of effective therapies (2003) (23)
Outcomes of diabetic patients following acute myocardial infarction: a review of the major thrombolytic trials. (1996) (23)
Acute Heart Failure and Atrial Fibrillation: Insights From the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure (ASCEND-HF) Trial (2015) (23)
Administration of thrombolytic therapy in the community hospital: established principles and unresolved issues. (1988) (23)
Comparative prognostic significance of simultaneous versus independent resolution of ST segment depression relative to ST segment elevation during acute myocardial infarction. (1997) (23)
Use of evidence-based medicine for acute coronary syndromes in the elderly and very elderly: insights from the Sibrafiban vs aspirin to Yield Maximum Protection from ischemic Heart events postacute cOroNary sYndromes trials. (2007) (23)
Regarding “Eteplirsen for the treatment of Duchenne muscular dystrophy” (2017) (23)
Effects of platelet glycoprotein IIb/IIIa receptor blockers in non-ST segment elevation acute coronary syndromes: benefit and harm in different age subgroups (2006) (23)
Cardiac troponin T and cardiac troponin I: relative values in short-term risk stratification of patients with acute coronary syndromes. GUSTO-IIa Investigators. (1998) (23)
Extent of coronary artery disease as a predictor of outcomes in acute myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. (2006) (23)
Stroke prevention in atrial fibrillation: re-defining ‘real-world data’ within the broader data universe (2018) (23)
Understanding the use of observational and randomized data in cardiovascular medicine. (2020) (23)
Simultaneous Consideration of Multiple Candidate Protein Biomarkers for Long-Term Risk for Cardiovascular Events (2015) (23)
Association between selective serotonin-reuptake inhibitor therapy and heart valve regurgitation. (2001) (23)
Complete atrioventricular block complicating inferior wall acute myocardial infarction treated with reperfusion therapy. TAMI Study Group. (1991) (23)
Comparison of two aspirin doses on ischemic stroke in post-myocardial infarction patients in the warfarin (Coumadin) Aspirin Reinfarction Study (CARS). (2001) (23)
Effects of the dual peroxisome proliferator-activated receptor activator aleglitazar in patients with Type 2 Diabetes mellitus or prediabetes. (2015) (23)
711-3-A Multicenter, Randomized, Double-Blind Pilot Trial of Standard Versus Low Dose Weight-Adjusted Heparin in Patients Treated with the Platelet GP IIb/IIIa Receptor Antibody c7E3 During Percutaneous Coronary Revascularization (1995) (22)
Use of evidence-based medical therapy in patients undergoing percutaneous coronary revascularization in the United States, Europe, and Canada. Coronary Angioplasty Versus Excisional Atherectomy Trial (CAVEAT-I) and Canadian Coronary Atherectomy Trial (CCAT) investigators. (1997) (22)
711-3-A Multicenter, Randomized, Double-Blind Pilot Trial of Standard Versus Low Dose Weight-Adjusted Heparin in Patients Treated with the Platelet GP IIb/IIIa Receptor Antibody c7E3 During Percutaneous Coronary Revascularization (1995) (22)
A randomized factorial trial of reperfusion strategies and aspirin dosing in acute myocardial infarction. The DUCCS-II Investigators. (1996) (22)
Clinical trial issues in weight-loss therapy. (2006) (22)
Favorable early and long-term prognosis following coronary bypass surgery therapy for myocardial infarction: results of a multicenter trial. TAMI Study Group. (1989) (22)
Economic implications of the prophylactic use of intraaortic balloon counterpulsation in the setting of acute myocardial infarction. The Randomized IABP Study Group. Intraaortic Balloon Pump. (1997) (22)
Incidence and impact on outcome of streptokinase allergy in the GUSTO-I trial (1997) (22)
Long-term outcomes of left bundle branch block in high-risk survivors of acute myocardial infarction: the VALIANT experience. (2006) (22)
The way of the future redux. (1995) (22)
Antithrombotic drug development for atrial fibrillation: proceedings, Washington, DC, July 25-27, 2005. (2008) (22)
Management and outcome of patients with atrial fibrillation during acute myocardial infarction: the GUSTO-III experience. Global use of strategies to open occluded coronary arteries. (2002) (22)
Activation of the inflammation, coagulation, and fibrinolysis systems, without influence of abciximab infusion in patients with non-ST-elevation acute coronary syndromes treated with dalteparin: a GUSTO IV substudy. (2004) (22)
Association between bleeding and mortality among women and men with high-risk acute coronary syndromes: insights from the Early versus Delayed, Provisional Eptifibatide in Acute Coronary Syndromes (EARLY ACS) trial. (2013) (22)
Influence of preoperative renal dysfunction on one-year bypass graft patency and two-year outcomes in patients undergoing coronary artery bypass surgery. (2008) (22)
Left ventricular assessment in myocardial infarction: the VALIANT registry. (2005) (21)
Use of bedside activated partial thromboplastin time monitor to adjust heparin dosing after thrombolysis for acute myocardial infarction: results of GUSTO-I. Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries. (1998) (21)
Beta‐blocker therapy in advanced heart failure: clinical characteristics and long‐term outcomes (1999) (21)
Anticoagulation in acute cardiac care in patients with chronic kidney disease. (2003) (21)
Angiographic follow-up after internal mammary artery graft angioplasty. (1992) (21)
The Patient-Centered Outcomes Research Network (2014) (21)
Sex-related differences in the use and adverse effects of angiotensin-converting enzyme inhibitors in heart failure: the study of patients intolerant of converting enzyme inhibitors registry. (2000) (21)
Coronary artery bypass surgery in patients with acute coronary syndromes is difficult to predict. (2008) (21)
An evidence-based score to detect prevalent peripheral artery disease (PAD) (2012) (21)
Hypertension and Diabetes and the Fosinopril Versus Amlodipine Cardiovascular Events Trial (FACET): More ammunition against surrogate end points (1998) (21)
Choosing between percutaneous coronary intervention and coronary artery bypass grafting for patients with multivessel disease: what can we learn from the Arterial Revascularization Therapy Study (ARTS)? (2004) (20)
Publication or presentation of results from multicenter clinical trials: evidence from an academic medical center. (2007) (20)
Outcomes of patients with acute coronary syndromes and prior percutaneous coronary intervention: a pooled analysis of three randomized clinical trials. (2005) (20)
Answers to complex questions cannot be derived from “simple” trials (1992) (20)
Abstract 152: Predictors of Intracranial Hemorrhage Among Anticoagulated Patients with Atrial Fibrillation: Insights from the Rivaroxaban Once-daily oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF) (2012) (20)
Pragmatic clinical trials: Emerging challenges and new roles for statisticians (2016) (20)
Is diagnostic certainty essential for the use of thrombolytic therapy during myocardial infarction in the 1990s? (1990) (20)
Erratum: Cardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetes (Lancet (2014) 383 (2008-17)) (2014) (20)
Predictors of left ventricular function after acute myocardial infarction: effects of time to treatment, patency, and body mass index: the GUSTO-I angiographic experience. (2001) (20)
Long-term clinical outcomes following coronary stenting. (2008) (20)
Evaluation of the dofetilide risk-management program. (2003) (20)
Impact of Internal Mammary Artery Conduit on Long-term Outcomes After Percutaneous Intervention of Saphenous Vein Graft (2006) (20)
An invasive strategy is associated with decreased mortality in patients with unstable angina and non-ST-elevation myocardial infarction: GUSTO IIb trial. (2003) (20)
Clinical risk factors for ischemic complications after percutaneous coronary interventions: Results from the EPIC trial (1999) (20)
Creatine kinase-MB elevation after coronary artery bypass grafting surgery in patients with non-ST-segment elevation acute coronary syndromes predict worse outcomes: results from four large clinical trials. (2007) (19)
Benefit assessment of therapeutic products: the Centers for Education and Research on Therapeutics (2007) (19)
Profound inhibition of platelet aggregation with monoclonal antibody 7E3 Fab thrombolytic therapy (1993) (19)
Multifaceted intervention to promote β-blocker use in heart failure (2006) (19)
Medication Discontinuation in the IMPROVE-IT Trial (2019) (19)
Circulating Kidney Injury Molecule-1 Levels in Acute Heart Failure: Insights From the ASCEND-HF Trial (Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure). (2015) (19)
Creating a New Structure for Research on Health Care Effectiveness (2005) (19)
Novel approaches to clinical trials: device-related infections. (2004) (19)
Issues in regulatory guidelines for data monitoring committees (2004) (19)
Influence of a randomized clinical trial on practice by participating investigators: lessons from the Coronary Angioplasty Versus Excisional Atherectomy Trial (CAVEAT). CAVEAT I and II Investigators. (1998) (19)
Rationale and clinical evidence for the use of GP IIb/IIIa inhibitors in acute coronary syndromes. (1998) (19)
Loop diuretic dose adjustments after a hospitalization for heart failure: insights from ASCEND‐HF (2015) (19)
Psychosocial and physical predictors of anginal pain relief with medical management. (1986) (18)
Thrombolytic Therapy for Acute Myocardial Infarction (1992) (18)
Comparison of ST-segment resolution with combined fibrinolytic and glycoprotein IIb/IIIa inhibitor therapy versus fibrinolytic alone (data from four clinical trials). (2005) (18)
There is a role for industry-sponsored education in cardiology. (2010) (18)
The future of cardiovascular clinical research in North America and beyond-addressing challenges and leveraging opportunities through unique academic and grassroots collaborations. (2015) (18)
Cardiovascular ischemic event rates in outpatients with symptomatic atherothrombosis or risk factors in the united states: insights from the REACH Registry. (2009) (18)
Task force 2: Investigator participation in clinical research. (2004) (18)
USE AND OUTCOMES OF ANTIARRHYTHMIC THERAPY IN PATIENTS WITH ATRIAL FIBRILLATION RECEIVING ORAL ANTICOAGULATION: RESULTS FROM THE ROCKET AF TRIAL (2014) (18)
COVID-19 Clinical Trials: A Teachable Moment for Improving Our Research Infrastructure and Relevance (2020) (18)
Outcome of Hispanic patients treated with thrombolytic therapy for acute myocardial infarction: results from the GUSTO-I and III trials. Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries. (1999) (18)
Association between angiographic complications and clinical outcomes among patients with acute coronary syndrome undergoing percutaneous coronary intervention: an EARLY ACS (Early Glycoprotein IIb/IIIa Inhibition in Non-ST-Segment Elevation Acute Coronary Syndrome) angiographic substudy. (2012) (18)
Combining baseline clinical descriptors and real-time response to therapy: the incremental prognostic value of continuous ST-segment monitoring in acute myocardial infarction. (2004) (18)
Reduction in vascular access site bleeding in sequential abciximab coronary intervention trials (2002) (18)
Electrocardiographic infarct size assessment after thrombolysis: insights from the Acute Myocardial Infarction STudy ADenosine (AMISTAD) trial. (2005) (18)
Prognostic value of predischarge electrocardiographic measurement of infarct size after thrombolysis: insights from GUSTO I Economics and Quality of Life substudy. (2004) (17)
Filling in the Evidence About Sunscreen. (2019) (17)
Public reporting of quality measures what are we trying to accomplish? (2009) (17)
Racial differences among high-risk patients presenting with non-ST-segment elevation acute coronary syndromes (results from the SYNERGY trial). (2007) (17)
Role of lifestyle and oral anti-diabetic agents to prevent type 2 diabetes mellitus and cardiovascular disease. (2007) (17)
Racial analysis of patients with myocardial infarction complicated by heart failure and/or left ventricular dysfunction treated with valsartan, captopril, or both. (2008) (17)
Safety of Placebo Controls in Pediatric Hypertension Trials (2008) (17)
24-hour ambulatory blood pressure monitoring. (2006) (17)
The need for a national infrastructure to improve the rational use of therapeutics (2002) (17)
Patient-reported frequency of taking aspirin in a population with coronary artery disease. (2002) (17)
Heparin dosing and outcome in acute coronary syndromes: the GUSTO-IIb experience. Global Use of Strategies to Open Occluded Coronary Arteries. (2002) (17)
The IAIMS at Duke University Medical Center: transition from model testing to implementation. (1993) (17)
Outcomes of Diabetic Patients Following Acute Myocardial Infarction: A Review of the Major Thrombolytic Trials (1997) (17)
Enoxaparin 0.3 mg/kg IV supplement for patients transitioning to PCI after subcutaneous enoxaparin therapy for NSTE ACS: A subgroup analysis from the SYNERGY trial (2010) (17)
Does Intracoronary Thrombus Influence the Outcome of High Risk Percutaneous Transluminal Coronary Angioplasty? Clinical and Angiographic Outcomes in a Large Multicenter Trial fn1fn1This study was suppported by a grant from Centocor, Inc. (1998) (17)
Incremental value of echocardiographic assessment beyond clinical evaluation for prediction of death and development of heart failure after high-risk myocardial infarction. (2011) (17)
Usefulness of beta blockers in high-risk patients after myocardial infarction in conjunction with captopril and/or valsartan (from the VALsartan In Acute Myocardial Infarction [VALIANT] trial). (2009) (16)
Alternative Calculations of Individual Patient Time in Therapeutic Range While Taking Warfarin: Results From the ROCKET AF Trial (2015) (16)
Using observational data to estimate prognosis: an example using a coronary artery disease registry (2001) (16)
Myocardial Infarction Adenosine as an Adjunct to Thrombolytic Therapy for Acute Myocardial Infarction (1999) (16)
Frequency, Regional Variation, and Predictors of Undetermined Cause of Death in Cardiometabolic Clinical Trials: A Pooled Analysis of 9259 Deaths in 9 Trials (2019) (16)
Acute coronary care: Principles and practice (1985) (16)
Lowering Cost and Increasing Access to Drugs Without Jeopardizing Innovation. (2019) (16)
Proceedings from Duke resistant hypertension think tank. (2014) (16)
A perspective on the regulation of the evaluation of new antithrombotic drugs. (1998) (16)
Organizational improvements to enhance modern clinical epidemiology. (2008) (16)
Tissue plasminogen activator: why the backlash? (1989) (16)
Coronary drug-eluting stent development: issues in trial design. (2005) (16)
Predictors of stroke within 30 days in patients with non-ST-segment elevation acute coronary syndromes. (2006) (16)
Rationale and design of the Clarification of Optimal Anticoagulation through Genetics trial. (2013) (16)
Preventing tomorrow's sudden cardiac death today: part II: Translating sudden cardiac death risk assessment strategies into practice and policy. (2007) (16)
Prior aspirin use predicts worse outcomes in patients with non–ST-elevation acute coronary syndromes11This study was sponsored by COR Therapeutics Inc., South San Francisco, California; and Schering-Plough Research Institute, Kenilworth, New Jersey. (1999) (16)
Forging stronger partnerships between academic health centers and patient-driven organizations. (2013) (16)
Cosmetics, Regulations, and the Public Health: Understanding the Safety of Medical and Other Products. (2017) (16)
Insights From the ESCAPE Trial (2008) (16)
Coronary revascularization surgery after myocardial infarction: impact of bypass surgery on survival after thrombolysis. GUSTO Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. (1997) (15)
Features of TMR for a Successful Clinical and Research Database (1982) (15)
Time-dependent predictors of primary cardiac arrest in patients with acute myocardial infarction. (2003) (15)
High-degree atrioventricular block, asystole, and electro-mechanical dissociation complicating non-ST-segment elevation myocardial infarction. (2014) (15)
Performance of an automated real-time ST-segment analysis program to detect coronary occlusion and reperfusion. (1996) (15)
Impact of diabetes mellitus on percutaneous revascularization (CAVEAT-I). CAVEAT-I Investigators. Coronary Angioplasty Versus Excisional Atherectomy Trial. (1997) (15)
Fondaparinux in ST-segment elevation myocardial infarction: the drug, the strategy, the environment, or all of the above? (2006) (15)
Age, treatment, and outcomes in high-risk non-ST-segment elevation acute coronary syndrome patients: insights from the EARLY ACS trial. (2013) (15)
Myocardial reperfusion: is it ever too late? (1989) (15)
Toward a Mobile Platform for Real-world Digital Measurement of Depression: User-Centered Design, Data Quality, and Behavioral and Clinical Modeling (2021) (15)
How changes in drug-safety regulations affect the way drug and biotech companies invest in innovation. (2006) (15)
Post-intervention cardiac enzyme elevations: Prognostic significance in IMPACT II (1996) (15)
Overcoming the Challenges of Conducting Early Feasibility Studies of Medical Devices in the United States. (2016) (15)
The natural history of single-vessel chronic coronary occlusion: a 25-year experience. (1997) (15)
Predictors of Incident Heart Failure Hospitalizations Among Patients With Impaired Glucose ToleranceClinical Perspective (2013) (15)
Acute decompensated heart failure patients admitted to critical care units: insights from ASCEND-HF. (2014) (14)
Evaluating the Potential ‘Economic Attractiveness’ of New Therapies in Patients with Non-ST Elevation Acute Coronary Syndrome (2000) (14)
Recurrent ischemia during continuous 12-lead ECG-ischemia monitoring in patients with acute coronary syndromes treated with eptifibatide: relation with death and myocardial infarction. PURSUIT ECG-Ischemia Monitoring Substudy Investigators. Platelet glycoprotein IIb/IIIa in Unstable angina: Receptor (2000) (14)
Precision Health Analytics With Predictive Analytics and Implementation Research: JACC State-of-the-Art Review. (2020) (14)
Assessment of the use of the age- and sex-specific United States population as a control group for analysis of survival in coronary artery disease. (1982) (14)
Effect of hirudin vs heparin on haemostatic activity in patients with acute coronary syndromes; the GUSTO-IIb haemostasis substudy. (2002) (14)
Considerations of net present value in policy making regarding diagnostic and therapeutic technologies. (2008) (14)
Antibodies to Platelet Factor 4/Heparin are Associated with Elevated Endothelial Cell Activation Markers in Patients with Acute Coronary Ischemic Syndromes (2004) (14)
Geographic variation in the treatment of acute myocardial infarction in the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial. (2006) (14)
Long-Term Mortality of Patients With Acute Myocardial Infarction in the United States and Canada (2004) (14)
Evidence for an Adverse Interaction Between ACE Inhibitors and Aspirin Following Myocardial Infarction: The GUSTO-I Trial (1998) (14)
New Approaches to Conducting Randomized Controlled Trials. (2020) (14)
Transcutaneous Ultrasound-Facilitated Coronary Thrombolysis During Acute Myocardial Infarction (2003) (14)
Cardiovascular research in India: a perspective. (2011) (14)
Cycle Time Metrics for Multisite Clinical Trials in the United States (2013) (14)
At home thrombolysis. (1990) (14)
Good news for experimental concept but bad news for clinically effective therapy. (1999) (14)
The relationship between meteorological conditions and index acute coronary events in a global clinical trial. (2013) (14)
Portfolio of Clinical Research in Adult Cardiovascular Disease as Reflected in ClinicalTrials.gov (2013) (14)
Preparedness of the CTSA's Structural and Scientific Assets to Support the Mission of the National Center for Advancing Translational Sciences (NCATS) (2012) (14)
Independent data monitoring committees: preparing a path for the future. (2014) (13)
Lessons Learned From a Clinical Trial (2004) (13)
Abstract 15544: Rivaroxaban Compared with Warfarin in Patients with Atrial Fibrillation and Diabetes: A Subgroup Analysis of the ROCKET AF Trial (2012) (13)
When Can Nonrandomized Studies Support Valid Inference Regarding Effectiveness or Safety of New Medical Treatments? (2021) (13)
Coronary bypass surgery improves global and regional left ventricular function following thrombolytic therapy for acute myocardial infarction (1991) (13)
Use of Intraaortic Balloon Counterpulsation in Patients Presenting With Cardiogenic Shock: Observations From the GUSTO-I Study fn1fn1This study was funded by grants from Bayer, New York, New York; CIBA-Corning, Medfield, Massachusetts; Genentech, South San Francisco, California; ICI Pharmaceuticals, (1997) (13)
The doctor and the computer. (1981) (13)
Randomized clinical trials--removing obstacles. (2013) (13)
One-year results from the Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries (GUSTO-I) trial. GUSTO-I Investigators. (1996) (13)
Medical resource use, costs, and quality of life in patients with acute decompensated heart failure: findings from ASCEND-HF. (2013) (13)
Metabolic syndrome and alanine aminotransferase: a global perspective from the NAVIGATOR screening population (2009) (13)
Implementation of management strategies for diabetes and hypertension: from local to global health in cardiovascular diseases. (2015) (13)
Is old blood bad blood? (2010) (13)
Impact of on-site cardiac interventional facilities on management and outcome of patients with acute coronary syndromes. (2003) (13)
Inhibition of Platelet Aggregation with a Glycoprotein IIb-IIIa Antagonist Does Not Prevent Thrombin Generation in Patients Undergoing Thrombolysis for Acute Myocardial Infarction (2004) (13)
A comparison of ionic versus nonionic contrast medium during primary percutaneous transluminal coronary angioplasty for acute myocardial infarction (GUSTO IIb). Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes. (2000) (13)
Prospective relationships between body weight and physical activity: an observational analysis from the NAVIGATOR study (2015) (13)
Translation of acute coronary syndrome therapies: from evidence to routine clinical practice. (2015) (13)
Research education and training in otolaryngology: Meeting summary and research opportunities (2006) (13)
Trends in clinical trials of non-ST-segment elevation acute coronary syndromes over 15 years. (2013) (12)
International differences in treatment effects in cardiovascular clinical trials. (2001) (12)
Treatment and outcomes of patients with evolving myocardial infarction: experiences from the SYNERGY trial. (2007) (12)
Relation between aspirin dose, all-cause mortality, and bleeding in patients with recent cerebrovascular or coronary ischemic events (from the BRAVO Trial). (2008) (12)
Digital clinical trials: creating a vision for the future. (2019) (12)
Careers for Clinician Investigators (2009) (12)
Use of larger versus smaller drug-safety databases before regulatory approval: the trade-offs. (2008) (12)
Avoiding the Coming Tsunami of Common, Chronic Disease (2021) (12)
Association between Angiographic Complications and Clinical Outcomes among Patients with Acute Coronary Syndrome undergoing Percutaneous Coronary Intervention: An EARLY ACS Angiographic Substudy (2012) (12)
Effect of subintimal resection on initial outcome and restenosis for native coronary lesions and saphenous vein graft disease treated by directional coronary atherectomy. A report from the CAVEAT I and II investigators. Coronary Angioplasty Versus Excisional Atherectomy Trial. (1996) (12)
A holistic approach for suppression of COVID-19 spread in workplaces and universities (2020) (12)
Altered Maturation Status and Possible Immune Exhaustion of CD8 T Lymphocytes in the Peripheral Blood of Patients Presenting With Acute Coronary Syndromes (2016) (12)
Opioid Use and Its Relationship to Cardiovascular Disease and Brain Health: A Presidential Advisory From the American Heart Association (2021) (12)
Outcomes of Second Revascularization Procedures after Stent Implantation (2008) (12)
Disease management in healthcare organizations: results of in-depth interviews with disease management decision makers. (2002) (12)
The benefits of moving quality to a national level. (2008) (12)
An Automated Strategy for Bedside aPTT Determination and Unfractionated Heparin Infusion Adjustment in Acute Coronary Syndromes: Insights from PARAGON A (2002) (11)
Smoking status and antithrombin therapy in patients with non-ST-segment elevation acute coronary syndrome. (2008) (11)
Death and nonfatal reinfarction within the first 24 hours after presentation with an acute coronary syndrome: experience from GUSTO-IIb. Global Utilization of Strategies for Total Occlusion. (1999) (11)
The GUSTO trial and the open artery theory. (1997) (11)
Documentation of study medication dispensing in a prospective large randomized clinical trial: experiences from the ARISTOTLE Trial. (2013) (11)
Patients with non-ST-elevation acute coronary syndromes undergoing coronary artery bypass grafting in the modern era of antithrombotic therapy. (2008) (11)
Relationship Between Enrolling Country Income Level and Patient Profile, Protocol Completion, and Trial End Points: From the ASCEND-HF Trial (2018) (11)
Assessing research results in the medical literature: trust but verify. (2013) (11)
Practitioner Acceptance of the Dofetilide Risk‐Management Program (2002) (11)
Effects of thrombolytic regimen, early catheterization, and predischarge angiographic variables on six-week left ventricular function. The TAMI Investigators. Thrombolysis and Angioplasty in Acute Myocardial Infarction. (1997) (11)
Predicting significant coronary artery disease in patients with left ventricular dysfunction. (2006) (11)
Fiolan International Randomized Survival Trial (FIRST): Final results (1996) (11)
Acute myocardial infarction and other acute ischemic syndromes (1996) (11)
Ethics and equipoise: rationale for a placebo-controlled study design of platelet glycoprotein IIb/IIIa inhibition in coronary intervention. (2003) (11)
Delivering heart failure disease management in 3 tertiary care centers: key clinical components and venues of care. (2008) (11)
LCZ696: too good to be true? (2015) (11)
Percutaneous intervention, surgery, and medical therapy: a perspective from the Duke Databank for Cardiovascular Diseases. (1994) (11)
Statistical approaches and policies for the operations of Data and Safety Monitoring Committees. (2001) (11)
737–5 Risk Stratification in Acute Ischemic Syndromes Using Serum Tropenin T (1995) (11)
Impact of extracardiac vascular disease on vein graft failure and outcomes after coronary artery bypass surgery. (2014) (11)
Centers for Education and Research on Therapeutics (CERTs)* (2002) (11)
A perspective on trials comparing enoxaparin and unfractionated heparin in the treatment of non-ST-elevation acute coronary syndromes. (2005) (11)
Hormone replacement therapy among postmenopausal women presenting with acute myocardial infarction: insights from the GUSTO-III trial. (2010) (11)
Data and safety monitoring boards: academic credit where credit is due? (2013) (11)
Key issues for global cardiovascular medicine (2009) (11)
Assessing heterogeneity of treatment effect analyses in health-related cluster randomized trials: A systematic review (2019) (11)
Physical activity as a determinant of fasting and 2‐h post‐challenge glucose: a prospective cohort analysis of the NAVIGATOR trial (2015) (11)
Report from the task force on surgeon-industry relationships in the discipline of orthopaedic surgery. (2012) (11)
Randomized trials of coronary artery bypass surgery: impact on clinical practice at Duke University Medical Center. (1985) (10)
Combination Reperfusion Therapy with Eptifibatide and Tenecteplase for Acute Myocardial Infarction (2000) (10)
The Exclusion of Women from Clinical Trials of Thrombolytic Therapy (1995) (10)
Clinical Outcomes at 180 days in the ASCEND-HF Trial: Double-Blind, Placebo-Controlled, Multicenter Acute Study of Clinical Effectiveness of Nesiritide in Subjects With Decompensated Heart Failure (2011) (10)
Towards a new order in cardiovascular medicine: re-engineering through global collaboration. (2010) (10)
Predictive models in heart failure: who cares? (2013) (10)
Postmenopausal hormone use in women with acute coronary syndromes. (2004) (10)
Duration of eptifibatide infusion after percutaneous coronary intervention and outcomes among high-risk patients with non-ST-segment elevation acute coronary syndrome: insights from EARLY ACS (2013) (10)
Clinical, Electrocardiographic, and Biochemical Data for Immediate Risk Stratification in Acute Coronary Syndromes (2001) (10)
Optimizing use of revascularization and clinical outcomes in ST-elevation myocardial infarction: insights from the GUSTO-V trial. (2006) (10)
Cardiologists should care about glucose: most people with CV disease or risk factors have diabetes or significant glycaemic abnormalities. Results of screening over 39,000 subjects for NAVIGATOR (2004) (10)
788-2 Six Minute Walk Test Gives Prognostic Information in Severe Hear Failure (1995) (10)
Baseline characteristics of the Nateglinide and Valsartan Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) trial population: comparison with other diabetes prevention trials. (2010) (10)
Holding GUSTO up to the light. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. (1994) (10)
Translation of academic discovery into societal benefit: proposal for a balanced approach--part 2. (2003) (10)
TRENDS IN THE CARE AND OUTCOMES OF MEDICARE BENEFICIARIES WITH TYPE 2 DIABETES, 2002-2011. (2016) (10)
Angiographic outcomes with early eptifibatide therapy in non-ST-segment elevation acute coronary syndrome (from the EARLY ACS Trial). (2014) (10)
People at increased risk of cardiovascular disease screened for the NAVIGATOR trial frequently have undiagnosed diabetes or impaired glucose tolerance (2003) (10)
Facilitating translational team science: The project leader model (2019) (10)
A new look at an old therapy. (2012) (10)
Chronic obstructive pulmonary disease and cardiovascular risk: insights from the NAVIGATOR trial. (2014) (10)
International differences in cardiovascular clinical trials. (2001) (10)
Recurrent ischemia after thrombolysis for acute myocardial infarction. (2001) (10)
Comparative Effectiveness of Angiotensin‐Converting Enzyme Inhibitors and Angiotensin Receptor Blockers for Hypertension on Clinical End Points: A Cohort Study (2012) (10)
Using observational data to estimate prognosis: an example using a coronary artery disease registry. (2001) (10)
Arrival by ambulance in acute heart failure: insights into the mode of presentation from Acute Studies of Nesiritide in Decompensated Heart Failure (ASCEND-HF) (2016) (10)
Use of resources, quality of life, and clinical outcomes in patients with and without new Q waves after thrombolytic therapy for acute myocardial infarction (from the GUSTO-I trial). (2000) (9)
901-14 Impact of Ionic and Non-ionic Contrast Media on Post-PTCA Ischemic Complications: Results from the EPIC Trial (1995) (9)
FDA as a catalyst for translation (2015) (9)
Angina, myocardial ischemia and coronary disease: gold standards, operational definitions and correlations. (1989) (9)
Interventional Cardiac Catheterization at Duke Medical Center - The Duke Interventional Cardiac Catheterization Program (1988) (9)
Is all unstable angina the same? insights from the Coronary Angioplasty Versus Excisional Atherectomy Trial (CAVEAT-I). The CAVEAT-Investigators. (1999) (9)
Developing a Robust Clinical Trials Workforce (2012) (9)
New antithrombotics. (1995) (9)
Maximal benefit of integrelin platelet IIB/IIIa blockade 6–24 hours after therapy: Results of the IMPACT-II trial (1996) (9)
Dual randomization in cardiovascular trials. (2000) (9)
Temporal evolution in the management of acute ST elevation myocardial infarction: the seven-year GUSTO experience from canada and the united states. The North American GUSTO-I and GUSTO-III investigators. (2000) (9)
Abstract 1515: Outcomes of Patients With Acute Coronary Syndromes and Prior Coronary Artery Bypass Grafting. Results From the Pravastatin or Atorvastatin Evaluation and Infection Therapy (PROVE-IT-TIMI 22) and the Aggrastat to Zocor (A to Z) trials. (2007) (9)
Tenecteplase and tirofiban in ST-segment elevation acute myocardial infarction: results of a randomized trial. (2005) (9)
Dynamic modeling of 90-day mortality in ST-elevation myocardial infarction patients undergoing primary percutaneous coronary intervention. (2013) (9)
What we publish in the American Heart Journal and why (2007) (9)
Evaluation of the National Cholesterol Education Program Adult Treatment Panel III algorithm for selecting candidates for statin therapy: insights from the A to Z trial. (2006) (9)
Data and safety monitoring committees: philosophy and practice. (2001) (9)
Intracranial hemorrhage after thrombolytic therapy for acute myocardial infarction: Clinical characteristics and in-hospital outcome (1990) (9)
A Call to Action for New Global Approaches to Cardiovascular Disease Drug Solutions. (2021) (9)
Characteristics, Treatment and Outcome of Patients with Non-ST-Elevation Acute Coronary Syndromes and Multivessel Coronary Artery Disease: Observations from PURSUIT (Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrelin Therapy) (2002) (9)
Coordinated series of studies to evaluate characteristics and mechanisms of acute coronary syndromes in high-risk patients randomly assigned to enoxaparin or unfractionated heparin: design and rationale of the SYNERGY Library. (2004) (8)
Evaluating the Impact of Public Health Notification: Duke Clopidogrel Experience (2012) (8)
The US Food and Drug Administration and the Future of Cardiovascular Medicine. (2016) (8)
Multifaceted intervention to promote beta-blocker use in heart failure. (2006) (8)
Impact of saphenous vein graft radiographic markers on clinical events and angiographic parameters. (2008) (8)
Failure of adjuvant heparin to reduce myocardial ischemia in the early treatment of patients with unstable angina. (1991) (8)
Heuristic and logistic principles of ST-segment interpretation in the time domain. Evolution in the context of the TAMI 7 trial design. (1990) (8)
Higher rates of coronary angiography and revascularization following myocardial infarction may be associated with greater survival in the United States than in Canada. The CARS Investigators (Coumadin/Aspirin Reinfarction Study). (1999) (8)
Claims-based cardiovascular outcome identification for clinical research: Results from 7 large randomized cardiovascular clinical trials. (2019) (8)
Predicting survival from the coronary arteriogram: an experience-based statistical index of coronary artery disease severity (2002) (8)
Defining and utilizing surrogates in the evaluation of coronary stents: what do we really want and need to know? (2008) (8)
Simultaneous platelet glycoprotein IIb/IIIa integrin blockade and front-loaded tissue plasminogen activator in acute myocardial infarction: Results from a randomized trial (1996) (8)
Venous thromboembolism and cardiovascular risk: results from the NAVIGATOR trial. (2015) (8)
Conduct of clinical trials in acute heart failure: regional differences in heart failure clinical trials. (2011) (8)
The prognostic value of the admission and predischarge electrocardiogram in acute coronary syndromes: the GUSTO-IIb ECG Core Laboratory experience. (2006) (8)
Economic and cost-effectiveness in evaluating the value of cardiovascular therapies. The impact of the cost-effectiveness study of GUSTO-1 on decision making with regard to fibrinolytic therapy. (1999) (8)
Acute ischemic syndromes. (1995) (8)
Prognostic value of ventricular arrhythmias (1981) (8)
Improving Cardiovascular Drug and Device Development and Evidence Through Patient-Centered Research and Clinical Trials (2020) (8)
Safety and efficacy of adjusted-dose eptifibatide in patients with acute coronary syndromes and reduced renal function. (2011) (8)
COVID-19 Vaccination-Becoming Part of the New Normal. (2022) (8)
Biomarkers, putative surrogates, surrogates, and decision making. (2013) (8)
A 25-Year Experience in Patients (Pts) With Coronary Artery Disease (CAD) and Chronic Heart Failure (CHF): Outcomes With Medical Therapy and Bypass Surgery (CABG) (1996) (8)
Achieving optimal results with standard balloon angioplasty: can baseline and angiographic variables predict stent-like outcomes? (2001) (8)
Importance of Social Determinants in Screening for Depression (2021) (8)
Lack of impact of early catheterization and fibrin specificity on bleeding complications after thrombolytic therapy. The TAMI Study Group. (1993) (8)
Views from Academia, Industry, and Regulatory Agencies (2013) (8)
Two-year outcome after angiographically documented myocardial reperfusion for acute coronary occlusion. Thrombolysis and Angioplasty Study Group. (1990) (8)
901-3 The Potential for Unexpected Hazard of Intravenous Beta-Blockade for Acute Myocardial Infarction: Results from the GUSTO Trial (1995) (8)
Part II: Sealing holes in the safety net. (2004) (8)
A Perspective on the K-Index∗ (2020) (8)
Seven Former FDA Commissioners: The FDA Should Be An Independent Federal Agency. (2019) (8)
Intracranial hemorrhage risk and new thrombolytic therapies in acute myocardial infarction. (1994) (8)
Development and validation of a simple model to predict severe coronary artery disease after myocardial infarction: potential impact on cardiac catheterization use in the United States and Canada. (2003) (7)
Post-procedure heparin: boon or burden? (1998) (7)
861-2 Enoxaparin versus unfractionated heparin in patients treated with tirofiban, aspirin, and an early conservation initial management strategy: Results from the A phase of the A to Z trial (2004) (7)
A comparison of clinical outcomes between Canadian and American patients after nonurgent coronary stenting. (2004) (7)
Effect of institutional volume and academic status on outcomes of coronary interventions: the IMPACT-II experience. (1999) (7)
When Can We Trust Real‐World Data To Evaluate New Medical Treatments? (2021) (7)
Differences in Health Outcomes between Men and Women: Biological, Behavioral, and Societal Factors. (2019) (7)
Predictors of Stroke in Patients With Impaired Glucose Tolerance: Results From the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research Trial (2013) (7)
Big Data in the Assessment of Pediatric Medication Safety (2020) (7)
Physician Understanding of Patient Resuscitation Preferences (2000) (7)
918-19 The Effect of Preprocedural Intracoronary Thrombus on Patient Outcome After Percutaneous Coronary Intervention (1995) (7)
BASELINE LDL-C AND CLINICAL OUTCOMES WITH ADDITION OF EZETIMIBE TO STATIN IN 18,144 PATIENTS POST ACS (2015) (7)
Prospective demonstration of myocardial infarction by CT. (1984) (7)
Restenosis after angioplasty: Overview of clinical trials using aspirin and omega-3 fatty acids (1990) (7)
In-hospital clinical outcomes in the TAMI 5 study (1990) (7)
Reduction in the need for unplanned stenting with the use of platelet glycoprotein IIb/IIIa blockade in percutaneous coronary intervention. (1998) (7)
Large simple trials: really, it can't be that simple! (2014) (7)
Anatomic propensity for restenosis following coronary angioplasty (1991) (7)
Blood Transfusion in Patients With Acute Coronary Syndrome—Reply (2005) (7)
Medications That Prolong the QT Interval (2003) (7)
The Future of Cardiovascular Medicine From the Regulatory Perspective. (2016) (7)
A novel risk classification paradigm for patients with impaired glucose tolerance and high cardiovascular risk. (2013) (7)
TIMI IIB follow-up. Lessons for clinicians and investigators. (1992) (7)
Prediction of the infarct-related artery in acute myocardial infarction by a scoring system using summary ST-segment and T-wave changes. (1996) (7)
The Need for Academic Leadership in Full‐Spectrum Translational Research (2011) (7)
Roadmap to 2030 for Drug Evaluation in Older Adults (2021) (7)
Intravenous Heparin, Thrombolytics, and Medical Marketing (1991) (7)
Translation of academic discovery into societal benefit: proposal for a balanced approach--part 1. (2003) (7)
Association of a pulsatile blood flow pattern on coronary arteriography and short-term clinical outcomes in acute myocardial infarction. (2004) (7)
Prediabetes and the risk of diabetes (2012) (7)
Balancing the Need for Access With the Imperative for Empirical Evidence of Benefit and Risk. (2017) (6)
Return of individual research results: What do participants prefer and expect? (2021) (6)
Evolution of an automated ST-segment analysis program for dynamic real-time, noninvasive detection of coronary occlusion and reperfusion. (1992) (6)
Association of pre-intervention activated clotting times (ACT) and clinical outcomes following percutaneous coronary revascularization: Results from the IMPACT-II trial (1996) (6)
Progress culminating from ten years of clinical trials on thrombolysis for acute myocardial infarction. GUSTO-I Steering Committee. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. (1995) (6)
Thrombolytic therapy for patients with prior percutaneous transluminal coronary angioplasty and subsequent acute myocardial infarction. GUSTO-I Investigators. Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries. (1996) (6)
Check It, Change It: A Community-Based Intervention to Improve Blood Pressure Control (2013) (6)
High-quality evidence to inform clinical practice (2019) (6)
Establishing a framework for improving the quality of clinical and translational research. (2012) (6)
The failure to fail smartly (2020) (6)
Resourcing Drug Development Commensurate With its Public Health Importance (2016) (6)
Generating evidence for therapeutic effects: the need for well-conducted randomized trials. (2020) (6)
Influence of body mass index on the efficacy of revascularization in patients with coronary artery disease. (2009) (6)
Importance of cost and quality of life in decisions about routine angiography after acute myocardial infarction. The role of cost-effectiveness models. (1996) (6)
The Project Baseline Health Study: a step towards a broader mission to map human health. (2020) (6)
Continuous computer-assisted electrocardiographic monitoring in patients with acute myocardial infarction: early experience (1989) (6)
Incidence and impact on outcome of streptokinase allergy in the GUSTO-I trial. Global Utilization of Streptokinase and t-PA in Occluded Coronary Arteries. (1997) (6)
Impact of baseline covariate imbalance on bias in treatment effect estimation in cluster randomized trials: Race as an example. (2020) (6)
Clinical risk factors for ischemic complications after percutaneous coronary interventions: results from the EPIC trial. The EPIC Investigators. (1999) (6)
Impact of enoxaparin on thrombus formation, coronary blood flow, and myocardial perfusion after early invasive treatment during acute coronary syndrome: Results from the SYNERGY library (2006) (6)
Valuing Health Care: Improving Productivity and Quality (2012) (6)
Early treatment with intravenous metoprolol for suspected acute myocardial infarction: a phase IV United States trial. Phase IV Metoprolol in Myocardial Infarction Study Group. (1989) (6)
A Major Dichotomy in Unstable Angina Outcome : ST Depression Versus T-Wave Inversion : GUSTO-II Results (1996) (6)
The rationale for thrombolytic therapy. (1996) (6)
Abstract 13482: Ischemic Cardiac Outcomes in Patients with AF Treated with Vitamin K Antagonism or Factor Xa Inhibition: Results from the ROCKET AF Trial (2011) (6)
CTSA Consortium Consensus Scientific Review Committee (SRC) Working Group Report on the SRC Processes (2015) (5)
Abrupt closure: the CAVEAT I experience. Coronary Angioplasty Versus Excisional Atherectomy Trial. (1995) (5)
Timing of death and myocardial infarction in patients with non-ST elevation acute coronary syndromes: insights from randomized clinical trials. (2007) (5)
Acute Coronary Care 1987 (1987) (5)
Integrating antithrombin and antiplatelet therapies with early invasive management for non-ST-segment elevation acute coronary syndromes. (2004) (5)
Identifying patient risk: The basis for rational discharge planning after acute myocardial infarction (2004) (5)
Hierarchy of risk based on history and location of prior myocardial infarction in the thrombolytic era. GUSTO-I Investigators. (2000) (5)
Predictors of outcome of reperfusion therapy. (1997) (5)
Individual Patient-Level Data Sharing for Continuous Learning: A Strategy for Trial Data Sharing. (2019) (5)
Abstract 9150: Re-Elevation of Troponin Following Percutaneous Coronary Intervention Significantly Predicts 1-Year Mortality in Patients with High-risk Non-ST-Segment Elevation Acute Coronary Syndromes (2011) (5)
Recurrent Ischemia After Thrombolysis: Importance of Associated Clinical Findings fn1fn1This study was supported by grants from Bayer, New York, New York; CIBA-Corning, Medfield, Massachusetts; Genentech, South San Francisco, California; ICI Pharmaceuticals, Wilmington, Delaware; and Sanofi Pharmace (1998) (5)
Long-term adherence to evidence-based therapies for coronary artery disease and heart failure in the outpatient setting (2003) (5)
RE: Docket No. FDA-2021-N-1349 Tobacco Product Standard for Menthol in Cigarettes (5)
Complementarity of stenting and abciximab for percutaneous coronary intervention (1998) (5)
Does eptifibatide confer a greater benefit to patients with unstable angina than with non-ST segment elevation myocardial infarction? Insights from the PURSUIT Trial. (2002) (5)
Assessing the value of newer pharmacologic agents in non-ST elevation patients: a decision support system application (1997) (5)
Biological and clinical correlates of the patient health questionnaire-9: exploratory cross-sectional analyses of the baseline health study (2022) (5)
Complete heart block in Reiter's syndrome. (1984) (5)
Glycoprotein IIb/IIIa receptor antagonists in non-ST elevation acute coronary syndromes and percutaneous revascularisation: a review of trial reports. (1999) (5)
Employ Cybersecurity Techniques Against the Threat of Medical Misinformation. (2019) (5)
Better late than never: a welcome publication of tardy clinical trial results. (2013) (5)
The effect of diabetes on restenosis (1991) (5)
Risk Factors for In-hospital Nonhemorrhagic Stroke in Patients With Acute Myocardial Infarction Treated With Thrombolysis: Results from GUSTO-I : Results From Gusto-I (1998) (5)
The balance of benefit and safety of rosiglitazone: important lessons for our system of drug development and postmarketing assessment (2008) (5)
Clinical Perspective--Early Feasibility Device Medical Studies in the United States: Time for More Than Regulatory Reform. (2016) (5)
Heart failure and/or left ventricular systolic dysfunction complicating myocardial infarction is common and accounts for the majority of in-hospital myocardial infarction mortality: Results of the VALIANT registry (2003) (5)
Experience with the use of tPA in the treatment of acute myocardial infarction. (1988) (5)
The trouble with ischemia. (2012) (5)
755-5 Risk Factors for Stroke Following Thrombolytic Therapy: Case-Control Study from the GUSTO Trial (1995) (5)
Thrombin Generation, Inhibition and Clinical Outcomes in Patients With Acute Myocardial Infarction Treated With Thrombolytic Therapy and Heparin: Results From the GUSTO-I Trial fn1fn1This study was supported by Genentech, Inc., South San Francisco, California; Bayer Corporation, New York, New York; (1998) (5)
Serum cholesterol in patients undergoing cardiac catheterization for suspected coronary artery disease: diagnostic and prognostic implications. (1992) (5)
JACC: Heart Failure Series: FDA in the 21st Century: Focus on Nutrition and Heart Failure Prevention. (2017) (5)
Evaluation of diagnostic imaging technologies and therapeutics devices: better information for better decisions: proceedings of a multidisciplinary workshop. (2006) (5)
Deficits in knowledge related to the QT interval that could impact patient safety (2002) (5)
Analysis of the occurrence and clinical significance of thrombocytopenis with c7E3 (abciximab) in the EPIC trial (1996) (5)
1001-2 Is the “hub-and-spoke” model working? Patterns of transfer for high-risk acute coronary syndromes patients from community hospitals without revascularization capacity (2004) (5)
Low Molecular Weight Heparin in Prevention of Restenosis After Angioplasty (2005) (5)
Benefits of Streamlined Point-of-Care Trial Designs: Lessons Learned From the UK RECOVERY Study. (2022) (5)
Inhaled ethyl nitrite gas for persistent pulmonary hypertension in infants (2002) (5)
The Abciximab ST-Recovery on AMI (ASTRONAMI) GUSTO V substudy: enhanced early speed, stability, and quality of reperfusion with anti-pletelet augmented thrombolytic therapy for ST-elevation AMI (2002) (4)
Randomized, placebo-controlled study of Lamifiban with thrombolytic therapy for the treatment of acute myocardial infarction: Rationale and design for the Platelet Aggregation Receptor Antagonist Dose Investigation and Reperfusion Gain in Myocardial Infarction (PARADIGM) study (1995) (4)
Marketing Drugs Too Early in Testing (2006) (4)
The Ecosystem to Support People with Heart Failure. (2021) (4)
Why are large-scale trials needed? (1992) (4)
Cigarette smoking: how much worse can it get? (2000) (4)
Complete heart block in better's syndrome (1984) (4)
Expedited and facilitated drug evaluations and evidence of benefit and risk: The cup is half-full (2018) (4)
Highlights from the III International Symposium of Thrombosis and Anticoagulation (ISTA), October 14–16, 2010, São Paulo, Brazil (2010) (4)
Prognostic significance of left main equivalent stenosis (1981) (4)
Diabetes and cardiovascular disease: current opinions and future directions. (1999) (4)
Abstract 14365: Rivaroxaban is Associated with a Reduced Risk of Thromboembolic events and Hemorrhagic Stroke in Patient with Heart Failure: Insights from ROCKET AF (2012) (4)
Six-month outcomes of percutaneous coronary balloon angioplasty in acute coronary syndromes: Results from the PURSUIT trial. (2004) (4)
The Value of Exercise Thallium Imaging (1994) (4)
Current Controversies and Implications for Clinical Trials (2018) (4)
Variation in the use of stress testing and outcomes in patients with non-ST-elevation acute coronary syndromes: insights from GUSTO IIb. (2008) (4)
Perspective: Autonomic care systems for hospitalized patients. (2009) (4)
35th Bethesda Conference. Cardiology's Workforce Crisis: a pragmatic approach. Bethesda, Maryland, 17-18 October 2003. (2004) (4)
Individual risk prediction using data beyond the medical clinic (2018) (4)
Aggressive therapy of acute MI in the elderly. (1992) (4)
Classification and regression trees (CART) models to delineate use of angiography and revascularization after thrombolysis for acute myocardial infarction (1996) (4)
Conflicting information about conflict of interest. (2013) (4)
Issues of cost-effectiveness in the use of antithrombotic therapy for ischemic heart disease. (1997) (4)
Physicians' Use of Heparin Following Thrombolytic Therapy: An International Perspective (1997) (4)
Chapter 2 – Clinical Trials (2009) (4)
Patient-centered outcomes composites: a glimpse of the future. (2014) (4)
Abstract 3803: Influence of Autopsy Records on Classification of Sudden Unexpected Death in Patients With Myocardial Infarction and Left Ventricular Dysfunction, Heart Failure or Both (2009) (4)
1017-68 Influence of Platelet GP IIb/IIIa Receptor Inhibition with c7E3 on the Sequelae of Dissection During Percutaneous Coronary Revascularization (1995) (4)
A virtuous cycle to improve hypertension outcomes at a national level: linking public health and individualized medicine. (2009) (4)
Knowing When and How to Use Medical Products: A Shared Responsibility for the FDA and CMS. (2016) (4)
The Impact of Postrandomization Crossover of Therapy in Acute Coronary Syndromes Care (2011) (4)
Prognostic importance of new small Q waves following non-ST-elevation acute coronary syndromes. (2003) (4)
Large Clinical Trials (2002) (4)
Consequences of Slow Progress Toward Pragmatism in Randomized Clinical Trials: It Is Time to Get Practical. (2019) (4)
Reimagining What We Measure in Atherosclerosis-a "Phenotype Stack". (2020) (4)
Future of Personalized Cardiovascular€Medicine (2018) (4)
790-4 The Prognostic Importance of Anterior ST-Segment Depression in Inferior Myocardial Infarctions: Results in 16,185 Patients (1995) (4)
DIABETIC PATIENTS HAVE SIMILAR VEIN GRAFT FAILURE AT 1 YEAR, BUT HIGHER 5-YEAR MORTALITY THAN NON-DIABETIC PATIENTS UNDERGOING CORONARY ARTERY BYPASS SURGERY: INSIGHTS FROM THE PREVENT-IV TRIAL (2012) (4)
Abstract 2015: Sudden Cardiac Death in Patients with Diastolic Heart Failure (2006) (4)
All that glitters is not gold (2000) (4)
Gender differences in survival in patients with advanced heart failure. (1996) (4)
ST-segment recovery as an endpoint in acute myocardial infarction trials. Past, present, and future. (1993) (4)
Should the emergence of new agents change the management of patients with acute coronary syndromes without ST-segment elevation? (1999) (4)
The cycle of quality as a model for improving health outcomes in the treatment of hypertension (2007) (4)
Clinical outcome of “high-risk” vs “elective” patients undergoing percutaneous coronary intervention: Results from IMPACT-II (1996) (4)
Early use of beta-blockade in complicated myocardial infarction: The VALIANT trial (2003) (4)
Outcomes of patients with atrial fibrillation and significant valvular lesions: Comparison of the effects of rivaroxaban and warfarin in the ROCKET AF trial (2013) (4)
Aggressive therapy of acute myocardial infarction in the elderly (1990) (4)
Fibrinolysis for Acute Myocardial Infarction in the Elderly Patient: Is it Effective or Too Dangerous? (1998) (4)
Cardiovascular outcome trials of glucose-lowering strategies in type 2 diabetes–Authors' reply (2014) (4)
Reassessing the clinical significance of ST-segment depression that occurs concomitantly with the ST-segment elevation during acute myocardial infarction with the use of continuous ST-segment analysis. (1994) (4)
When Can We Rely on Real‐World Evidence to Evaluate New Medical Treatments? (2021) (4)
Prospective Evaluation of Malignancy in 17,708 Patients Randomized to Ezetimibe Versus Placebo (2020) (4)
Abstract 15686: Polypharmacy and the Efficacy and Safety of Rivaroxaban versus Warfarin in the Prevention of Stroke: Results From the ROCKET AF Trial (2014) (4)
Introduction: evidence to practice in acute coronary syndromes. (2000) (4)
Activated partial thromboplastin time measurement is not associated with clinical outcomes in patients with high-risk non-ST-segment elevation acute coronary syndromes treated with unfractionated heparin (2012) (4)
DO COUNTRIES OR HOSPITALS WITH LONGER STAYS HAVE LOWER READMISSION RATES? FINDINGS FROM THE ASCEND-HF TRIAL (2012) (3)
The Last Word on GUSTO, for Now (1994) (3)
Routine early eptifibatide versus delayed provisional use at percutaneous coronary intervention in high-risk non-ST-segment elevation acute coronary syndromes patients: an analysis from the Early Glycoprotein IIb/IIIa Inhibition in Non-ST-Segment Elevation Acute Coronary Syndrome trial. (2013) (3)
RISK STRATIFICATION FOR CARDIOVASCULAR EVENTS IN THE IMPROVE-IT TRIAL (2015) (3)
Assessment of North American Clinical Research Site Performance During the Start-up of Large Cardiovascular Clinical Trials (2021) (3)
Comparison of site-reported and core laboratory-reported creatine kinase-MB values in non-ST-segment elevation acute coronary syndrome (from the international trial SYNERGY). (2009) (3)
Watching the WATCH trial: the role of sponsors and data monitoring committees. (2004) (3)
Have Angiographically Documented Significant Coronary Disease Patients With NonST-Segment Elevation Acute Coronary Syndromes Who Prevalence, Predictors, and Impact of Conservative Medical Management for (2011) (3)
810-4 Pexelizumab, a C5 complement inhibitor, reduces 30-day mortality in patients undergoing coronary artery bypass surgery or receiving reperfusion therapy for acute myocardial infarction (2004) (3)
901-7 The Survival Advantage of Early Grade 3 Patency After Thrombolysis for Infarction Increases Over Time (1995) (3)
Does the presence or absence of chest pain at initiation of thrombolysis in acute myocardial infarction affect outcome (1996) (3)
A-8 Complication during air transport of patients with acute myocardial infarction (1987) (3)
Prediction of reocclusion after successful reperfusion during acute myocardial infarction (1991) (3)
Benchmarking the Cost-Effectiveness of Interventions Delaying Diabetes: A Simulation Study Based on NAVIGATOR Data (2020) (3)
Introduction of a new section: Cardiology Fellows: Quick Evidence-Based Consult (2004) (3)
Critical concepts in cost-effectiveness for cardiovascular specialists. (2000) (3)
Geographic and network analysis of oncology trials: Portfolio assessment of ClinicalTrials.gov. (2012) (3)
Exploration of rapid bedside monitoring of coagulation and fibrinolysis parameters during thrombolytic therapy (1992) (3)
Matching resources to treatment decisions for patients with acute coronary syndromes (2002) (3)
Does late reperfusion therapy for myocardial infarction improve left ventricular function? preliminary results of the TAMI-6 randomized, controlled trial (1991) (3)
Abstract 15879: Management of Major Bleeding Events in Patients Treated With Rivaroxaban Versus Warfarin: Results From the ROCKET AF Trial (2013) (3)
Is There a Price to Pay for Short-Term Savings in the Clinical Development of New Pharmaceutical Products? (2007) (3)
Hemorrhagic complications of thrombolytic therapy in the treatment of myocardial infarction and venous thromboembolism. (1992) (3)
Influence of a Randomized Clinical Trial on Practice by Participating Investigators: Lessons From the Coronary Angioplasty Versus Excisional Atherectomy Trial (CAVEAT) fn1fn1To discuss this article on-line, visit the ACC Home Page at www.acc.org/membersand click on the JACC Forum (1998) (3)
The SUPPORT Project and Improving Care for Seriously III Patients-Reply (1996) (3)
Angiographic profiles in courage. (2009) (3)
No beneficial effect of 24-48 hours abciximab infusion in aspirin and heparin treated acute coronary syndrome patients with elevated troponin without early revascularisation procedures A GUSTO-IV ACS Substudy (2001) (3)
Life expectancy and voting patterns in the 2020 U.S. presidential election (2021) (3)
Is pediatric exclusivity working (2007) (3)
Association of left ventricular diastolic function with coronary artery calcium score: A Project Baseline Health Study. (2022) (3)
TARGET versus GUSTO-IV: appropriate use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes and percutaneous coronary intervention (2002) (3)
MITRAL REGURGITATION AFTER MYOCARDIAL INFARCTION PREDICTS INCREASED MEDICAL COSTS AND DECREASED QUALITY OF LIFE: ANALYSIS OF THE VALIANT (VALSARTAN IN ACUTE MYOCARDIAL INFARCTION) TRIAL (2010) (3)
The Role of Tissue Plasminogen Activator in Myocardial Infarction (1987) (3)
Mapping and quantification of the twitter footprint of cardiologists (2021) (3)
Warning About Shortcuts in Drug Development (2017) (3)
No prognostic significance of chronic infection with Chlamydia pneumoniae in acute coronary syndromes: insights from the Global Utilization of Strategies to Open Occluded Arteries IV Acute Coronary Syndromes trial. (2007) (3)
Recombinant Hirudin for Unstable Angina Pectoris (2005) (3)
Relation of temporal creatine kinase-MB release and outcome after thrombolytic therapy for acute myocardial infarction∗∗A complete list of the TAMI Study Group appears in J Am Coll Cardiol 1992;19:482–489. (2000) (3)
Integrated Efficacy to Effectiveness Trials (2014) (3)
Rational use of medications: If Canada can’t do it … (2009) (3)
Sunscreen and the FDA. (2015) (3)
Plasma Volume Status and its Association with In-Hospital and Post-Discharge Outcomes in Decompensated Heart Failure. (2020) (3)
The use of tomographic myocardial perfusion scanning to evaluate an electrocardiographic salvage estimation method in patients with acute myocardial infarction: an AMISTAD substudy. Acute Myocardial Infarction Study Adenosine. (1999) (3)
Sudden Cardiac Death in Patients with Diastolic Heart Failure (2006) (3)
The FDA in the 21st Century: How Is the FDA Responding to the New World? A Focus on Cardiovascular Drug Development. (2017) (3)
The coxib story: some lessons and more questions. (2002) (3)
UPFRONT CLOPIDOGREL USE AND THE EFFICACY AND SAFETY OF EARLY EPTIFIBATIDE USE IN PATIENTS WITH ACUTE CORONARY SYNDROME: AN ANALYSIS FROM THE EARLY VERSUS DELAYED PROVISIONAL EPTIFIBATIDE IN ACUTE CORONARY SYNDROMES (EARLY ACS) TRIAL (2010) (3)
The new era of clinical research: using data for multiple purposes. (2014) (3)
THROMBOLYTIC THERAPY FOR ACUTE MYOCARDIAL INFARCTION : GUSTO CRITICIZED. AUTHORS REPLY (1994) (3)
Trials in myocardial infarction. (1997) (3)
Survival in single vessel coronary disease (1982) (3)
935-34 Special Considerations for Diabetics Receiving Platelet IIb/IIIa Antagonists During Coronary Interventions: Results from the EPIC Trialart (1995) (3)
Natural History of Patients Postacute Coronary Syndrome Based on Heart Failure Status. (2018) (3)
Cardiac markers in acute coronary syndromes-refining our knowledge. (2003) (3)
OBESITY PARADOX FOR STROKE IN PATIENTS WITH ATRIAL FIBRILLATION TREATED WITH RIVAROXABAN AND WARFARIN IN THE ROCKET AF TRIAL (2014) (3)
Cost avoidance through early discharge of the uncomplicated acute myocardial infarction patient (1996) (3)
Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Evaluating the economic implications of cardiovascular therapeutics. (1999) (3)
Clinical Trials The STARBRITE Trial: A Randomized, Pilot Study of B-Type Natriuretic PeptideeGuided Therapy in Patients With Advanced Heart Failure (2011) (2)
Introduction: Cardiologists should target obesity (2001) (2)
Standardized classification and framework for reporting and interpreting medication non-adherence in clinical trials. (2018) (2)
Transparency at the U.S. Food and Drug Administration (2017) (2)
Noninvasive testing is done only in low risk patients with unstable angina and non-Q-wave Myocardial Infarction (MI): Results from GUSTO-IIa (1996) (2)
The Practice Management Workstation: Providing Incentive Across Subgroups of Users. (1990) (2)
Evaluating the costs and effectiveness of cardiovascular therapies: who cares about economic analyses? (2002) (2)
Atrial fibrillation in congestive heart failure: is rhythm control therapy superior to rate control therapy? (2003) (2)
Comparison of Observational Data and the ONTARGET Results for Telmisartan Treatment of Hypertension: Bull's-eye or Painting the Target Around the Arrow? (2018) (2)
Diets and Clinical Coronary Events (2002) (2)
Abstract Tenth annual meeting of the society for clinical trials May 15–18, 1989 Hyatt Regency Minneapolis, Minneapolis, MinnesotaUse of ejection fraction as a surrogate endpoint for death in clinical trials of acute myocardial infraction (1989) (2)
Association of height with outcomes in patients with acute myocardial infarction receiving reperfusion therapy. (2005) (2)
790-2 Baseline Electrocardiogram Predicts 30-day Mortality Among 32,812 Patients with Acute Myocardial Infarction Treated with Thrombolysis (1995) (2)
Framework for Curating and Applying Data Elements within Continuing Use Data: A Case Study from the Durham Diabetes Coalition. (2013) (2)
The FDA in the 21st Century: How Is the FDA Responding to the New World? A Focus on Heart Failure Devices. (2016) (2)
Telephone Heart Failure Disease Management: Getting Something for Nothing (2007) (2)
Different Outcome of Patients With Sustained Monomorphic Ventricular Tachycardia Requiring Cardioversion During Acute Myocardial Infarction: Analysis in the GUSTO I Study (1998) (2)
1017-71 Patient-Specific Heparin Dosing During Angioplasty (1995) (2)
737–6 Combining Myoglobin and Clinical Variables for Assessing Coronary Reperfusion After Thrombolytic Therapy (1995) (2)
The ESCAPE Discharge Risk Score: Don't Go Home without It (2006) (2)
Over-the-counter Hearing Aids: From Research to Policy to Practice. (2022) (2)
Safety of adjunctive glycoprotein IIb/IIIa blockade during rescue/early percutaneous coronary intervention following full-dose fibrinolytic therapy for acute myocardial infarction (2003) (2)
Missing signposts on the roadmap to quality: a call to improve medication adherence indicators in data collection for population research (2013) (2)
Abstract 2996: The Relationship of Heart Rate in the Early Post Myocardial Infarction Period and Long Term Outcome: Results From the VALsartan in Acute Myocardial iNfarcTion (VALIANT) Trial (2009) (2)
Early hospital discharge after uncomplicated acute myocardial infarction. (1982) (2)
Identification of Patients With Coronary Disease (2005) (2)
Change in levels of physical activity after diagnosis of type 2 diabetes: an observational analysis from the NAVIGATOR study (2014) (2)
Left Ventricular Assessment in Myocardial Infarction (2013) (2)
The Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) Trials: A Decade of Reperfusion Strategies (1996) (2)
Clinical quality in non-ST-elevation acute coronary syndromes. (2007) (2)
The complexity of studying coronary heart disease in women. (1995) (2)
Lack of impact of early catheterization and fibrin specificity on bleeding complications after thrombolytic therapy: Results of a randomized trial (1990) (2)
P73 Comparison of investigator and central events review of myocardial infarction rates as a means to improve events classification: Results from GUSTO-IIa (1996) (2)
Use of calcium channel antagonists in myocardial revascularization procedures. (1996) (2)
Oral Fluoroquinolones. (2019) (2)
Comparison of immediate and long term outcome of patients having emergent or deferred coronary bypass surgery following intravenous thrombolytic therapy for acute myocardial infarction (1991) (2)
Roxifiban in the prevention of ischemic events in peripheral arterial disease (2002) (2)
Case Study for Lean Management in the Public Sector: Improving Combination Product Review at the Food & Drug Administration (2017) (2)
Long-term prognostic implications of abnormal stress elecrocardiographic or myocardial perfusion scintigraphic measures in patients with anglo-graphically-insignificant coronary artery disease (1996) (2)
The GUSTO Trials (1999) (2)
A comparison of phenotype de ﬁ nitions for diabetes mellitus (2013) (2)
Centralized systematic adjudication of clinical endpoints in multicenter trials of acute coronary syndromes identifies patients at high risk for adverse clinical outcomes (1996) (2)
Effects of changes in potassium with valsartan use on diabetes risk: Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) trial. (2013) (2)
State of the art : ACS treatment at the turn of the century (2000) (2)
Translating clinical trials into practice. (2006) (2)
A Beginning to Principles of Ethical and Regulatory Oversight of Patient-Centered Research (2018) (2)
Levels of evidence supporting drug, device, and other recommendations in the American Heart Association/American College of Cardiology guidelines. (2020) (2)
Working group 1: How to increase the output of cardiologists. (2004) (2)
The design of an observational study of hypertension management, adherence and pressure control in Blood Pressure Success Zone Program participants (2008) (2)
Large Clinical Trials and Registries—Clinical Research Institutes (2012) (2)
When Are Treatment Blinding and Treatment Standardization Necessary in Real‐World Clinical Trials? (2021) (2)
Thrombin and fibrin activity in patients treated with enoxaparin, ticlopidine and aspirin versus the conventional coumadin regimen after elective stenting: The ENTICES trial (1996) (2)
Would tirofiban have been shown non-inferior to abciximab had the TENACITY trial not been terminated for financial reasons? (2013) (2)
Providing Individual Research Results to Participants-Reply. (2018) (2)
901-84 Prognostic Value of Right Heart Catheterization Hemodynamic Data in Surgically Treated Patients with Coronary Artery Disease (1995) (2)
LONG-TERM PROTECTION FROM MYOCARDIAL ISCHEMIC EVENTS IN A RANDOMIZED TRIALOF BRIEF INTEGRIN BETA 3 BLOCKADE WITH PERCUTANEOUS CORONARY INTERVENTION. COMMENTARY (1997) (2)
Left bundle branch block in non-ST-segment elevation acute coronary syndromes. Incidence, angiographic characteristics, and clinical outcomes. (2013) (2)
Department of Error (2014) (2)
CHARACTERISTICS AND OUTCOMES OF PATIENTS WITH ATRIAL FIBRILLATION AND SIGNIFICANT VALVULAR LESIONS: EXPERIENCE FROM THE ROCKET AF TRIAL (2013) (2)
OUTCOMES OF TEMPORARY INTERRUPTIONS OF RIVAROXABAN OR WARFARIN IN PATIENTS WITH ATRIAL FIBRILLATION IN THE ROCKET AF TRIAL (2013) (2)
The use of coronary artery bypass grafting in the GUSTO trial (1994) (2)
725-1 Long-term Impact of a Patent Infarct-related Artery: 1-Year Survival In the GUSTO Trial (1995) (2)
A47 Differences in endpoint identification by investigators versus independent review (1996) (2)
Response to Letter Regarding Article, “Impact of Internal Mammary Artery Conduit on Long-Term Outcomes After Percutaneous Intervention of Saphenous Vein Graft” (2006) (2)
Glycoprotein IIb/IIIa Receptor Antagonists in Non-ST Elevation Acute Coronary Syndromes and Percutaneous Revascularisation (1999) (1)
Abstract 3430: Ethnic Differences in the Prevalence and Treatment of Cardiovascular Risk Factors in Outpatients with Peripheral Arterial Disease: Insights from the REACH Registry (2007) (1)
The FDA and the Clinical Community. (2022) (1)
A View from Academia (2007) (1)
Are the results of the multicenter automatic defibrillator implantation trial-II applicable to patients seen at a tertiary referral center? (2003) (1)
Abstract 14642: Do Diuretics, Beta-Blockers, and Statins Increase the Risk of Diabetes in Patients with Impaired Glucose Tolerance? Insights from the NAVIGATOR Study (2012) (1)
Improved outlook for patients with acute myocardial infarction: an interim progress report. (1998) (1)
Chapter 1 – Tools for Assessment of Cardiovascular Tests and Therapies (2007) (1)
Abstract 12297: Relations between Baseline Physical Activity by Pedometer Counts and Future Cardiovascular Events in the NAVIGATOR Study (2012) (1)
The US Food and Drug Administration and Cardiovascular Medicine: Reflections and Observations. (2016) (1)
Moderate obesity is associated with better intermediate-term survival in acute coronary syndromes: Results from the SYMPHONY and 2nd SYMPHONY clinical trials (2003) (1)
Commentary on Vickers (2014) (1)
What to do with acute atrial fibrillation? (1999) (1)
Strategies for Assessing the Risk Status of Patients Following Acute Myocardial Infarction or Unstable Angina (1985) (1)
Patterns and outcomes of revascularization in patients with heart failure and/or left ventricular systolic dysfunction following acute myocardial infarction: observations from the VALIANT registry (2004) (1)
Risk factors and outcomes in patients with ventricular septal defects (VSD) complicating acute MI (1996) (1)
Abstract 3725: Greater Use of Secondary Prevention Medications Following Coronary Artery Bypass Graft Surgery is Associated with Improved Two-Year Outcomes (2006) (1)
Publication policy, informed consent, and the randomized clinical trial. (2002) (1)
715-1 Predictors of Mortality in Cardiogenic Shock: The GUSTO Experience (1995) (1)
Impact of known and newly diagnosed diabetes mellitus after a myocardial infarction (2003) (1)
A time of accelerated change in academic cardiovascular medicine: implications for academic divisions of cardiology and their training programs. (2004) (1)
Practice Guidelines College of Cardiology Foundation/American Heart Association Task Force on Angina/Non ST-Elevation Myocardial Infarction: A Report of the American Guidelines for the Management of Patients With Unstable 2011 ACCF/AHA Focused Update Incorporated Into the ACC/AHA 2007 (2011) (1)
Ischemia after thrombolysis is frequent, somewhat predictable, and pre-empted by early angiography (1996) (1)
Attribution of causality in clinical research: an important element for learning health systems. (2013) (1)
Improved clinical outcomes with abciximab therapy in acute myocardial infarction: A systematic overview of randomized clinical trials (2003) (1)
When can noninferior be superior? The multidimensional nature of clinical decision-making calls for innovative approaches to clinical trials. (2010) (1)
RISK STRATIFICATION AFTER MYOCARDIAL INFARCTION. AUTHORS 'REPLY (1997) (1)
Quality-of-life outcomes for patients with severe CHF (1999) (1)
Implementation of a responsible conduct of research education program at Duke University School of Medicine (2019) (1)
CHAPTER 18 – Large Clinical Trials and Registries—Clinical Research Institutes (2007) (1)
Abstract 1261: Plasma Metabolomic Profiles Predict Future Cardiovascular Events (2009) (1)
When I have acute coronary syndrome, treat me gingerly (1999) (1)
Association Between Angiographic Complications During Percutaneous Coronary Intervention and Clinical Outcomes Among Patients with Acute Coronary Syndrome: An EARLY ACS Angiographic Substudy (2011) (1)
The ubiquity of data & communication: A double-edged sword for disparities (2019) (1)
Abstract 3075: Evaluation of Monocyte Chemoattractant Protein 1 as a Prognostic Marker in the A to Z Trial (2006) (1)
Magnesium in in-hospital cardiac arrest (1998) (1)
Introduction: Redefining acute coronary syndrome care in the era of aggressive revascularization (2002) (1)
Analysis of risk factors for sudden death after acute myocardial infarction. (1985) (1)
A randomized study would answer the question. (1996) (1)
Advanced heart failure patients unable to reach ACE inhibitor targets: a high risk population identified during hospitalization (2002) (1)
Abstract Seventeenth annual meeting of the society for clinical trialP29 Prognostic significance of cardiac enzyme elevations detected through systematic screening in clinical trials (1996) (1)
Coronary Heart Disease / Myocardial Infarction Diminished Vascular Response to Inhibition of Endothelium-Derived Nitric Oxide and Enhanced Vasoconstriction to Exogenously Administered Endothelin-1 in Clinically Healthy Smokers (2005) (1)
924-119 Angiographic Findings in Diabetics Treated with Thrombolytic Therapy After Acute Myocardial Infarction (1995) (1)
Reflections on the Clinical Research Enterprise: Past, Present and Future. (2018) (1)
Abstract 9904: Trends in Enrollment, Patient Characteristics, Treatments and Outcomes of Older Adults With Non-ST-segment Elevation Acute Coronary Syndromes (ACS) in Clinical Trials (2013) (1)
Abstract 4165: Impact of the National Cholesterol Education Program Third Adult Treatment Panel Lipid-Lowering Recommendations on the Management of Patients With Non-ST-Segment Elevation Acute Coronary Syndromes (2006) (1)
Strengthening of regulatory systems for medicines in the Americas. (2016) (1)
Stroke in Patients With Acute Coronary Syndromes Incidence and Outcomes in the Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) Trial Clinical Investigation and Reports (1999) (1)
Prior cardiovascular interventions are not associated with worsened clinical outcomes in patients with symptomatic atherothrombosis. (2010) (1)
RESULTS OF COAGULATION - FIBRINOLYSIS ANALYSES IN 386 PATIENTS WITH ACUTE MYOCARDIAL INFARCTION TREATED WITH RECOMBINANT TISSUE-TYPE PLASMINOGEN ACTIVATOR (rt-PA) (TAMI TRIAL) (1987) (1)
Evaluating Evolving Technologies in a Time of Rapid Change: The Case of Transcatheter Aortic Valve Replacement. (2017) (1)
Vascular access site complications during angioplasty with glycoprotein IIbIIIa receptor inhibition in the IMPACT II trial (1996) (1)
The evolution of PCI registries: implementing a sustainable future for health systems and clinicians. (2018) (1)
Supplement on acute coronary syndromes: introduction. (2003) (1)
THE USE OF DUAL ANTIPLATELET THERAPY AND PATIENT OUTCOMES IN THOSE UNDERGOING PCI IN THE ROCKET AF TRIAL (2014) (1)
Balanced Dysfunction in the Healthcare Ecosystem Harms Patients. (2019) (1)
Trial Reporting and the Clinical Trials Enterprise. (2021) (1)
Unstable infarct artery. Quantification across angiographic subgroups using continuous digital 12-lead ST-segment recovery analysis. (1992) (1)
Development and Validation of a Natural Language Processing Tool to Generate the CONSORT Reporting Checklist for Randomized Clinical Trials (2020) (1)
SEX DIFFERENCES IN HIGH-RISK ACUTE CORONARY SYNDROMES: INSIGHTS FROM EARLY-ACS (2010) (1)
Observational Cacophony, Randomized Harmony: Weighing the Benefits and Risks of Proliferating Observational Treatment Assessments (2020) (1)
NT-PROBNP IN ACUTE DECOMPENSATED HEART FAILURE: FINDINGS FROM THE ASCEND-HF STUDY (2013) (1)
Trust in the Medical Literature—and Viewpoints in JAMA Internal Medicine (2016) (1)
Genetics, genomics, proteomics: what is a cardiologist to do? (2000) (1)
The irony of biased editors who write editorials (1993) (1)
Opportunities for Enhancing the Use of Evidence-Based Medicines for Acute Coronary Syndromes: Insights From the Symphony Studies (2002) (1)
In search of the efficient way to medical decisions: the case of acute heart failure syndrome. (2012) (1)
Reframing Global Variation in Heart Failure Trials: Thinking Beyond Location on the Map. (2019) (1)
SHORTER HOSPITAL STAYS AND OUTCOMES AFTER NON-ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION (2014) (1)
The TAMI Trials (1994) (1)
Serum levels of vascular endothelial growth factor (VEGF) are increased in patients with acute coronary ischemia (1996) (1)
Abstract 16840: Predictors of Hospitalization in Patients With Atrial Fibrillation: An Analysis From ROCKET AF (2014) (1)
Prognostic significance of serial rest and exercise radionoclide angiography after acute myocardial infarction (1982) (1)
COVID-19 test positivity: predictive value of various symptoms in a large community-based testing program in California (2021) (1)
Activated Partial Thromboplastin Time and Clinical Outcome Among Patients with Unstable Angina or Non-Q-Wave MI Treated with Intravenous Heparin (1995) (1)
988-2 Thrombin Activity, but not Generation, is Inhibited by Intravenous Heparin Following Thrombolysis: Results from the GUSTO Hemostasis Substudy (1995) (1)
The inter-relationship between creatinine clearance, cardiac troponin T and outcomes in patients with acute coronary syndromes (2002) (1)
Introduction. Quality of health care. (2004) (1)
Abstract 1583: Differences in Bleeding Rates Accounts for All of the Excess Mortality in African Americans Compared With Caucasians With ST-Elevation Myocardial Infarction treated With Fibrinolysis (2009) (1)
Use of Computerized Statistical Models to Educate Medical Housestaff in Estimating Clinical Outcomes (1987) (1)
Chapter 3 – Clinical Trials (2017) (1)
Independent Predictors of Mortality in Patients with Nonvalvular Atrial Fibrillation: Results from ROCKET AF (2012) (1)
988-4 Hemorrhagic Stroke Associated with High aPTTs Following Thrombolytic Therapy and Heparin or Hirudin (1995) (1)
Acute myocardial infarction in young patients: The significance of smoking. Results from the GUSTO-1 trial (1996) (1)
Abstract 12776: Non-ST-segment Elevation Acute Coronary Syndromes Patients without Angiographically Detected Obstructive Coronary Artery Disease are Low-risk but Not No-risk: A Meta-analysis of 8 Trials of 37,101 Patients (2010) (1)
Poster Discussion Sessions (2009) (1)
Commentary on Anand et al. (2011) (1)
715-4 Thrombolytic Therapy During the “Golden Rrst Hour” in GUSTO (1995) (1)
738–2 The Evolution of Therapy for Single Vessel Disease: A Treatment Comparison of Medicine, Angioplasty and Left Internal Mammary Artery Graft for Proximal Left Anterior Descending Disease (1995) (1)
Finding ideal blood pressure targets in ischaemic stroke: prospective insight or retrospective guesswork? (2017) (1)
Abciximab associated thrombocytopenia: evidence for a complex interaction with heparin (1998) (1)
Diabetes and cardiovascular disease: Current opinions and future directions: Introduction (1999) (1)
PLASMA ENDOTHELIN-1 INDEPENDENTLY PREDICTS 180-DAY MORTALITY IN ACUTE HEART FAILURE: AN ASCEND-HF SUB-STUDY (2015) (1)
Race/Ethnicity Reporting for Pulmonary Clinical Trials in ClinicalTrials.gov (2015) (1)
Our vision for the American Heart Journal. (1997) (1)
Surgical therapy for coronary disease: randomized and observational studies. (1990) (1)
Regional variations in treatment costs and resource utilization for uncomplicated acute myocardial infarction (UMI) (1996) (1)
Topol Tratado de Medicina cardiovascular (2008) (1)
Response to letter regarding article, “sustained ventricular tachycardia and ventricular fibrillation complicating non–ST-segment elevation acute coronary syndromes”. (2013) (1)
P71 Impact of the clinical events committee process on data safety monitoring (1996) (0)
Abstract 2766: Racial Differences in Blood Pressure Response to Angiotensin Converting Enzyme Inhibitors in Children: An Analysis of 6 Pediatric Hypertension Trials (2007) (0)
Connecting the Dots: A Primate Subordination Syndrome? (2013) (0)
Survival after diagnosis of idiopathic dilated cardiomyopathy (1993) (0)
Cardiovascular research in the elderly: challenges, opportunities, and impact. (2002) (0)
Women with heart failure are less likely to receive ACE-inhibitors: Findings from the SPICE (Study of patients intolerant of converting enzyme inhibitors) registry (1999) (0)
Clinical findings in patients with and without coronary bypass surgery Type of surgery Age * Male sex Diabetes ? Prior infarction 1 Smoking Cardiogenic shocks Time from chest pain onset to thrombolytic therapy (2004) (0)
Use of the Intra-Aortic Balloon Pump in Unstable Angina (1987) (0)
Abstract 16873: Check It Change It: A Community Based Hypertension Program (2012) (0)
Randomized Trial of Low Molecular Weight Heparin (Enoxaparin) Versus Unfractionated Heparin for Unstable Coronary Artery Disease One-Year Results of the ESSENCE Study Enoxaparin in Non–Q (2016) (0)
Role and significance of coagulation markers in understanding and treating acute coronary syndromes (1998) (0)
PCV62 ASSESSING SYSTEMATIC DIFFERENCES IN PHYSICIAN'S TENDENCY TO REPORT ROUNDED BLOOD PRESSURE MEASUREMENTS (2007) (0)
The Duke databank interventional cardiology database (1991) (0)
Evolution of Drug Development in Evidence-Based Medicine: Summary and the Future (2003) (0)
P82 Objective classification of clinical events in large clinical trials: Is it worth the cost? (1995) (0)
130 Heart failure care and quality of life / Diagnostic tools in heart failure (2015) (0)
Possible beneficial interaction between statins and combination anglotensin receptor blocker (ARB) and ACE inhibitor treatment in patients with myocardial infarction: A post hoc analysis of the VALsartan in acute myocardial iNfarcTion trial (VALIANT) (2005) (0)
Valsartan, captopril, or both in myocardial infarction - Reply (2004) (0)
Abstract 6083: Sex Differences in 1-Year Mortality Following Acute Coronary Syndromes (2008) (0)
Who is at risk of early Hypotension and renal dysfunction with an inhibitor of the Renin Angiotensin System after myocardial infarction? data from VALIANT (2004) (0)
Elevation Myocardial Infarction Treated With Fibrinolysis Association of Mortality With Years of Education in Patients With ST-Segment (2012) (0)
The paradox of cigarette smoking and long-term benefit after coronary interventions with platelet IIb/IIIa receptor blockade (1996) (0)
Title : Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes (0)
P80 Source verification in large clinical trials: Is 10% enough? (1993) (0)
Abstract 10050: Peripheral Blood Metabolic Profiles Predict the Future Occurrence of New Onset Atrial Fibrillation (2011) (0)
MAGNESIUM IN IN-HOSPITAL CARDIAC ARREST. AUTHORS' REPLY (1998) (0)
Impact of percutaneous revascularization on clinical outcome following acute myocardial infarction — An analysis of 40,745 patients (1996) (0)
Prevention of reinfarction using half-dose reteplase and abciximab: observation from the GUSTO-5 trial (2002) (0)
Can delaying the onset of type 2 diabetes be cost-effective? (2014) (0)
P31 Reliability of economic and quality of life data for collection of follow-up clinical outcome information (1996) (0)
Response to Letter Regarding Article, “Long-Term Adherence to Evidence-Based Secondary Prevention Therapies in Coronary Artery Disease” (2006) (0)
Life Expectancy and Voting Patterns in 2018 US House of Representative Elections (2020) (0)
The combination of troponin and CRP levels at admission: a strong prognostic indicator of one-year mortality in both men and women with unstable coronary artery disease (2002) (0)
TEMPORAL TRENDS OVER 15 YEARS IN CLINICAL TRIALS OF NON-ST ELEVATION ACUTE CORONARY SYNDROMES: MORE AGGRESSIVE TREATMENT YIELDS SIMILAR MORTALITY DESPITE HIGHER-RISK PROFILES (2010) (0)
Coronary bypass surgery improves global and regional left ventricular function following thrombolytic therapy for acute myocardial infarction. TAMI Study Group. (1991) (0)
The Need for a Smoking Cessation "Care Package". (2022) (0)
Abstract 13302: Worsening Heart Failure During Acute Heart Failure Hospitalization: Insights from ASCEND-HF (2014) (0)
Plasma Angiotensin-Converting Enzyme Activity and Carotid Wall Thickening (2005) (0)
Abstract 14869: Effects of Atrial Fibrillation on Hospitalizations and Survival in Patients Hospitalized for Systolic Heart Failure: Insights from the ESCAPE Trial. (2010) (0)
An Analysis of Determinants of Improvement: Systolic Left Ventricular Function After Reperfusion Therapy for Acute Myocardial Infarction (1993) (0)
CORONARY ARTERY DISEASE Effects of physical conditioning on left ventricular ejection fraction in patients with coronary artery disease (0)
Abstract 5604: Refining Clinical Trial Composite Outcomes With Investigator-Assessed Weights: An Application to the ASSENT-3 Trial (2009) (0)
Remarks of the FDA Commissioner: The Food and Drug Law Institute's 59th Annual Conference. (2016) (0)
Abstract 13770: Geographic Variation in Clinical Course Among Patients Hospitalized for Acute Heart Failure: Insights From ASCEND-HF (2011) (0)
Thrombolytic therapy after GUSTO: medical roundtable. Discussion (1994) (0)
Contents Vol. 37, 2013 (2013) (0)
Characteristics and outcome of patients in whom reperfusion with intravenous tissue-type plasminogen activator fails: results of the Thrombolysis and Angioplasty (2005) (0)
Do sudden cardiac death rates warrant earlier treatment following myocardial infarction? experience from the VALIANT Trial (2004) (0)
Coronary heart disease The impact of anthropomorphic indices on clinical outcomes in patients with acute ST-elevation myocardial infarction (2007) (0)
Toward a Mobile Platform for Real-world Digital Measurement of Depression: User-Centered Design, Data Quality, and Behavioral and Clinical Modeling (Preprint) (0)
Proposals to Lower Medication Costs-Reply. (2019) (0)
Isotretinoin and Staphylococcus aureus Infection (2016) (0)
PCV70 MULTINOMIAL PROPENSITY SCORE ESTIMATORS AND MULTIVARIATE EXPLANATORYTECHNIQUES IN A REAL-LIFE ACUTE CORONARY HEART DISEASE STUDY—THE QALYS AND COSTS OF MEDICATION, PTCAAND CABG TREATMENT MODALITY ARE HIGHLY DEPENDENT ON THE METHODS USED (2010) (0)
Limitations of balloon angioplasty: Possible causes of restenosis (1988) (0)
PREVALENCE, PREDICTORS AND EFFECTS OF NESIRITIDE ON CHANGES IN RENAL FUNCTION DURING HOSPITALIZATION FOR ACUTE DECOMPENSATED HEART FAILURE (2013) (0)
Postmarket surveillance and returned product analysis: success but not transparency. (2013) (0)
Abstract 14618: Fasting Glucose, NT-proBNP, Treatment With Glycoprotein IIb/IIIa Inhibitors, and Outcomes in Non-ST-Segment Elevation Acute Coronary Syndromes: An Analysis From EARLY ACS (2013) (0)
age subgroups coronary syndromes: Benefit and harm in different blockers in non-ST-segment elevation acute Effects of platelet glycoprotein IIb/IIIa receptor (2008) (0)
Abstract 14160: Preservation Solutions, Patency, and Outcomes After Coronary Bypass Surgery (2013) (0)
Association of non-alcoholic steatothepatitis with components of the metabolic syndrome in 43,509 patients screened for NAVIGATOR (2005) (0)
1007-177 Predictors of major hemorrhage following initiation of warfarin therapy (2004) (0)
715-3 Cost Implications of Aortic Counterpulsation in Acute Myocardial Infarction: Results from a Randomized Clinical Trial (1995) (0)
High-Dose Statins in Acute Coronary Syndromes—Reply (2005) (0)
Epidemiology/Genetics (2014) (0)
IMPLICATIONS FOR COST-EFFECTIVENESS (1995) (0)
Modiﬁable Risk Factors for Vascular Access Site Complications in the IMPACT II Trial of Angioplasty With Versus Without Eptiﬁbatide (2016) (0)
Patients with a first non-Q-wave myocardial infarction had more re-infarctions, more coronary insufficiency, less congestive heart failure, and similar mortality rates as patients with a first Q-wave myocardial infarction (1993) (0)
Original Research Reports Association of Depression and Survival in Patients with Chronic Heart Failure over 12 Years (2012) (0)
The FDA and the State of Chronic Diseases: Cardiovascular, Endocrine, Pulmonary, and Renal Diseases (2018) (0)
Cost and quality of life outcomes in the TAMI 5 trial: The primacy of secondary endpoints (1990) (0)
Abstract 14185: Heart Failure Occurring at any Time During Hospitalization is Associated with Higher Mortality in Non-ST Elevation-Acute Coronary Syndromes (2011) (0)
804-1 Heparin Pretreatment May Confer Additional Benefit in Patients Treated with 7E3 and PTCA for Unstable Coronary Syndromes (1995) (0)
Worsening Heart Failure During Hospitalization for Acute Heart Failure: Insights from ASCEND-HF (2015) (0)
755-3 Improved Prognosis for Heavy Weight Patients Receiving Thrombolysis in Acute Myocardial Infarction — Bigger is Better: Results from GUSTO (1995) (0)
Abstract 3595: Amiodarone Use After Acute Myocardial Infarction Complicated by Heart Failure and/or Left Ventricular Dysfunction Is Associated with Excess Mortality (2006) (0)
Early Intravenous Heparin in Acute Myocardial Infarction (2005) (0)
Evaluating the Impact of Public Health Notification (2012) (0)
Answers tocomplex questions cannotbederived from"simple" trials (2000) (0)
The FDA and scientific priorities (2022) (0)
Neel Distinguished Research Lecturer (2006) (0)
A simple risk score for prediction of 30-day mortality in patients with acute coronary syndrome: insights from GUSTO IV (2002) (0)
791-2 Regional Variations in the Use of Cardiac Procedures After Thrombolysis: New England is an Outlier in the GUSTO Trial (1995) (0)
ST Segment Monitoring Substudy patients with myocardial infarction treated with thrombolytic therapy: the GUSTO-I Prognostic significance of ST segment shift early after resolution of ST elevation in (2011) (0)
Rationale for key elements of Sino-American collaboration in clinical research (2012) (0)
Dealing with success at the American Heart Journal (1999) (0)
A Multicenter, Randomized Angiographic Trial (2005) (0)
Opening the window of facilitated percutaneous coronary intervention in acute infarction: The role of combined IIb/IIIa inhibition and thrombolytic therapy (2003) (0)
Termination Based on Event Accrual in Per Protocol Versus Intention to Treat in the ROCKET AF Trial (2021) (0)
Heart failure roundtable: beta-blockers in the elderly. Introduction. (2002) (0)
revalence , Predictors , and Impact of onservative Medical Management for Patients ith Non – ST-Segment Elevation Acute Coronary yndromes Who Have Angiographically Documented ignificant Coronary Disease (2008) (0)
Abstract 3150: Renal Dysfunction Influences the Relationship Between Left Ventricular Systolic Dysfunction and Survival in the Post-Myocardial Infarction Patient (2007) (0)
HYPOTENSION IN ACUTE DECOMPENSATED HEART FAILURE: FINDINGS FROM ASCEND-HF (2013) (0)
Angiographic Parameters Impact of Saphenous Vein Graft Radiographic Markers on Clinical Events and (2013) (0)
Conclusion (2002) (0)
Quality and Safety Perspective: Autonomic Care Systems for Hospitalized Patients (2009) (0)
Paradoxical use of angiography with advancing age: insights from an international trial population (2002) (0)
Medical Management of Acute Coronary Syndromes (2010) (0)
Intravenous milrinone is no better than standard therapy for people admitted with acute exacerbation of chronic heart failure (2002) (0)
725-5 Improved Outcome in Patients with Prior Percutaneous Transluminal Coronary Angioplasty and an Evolving Myocardial Infarction (1995) (0)
Is the combination of valsartan and captopril better than captopril alone in patients with heart failure and left ventricular systolic dysfunction after myocardial infarction? results of VALIANT (2004) (0)
THERAPY AND PREVENTION (2005) (0)
738–3 Long-term Survival with a Chronic Total Coronary Occlusion: A Comparison of Medical Therapy versus Angloplasty in Patients with Single Vessel Disease (1995) (0)
Transitions at the American Heart Journal (2015) (0)
A Randomized Trial of Intravenous Heparin in 12 (Anisoylated Plasminogen Streptokinas Complex) in Nuae Myocardial Infarction : The Duke Clinical Cardiology Study (_1J_CCS) I 11action With Activator University THE DUCCS GROUP* (2016) (0)
Diet and other health‐related behaviors of individuals with impaired glucose tolerance, cardiovascular disease (CVD) or CVD risk: A global view from the NAVIGATOR study (2013) (0)
Corrigendum to "Impact of baseline covariate imbalance on bias in treatment effect estimation in cluster randomized trials: Race as an example" [Contemporary Clinical Trials volume 88 (2020) 105775]. (2021) (0)
Myocardial Infarction Treated With Thrombolysis : Results From GUSTO-I Risk Factors for In-hospital Nonhemorrhagic Stroke in Patients With Acute (1998) (0)
Department of Error (2020) (0)
Cardiovascular Disease in the Young : Endorsed by the American Heart Association Scientific Statement From the Councils on Cardiovascular Practice Standards for Electrocardiographic Monitoring in Hospital Settings : An Print (2004) (0)
924-120 The Sick-Euthyroid Syndrome in Acute Myocardial Infarction (1995) (0)
Remembering Dr Ray Lipicky. (2018) (0)
P20 Huge variability in data quality exists according to country (1997) (0)
DEPARTMENT OF ERROR (1997) (0)
Update on Antithrombotic Therapy (2007) (0)
A double blind comparison of enoxaparin (a low molecular weight heparin) with standard heparin in the treatment of unstable coronary artery disease "The essence trial" (1997) (0)
Platelet Glycoprotein IIb/IIIa Inhibitors Reduce Mortality in Diabetic Patients With Non–ST-Segment-Elevation Acute Coronary Syndromes Clinical Investigation and Reports (2001) (0)
PCV69 SIMPLE SENSITIVITY ANALYSIS TO ASSESS THE IMPACT OF ROUNDING OF BLOOD PRESSURE MEASUREMENTS ON ESTIMATES OF CONTROL RATES (2007) (0)
Effect of single and dual renin-angiotensin blockade on stroke in patients with and without diabetes in VALIANT (2016) (0)
The Future of Glycoprotein IIb/IIIa Inhibitors (1999) (0)
Evolution of Drug Development in Evidence-Based Medicine (2003) (0)
The use of digital real-time 12-lead ST segment trends in the management of acute myocardial infarction patients during helicopter transport and early hospitalization (1989) (0)
Does the presence of electrocardiographic left ventricular hypertrophy predict one-year mortality in non-ST elevation acute coronary syndromes? (2003) (0)
Effect of heparin administration on fibrinogenolysis during thrombolytic therapy with tissue plasminogen activator for acute myocardial infarction (1993) (0)
Performance of an A u t o m a t e d Real-t ime ST-Segment Analysis Program to Detect Coronary Occlusion and Reperfusion (2005) (0)
CONTINUOUS 12-LEAD ST-SEGMENT RECOVERY PREDICTS OUTCOME IN ACUTE MYOCARDIAL INFARCTION BETTER THAN SNAPSHOT ANGIOGRAMS OF TIMI FLOW (1998) (0)
Assessment of clinical trials in oncology: An evaluation of 40,696 trials on ClinicalTrials.gov. (2011) (0)
Work and Cardiovascular Disease in China. (2018) (0)
Prognostic/Clinical Prediction Models: Using Observational Data to Estimate Prognosis: An Example Using a Coronary Artery Disease Registry (2005) (0)
889-1 A randomized controlled trial of internet-based academic detailing in heart failure: Failure to engage or change (2004) (0)
Our National Approach to Diabetes. (2023) (0)
Using experience to improve clinical decision making (1983) (0)
Thrombolytic therapy for myocardial infarction: A perspective of clinical trialists (1992) (0)
Waiting for GUSTO: current status of thrombolytic therapy. Medical panel discussion (1993) (0)
Event-free hospitalization after early and sustained patency using combination thrombolytic therapy in acute myocardial infarction (1991) (0)
Who Escaped Randomization To Receive a Pulmonary Artery Catheter? The ESCAPE Registry (2007) (0)
Atherosclerosis / Coronary Heart Disease Short-term Cholesterol Lowering Decreases Size and Severity of Perfusion Abnormalities by Positron Emission Tomography After Dipyridamole in Patients With Coronary Artery Disease : A Potential Noninvasive Marker of Healing Coronary Endothelium (2005) (0)
Ischemic Heart Disease Resource Use and Cost of Initial Coronary Revascularization (2005) (0)
Abciximab treatment does not influence levels of inflammatory markers in patients with acute coronary syndrome (2003) (0)
Heart attack. (1988) (0)
Platelet Glycoprotein IIb/IIIa Receptor Inhibition in Non–ST-Elevation Acute Coronary Syndromes Early Benefit During Medical Treatment Only, With Additional Protection During Percutaneous Coronary Intervention Brief Rapid Communication (1999) (0)
A47 Statistical treatment comparisons for a trial of thrombolytic therapy in acute myocardial infarction (1993) (0)
VEIN GRAFT FAILURE FOLLOWING CORONARY ARTERY BYPASS SURGERY: DOES IT MATTER? (2010) (0)
A combination of pro-BNP och troponin T at baseline provide the best prediction of risk of death and myocardial infarction early after acute coronary syndrome (2003) (0)
Improving Clinical Outcomes in the Era of Information Ubiquity. (2018) (0)
ARE ALL IIB/IIIA'S ALIKE? A FOCUS ON ONGOING CLINICAL TRIALS (1999) (0)
Red Blood Cell S-Nitrosohemoglobin Deficiency in Pulmonary Arterial Hypertension. (2004) (0)
New Agents, New Trials, New Solutions (1998) (0)
Role and significance of coagulation markers in understanding and treating acute coronary syndromes. Introduction. (1998) (0)
Helicopter Transport of Patients with Acute Ischemic Syndromes (1987) (0)
The natural history of single vessel chronic total occlusions (1996) (0)
Preclinical Investigation of Agents Used in Current Restenosis Trials Preclinical Animal Mechanism of Animal and in vitro data model injury findings Platelet receptor and mediator inhibitors GR 32191 Yes Rat Balloon injury Platelet inhibition I Intimal hyperplasia * Sulotroban No (2005) (0)
Update on thrombolytic agents : emerging options for AMI management : proceedings of a symposium held at the XVIIIth Congress of the European Society of Cardiology, Birmingham, U.K., August 1996 (1997) (0)
Now is the time to fix the evidence generation system (2023) (0)
should compare diet and lifestyle within Italian or within Greek populations. (2017) (0)
Atenolol reduced ischemia-related events in asymptomatic ischemia (1995) (0)
High-dose statins in acute coronary syndromes [1] (multiple letters) (2005) (0)
Long-term survival in patients with cardiogenic shock after acute myocardial infarction (1991) (0)
RESI-ENOSIS AFI'ER ANGIOPLAS'IT OVERVlEW OF CLINI- CAL TRIALS USING ASPIRIN AND OMEGA-3 FA'ITY ACIDS. (2013) (0)
A46 Patient self-addressed postcard follow-up is inadequate: Results from the Duke Clinical Research Institute (1996) (0)
Long-Term Mortality of Patients With Acute Myocardial Infarction in the United States and Canada Comparison of Patients Enrolled in Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO)-I of declining mortality (2004) (0)
P-450: Prognostic information derived from blood pressure indices in patients with left ventricular systolic dysfunction early post-myocardial infarction (2003) (0)
Abciximab with reduced heparin dosing during coronary intervention Final results of the EPILOG trial (1997) (0)
Abstract 17846: Weighing The Evidence: Geographic Variation And The Obesity Paradox In Patients With Acute Decompensated Heart Failure In The Ascend-hf Trial (2013) (0)
Abstract 14658: Comparative Effectiveness of Torsemide versus Furosemide in Acute Heart Failure Patients: Insights from ASCEND-HF (2014) (0)
Intravenous Fluosol intheTreatment ofAcuteMyocardial Infarction Results oftheThrombolysis andAngioplasty inMyocardial Infarction 9Trial (1994) (0)
Clinical Evidence Generation During a Pandemic (2022) (0)
PATHOPHYSIOLOGY AND NATURAL HISTORY RIGHT VENTRICULAR INFARCTION (2005) (0)
Abstract 2594: Post Myocardial Infarction Hypertension and Cardiovascular Outcomes in Patients with Left Ventricular Dysfunction, Heart Failure, or Both Following Acute Myocardial Infarction (2006) (0)
One-year follow-up of mortality in the GUSTO IV trial evaluating the effects of 24 – 48 hours abciximab infusion in noninvasively managed acute coronary syndrome patients (2002) (0)
Abstract 13621: Stroke in People with Impaired Glucose Tolerance (2011) (0)
P72 An iterative process for defining nonfatal endpoints in the context of clinical trials (1996) (0)
PREVALENCE, PREDICTORS AND EFFECTS OF NESIRITIDE ON CHANGES IN RENAL FUNCTION DURING HOSPITALIZATION FOR ACUTE DECOMPENSATED HEART FAILURE : RESULTS FROM ASCEND-HF (2013) (0)
Estratificación de los pacientes en subgrupos de riesgo alto, medio o bajo para los fines de control de los factores de riesgo (1999) (0)
Abstract 16866: Blood Pressure Control and Stroke or Bleeding Risk in Patients with Atrial Fibrillation: Results from the ROCKET AF Trial (2014) (0)
Risk factors for ischemic stroke in patients with acute myocardial infarction treated with thrombolytic therapy (1996) (0)
PCV69 BLOOD PRESSURE SUCCESS ZONE LONGITUDINAL STUDY OF SUCCESS (BPSZ-BLISS). AN OBSERVATIONAL, MULTICENTER STUDY OF THE IMPACT OF THE BPSZ EDUCATIONAL PROGRAM ON BLOOD PRESSURE CONTROL, PERSISTENCE, COMPLIANCE, AND TREATMENT SATISFACTION. DESIGN AND METHODS (2007) (0)
Biological therapies need definitive randomized controlled clinical trials (2023) (0)
Atrial fibrillation: a spectrum of risk with a uniform treatment effect of novel anticoagulants? (2013) (0)
Nesiritide Administration in Patients Hospitalized for Acute Decompensated Heart Failure: Does Timing Matter? (2013) (0)
Abstract P415: Association of Baseline Physical Activity by Pedometer Counts and Nutritional Behavior on Metabolic Syndrome in the NAVIGATOR Study (2013) (0)
Are stress imaging modalities of value in post-myocardial infarction predischarge risk stratification? A meta-analysis of stress perfusion and ventricular function imaging studies (1996) (0)
Does the extent of ST-segment depression predict short- and long-term mortality in patients with non-ST segment elevation acute coronary syndromes? Insights from the GUSTO IV (2003) (0)
Iconographies supplémentaires de l'article : Rationale and clinical evidence for the use of GP IIb/IIIa inhibitors in acute coronary syndromes (2011) (0)
Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation the Investigators* (0)
Loop Diuretic Dose Adjustments After a Hospitalization for Heart Failure: Insights from ASCEND-HF (2014) (0)
How should clinicians interpret clinical trials? (1995) (0)
Fortalecimiento de los sistemas regulatorios de los medicamentos en la Región de las Américas (2016) (0)
The current excitement over the potential for stem-cell therapy to improve patient outcomes or even cure diseases is understandable (2016) (0)
New international technology: The autoperfusion balloon catheter (1988) (0)
Abstract 5791: A New Score to Improve the Detection of Peripheral Artery Disease (2009) (0)
Clopidogrel: A Viewpoint by Robert M. Califf (2001) (0)
Comprar Topol Tratado de Medicina cardiovascular | Paul Thompson | 9788496921054 | LWW España (2008) (0)
High Sensitivity Troponin I in Acute Decompensated Heart Failure (2011) (0)
Benefit the patient, manage the risk: a system goal (2004) (0)
FDA in the 21st Century: Focus on Tobacco Policies and Heart Failure Prevention. (2017) (0)
on a National Heart, Lung and Blood Institute Working Group Guided Antithrombotic Therapy: Current Status and Future Research Direction: Report (2014) (0)
Abstract 6084: Long-Term Prognostic Impact of ST-elevation vs. Non-ST-elevation Myocardial Infarction (2008) (0)
Baseline Cystatin C is Associated with Short-Term Adverse Events in Acute Heart Failure but Does Not Predict Treatment Effects with Nesiritide Therapy (2011) (0)
Cardiovascular Research in the Elderly (2010) (0)
Acute Coronary Care 1986 (1985) (0)
Response to Letter Regarding Article, “Attained Educational Level and Incident Atherothrombotic Events in Low- and Middle-Income Compared With High-Income Countries” (2011) (0)
Abciximab partially attenuates adverse events associated with trombocytopenia: analysis of GUSTO IV ACS (2002) (0)
Contents Vol. 98, 2002 (2003) (0)
Subject Index Vol. 98, 2002 (2003) (0)
Variables Influencing Survival of Patients With Significant Coronary Artery Disease Variable 2 Ejection fraction 151 Age 121 Functional class for congestive heart failure (2005) (0)
Identifying electrocardiographic left ventricular hypertrophy was problematic among patients with suspected acute cardiac ischemia (1995) (0)
Abstract 2363: Antiarrhythmic Drug Therapy for Sustained Ventricular Arrhythmias Complicating Acute Myocardial Infarction (2009) (0)
Angina/Non ACC/AHA 2007 Guidelines for the Management of Patients With Unstable (2011) (0)
Abstract 16169: Individual and Regional Determinants of Time in Therapeutic Range Among Patients Randomized to Warfarin in the ROCKET AF Trial of Rivaroxaban (2011) (0)
Impact of Peri-Stent Remodeling on In-Stent Neointimal Proliferation in Acute Myocardial Infarction (2004) (0)
Chapter 26 – Large Clinical Trials and Registries—Clinical Research Institutes (2012) (0)
Use of GP IIb/IIIa inhibitors in coronary syndromes : state of the art : proceedings of an international rounstable held in Davos, Switzerland, 15-16 February 1997 (1998) (0)
Sex Differences in 1-Year Mortality Following Acute Coronary Syndromes (2008) (0)
Angioplasty for Acute Myocardial Infarction (2005) (0)
Abstract 1803: Catheterization without In-hospital Revascularization is Associated with Increased Long-term Mortality in Patients with Non-ST Elevation Myocardial Infarction and Significant Coronary Artery Disease (2007) (0)
Data management, design and implementation for the global utilization of streptokinase and t-PA for occluded coronary arteries study (1991) (0)
News and Innovations (2016) (0)
Coronary Angioplasty (2005) (0)
Abstract 2059: Differences between Site-Reported and Core Laboratory Creatine Kinase-MB Values in an International Clinical Trial: Results from the SYNERGY Trial (2006) (0)
InnaTtance of Thromboeyk Phase Afte ' ~ Adminl & traflon of ° hro (2016) (0)
When complete heart block complicates streptokinase-treated acute myocardial infarction, is urgent catheterization warranted? (1991) (0)
Coronary heart disease Predictors of stroke within 30 days in patients with non-ST-segment elevation acute coronary syndromes (2006) (0)
Rationale for key elements of Sino-American collaboration in clinical research (2012) (0)
PRIOR HEART FAILURE HOSPITALIZATION AMONG PATIENTS HOSPITALIZED FOR WORSENING CHRONIC HEART FAILURE: FROM THE ASCEND-HF TRIAL (2018) (0)
Luncheon Plenary Part 2: Innovation and the Future (2018) (0)
DEPARTMENT OF ERROR (1999) (0)
Geographic Variation in Clinical Course Among Patients Hospitalized for Acute Heart Failure (2011) (0)
Abstract 18048: Early Termination of Cardiovascular Clinical Trials Registered in ClinicalTrials.gov: Where Do We Stand? (2013) (0)
INTERLEUKIN-6 IS ASSOCIATED WITH, BUT DOES NOT INDEPENDENTLY PREDICT, MORTALITY IN ACUTE HEART FAILURE: AN ASCEND-HF SUBSTUDY (2015) (0)
Clinical characteristics and long-term outcomes of patients with diastolic heart failure (1998) (0)
High-dose statins in acute coronary syndromes. Authors' replies (2005) (0)
Predictors and long-term mortality of atrioventricular block after acute myocardial infarction treated with thrombolysis (2003) (0)
Abstract 9811: Medical Resource Use, Costs and Quality of Life are Similar Between Patients with Acute Decompensated Heart Failure Treated with Nesiritide Versus Placebo (2011) (0)
Lp(a) is a Predictor of Coronary Artery Disease in Pre-menopausal but not in Post-menopausal Women (2016) (0)
Predictors of abrupt closure and consequences of emergency endpoints in the IMPACT II trial (1996) (0)
EXTRA-CARDIAC VASCULAR DISEASE IS ASSOCIATED WITH WORSE FIVE-YEAR CLINICAL OUTCOMES BUT NOT WITH VEIN GRAFT FAILURE AFTER CORONARY ARTERY BYPASS GRAFT SURGERY: INSIGHTS FROM THE PREVENT-IV TRIAL (2013) (0)
Demographic and clinical predictors of excessive anticoagulation following initiation of warfarin therapy (2003) (0)
Higher T-Wave Amplitude Associated With Better Prognosis in Patients Receiving Thrombolytic Therapy for Acute Myocardial Infarction (a GUSTO-I Substudy) 11This study was funded by grants from Bayer, New York, New York; CIBA-Corning, Medfield, Massachusetts; Genentech, South San Francisco, California (1998) (0)
Clinical results and revascularization status five years following randomization to PTCA or CABQ in bypass angioplasty revascularization investigation (BARI) (1998) (0)
Thrombolytic therapy for women with acute myocardial infarction: is there a gender gap? (1995) (0)
Editorial Clinical Trials of Restenosis After Coronary Angioplasty (2005) (0)
A symposium : managing acute coronary syndromes : what is the new standard of care? (2000) (0)
myocardial infarction: the GUSTO-I experience Atenolol use and clinical outcomes after thrombolysis for acute (2011) (0)
Organization and Administration of the Cardiac Care Unit (1985) (0)
Bivalent Covid-19 Vaccines. (2023) (0)
P81 No more lost to follow-up! insuring complete patient tracking post hospital discharge: The caveat coordinating center experience (1993) (0)
Withdrawal of digoxin after treatment of chronic heart failure led to clinical deterioration and worsening heart failure (1994) (0)
Patients with Evolving Myocardial Infarction Have a Significant Missed Opportunity for Earlier Treatment: Experience from the SYNERGY Trial (2005) (0)
Heart failure post-myocardial infarction in the new millennium: how often does it occur, can we predict it, and what are the consequences? (2004) (0)
990-49 Inadequate Pre-Hospital Medical Therapy in Patients Undergoing Percutaneous Coronary Revascularization: Results from the CAVEAT Trial (1995) (0)
PCV8 BLOOD PRESSURE SUCCESS ZONE LONGITUDINAL STUDY OF SUCCESS (BPSZ-BLISS). AN OBSERVATIONAL, MULTI-CENTER STUDY OF THE IMPACT OF THE BPSZ EDUCATIONAL PROGRAM ON BLOOD PRESSURE CONTROL, PERSISTENCE, COMPLIANCE, AND TREATMENT SATISFACTION. ENROLLMENT METRICS AND BASELINE COHORT CHARACTERISTICS (2008) (0)
End Point of Thrombolytic Therapy Comparative Trials (2005) (0)
Aspirin , Non-Steroidal Anti-Inflammatories , and CAD spirin Dose and Six-Month utcome After an Acute Coronary Syndrome (2004) (0)
827-4 N terminal pro brain natriretic peptide is the most powerful predictor of long-term mortality in diabetic patients with acute coronary syndromes (2004) (0)
1096-71 A national survey of health care practitioners' knowledge of the QT interval (2004) (0)
abciximab therapy Occurrence and clinical significance of pseudothrombocytopenia during (2011) (0)
OutcomeinOne-vessel Coronary Artery Disease (1983) (0)
Early ischemia after thrombolytic therapy for a first myocardial infarction was associated with increased total cardiac events and emergency revascularization (1993) (0)
Hintergrund und Design der TECOS-Studie (Trial Evaluating Cardiovasular Outcomes with Sitagliptin) (2011) (0)
Foreword: Acute heart failure: a text that is better late than never (2005) (0)
Does Periprocedural MI During PTCA Reduce Subsequent Clinical Restenosis (1998) (0)
908-109 Incremental Prognostic Value of Electrocardiographic Findings when Added to Baseline Clinical Variables in Patients with Acute Myocardial Infarction (1995) (0)
Introduction: Managing the patient with advanced heart failure (1998) (0)
Results of Expert Meetings: Obesity and Cardiovascular Disease. Introduction: Cardiologists should target obesity. (2001) (0)
2018 Peer Reviewers (2019) (0)
The Changing Prognosis of Patients with Unstable Angina and Acute Myocardial Infarction (1985) (0)
Response to The J-Point Revisited (2008) (0)
Abstract 899: The Impact Of Attained Educational Level On Incident Cardiovascular Events Differs Between High-Income Countries and Low-and-Middle-Income Countries (2009) (0)
COOPERATIVE STUDIES Confronting the Issues of Patient Safety and Investigator Conflict of Interest in an International Clinical Trial of Myocardial Reperfusion (2016) (0)
755-6 Neurosurgical Evacuation for Intracranial Hemorrhage Associated with Improved Outcome in GUSTO (1995) (0)
A32 Simultaneous patient enrollment in multiple randomized trials: Experience in GUSTO (1993) (0)
Beyondrandomized clinical trials: applying clinical experience inthetreatment ofpatients with (1986) (0)
A Welcome Publication of Tardy Clinical Trial Results (2013) (0)
RIGHT VENTRICULAR INFARCTION Quantitative analysis of right and left ventricular infarction in the presence of postinfarction ventricular septal defect (2005) (0)
The Clinical Use of Thrombolytic Agents (1985) (0)
Powerful Predictor of Long-Term Mortality in Diabetic Patients With Acute Coronary Syndromes (2004) (0)
Do hemodynamics always predict survival in advanced heart failure? A second look at FIRST (2000) (0)
Saphenous Vein Graft Failure after Coronary Artery Bypass Surgery : Insights from PREVENT IV Running title : (2014) (0)
SAFETY AND EFFICACY OF ADJUSTED-DOSE EPTIFIBATIDE IN PATIENTS WITH ACUTE CORONARY SYNDROMES AND REDUCED RENAL FUNCTION (2010) (0)
Consent for Research Participation in Practice (2019) (0)
Relief of Angina Coronary Bypass Surgery in Chronic Stable Angina (2005) (0)
Analysis intheTAMI7Study Performance ofa Noninvasive MethodforReal-Time Detection ofFailed Myocardial Reperfusion (2011) (0)
INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN (IGFBP) 2: A NOVEL METABOLIC BIOMARKER STRONGLY PREDICTIVE OF FUTURE CARDIOVASCULAR EVENTS (2010) (0)
Abstract 16058: Country Income Level, Protocol Completion, and Trial Endpoints Among Patients With Acute Heart Failure: Insights From the ASCEND-HF Trial (2017) (0)
Lessons learned from clinical trials: a roundtable discussion. (2003) (0)
Absolute and relative truth in clinical trials (2002) (0)
P79 Global coordination of a 41,000 patient international trial (1993) (0)
1085-167 Dose-response study of the efficacy and safety of fosinopril in children with hypertension: A randomized, double-blind, placebo-controlled, multicenter clinical trial (2004) (0)
Enoxaparin vs Unfractionated Heparin in Acute Coronary Syndrome—Reply (2004) (0)
International differences in cardiovascular clinical trials. Introduction. (2001) (0)
Lessons for the editors (1997) (0)
The impact of implanting cardioverter-defibrillators in patients who meet the multicenter automatic defibrillator implantation trial-II criteria on the health care system at a tertiary referral center (2003) (0)
Results of expert meetings. Uncontrolled systolic hypertension Washington, DC, April 25-27, 2002 (2005) (0)
The role of angioplasty after failed thrombolysis for acute myocardial infarction. (1994) (0)
Twelve lead real-times ST segment monitoring during helicopter transport of acute myocardial infarction patients after thrombolytic therapy (1989) (0)
Prognostic value of a history of congestive heart failure in patients undergoing percutaneous coronary interventions (1996) (0)
Coronary interventions "to go": Is faster better? (1999) (0)
The digital revolution: the catalytic power of disruptive technologies (2018) (0)
Can the Risk of Sudden Death after myocardial infarction be predicted by simple clinical criteria? experience from the VALIANT trial (2004) (0)
PROGNOSTIC VALUE OF BASELINE AND CHANGES IN CIRCULATING SOLUBLE ST2 LEVELS AND THE EFFECTS OF NESIRITIDE IN ACUTE DECOMPENSATED HEART FAILURE (2015) (0)
SIMULTANEOUS ANALYSIS OF MULTIPLE PROTEIN BIOMARKERS IDENTIFIES INDEPENDENT MARKERS OF LONG-TERM RISK FOR DEATH OR MYOCARDIAL INFARCTION (2012) (0)
Over-the-counter Hearing Aids-Reply. (2023) (0)
Where's the flap? (2006) (0)
1042-78 Does chronic infection with chlamydia pneumoniae influence the prognosis of acute coronary syndromes? insights from a nested matched case-control substudy of the GUSTO IV acute coronary syndromes trial (2004) (0)
Platelet llb/llla blockade with integrelin: Atherectomy patients (1996) (0)
IEWPOINT ationale and Strategies for Implementing ommunity-Based Transfer Protocols for rimary Percutaneous Coronary Intervention for cute ST-Segment Elevation Myocardial Infarction (2016) (0)
The Future of Computing in Health Care: An Interview with Dr. Robert Califf (2017) (0)
Effects of four thrombolytic regimens in elderly patients (1998) (0)
Abstract 1876: Incremental Value of Echocardiographic Assessment Beyond Clinical Evaluation for Prediction of Death and Development of Heart Failure After Myocardial Infarction in Patients with Left Ventricular Dysfunction, Heart Failure, or Both (2007) (0)
Monitoring the Pediatric Clinical Trials Enterprise (2021) (0)
Changing Efficacy of Coronary Revascularization (2005) (0)
Is amiodarone associated with a higher risk of death in patients with advanced congestive heart failure (2005) (0)
Research Monitoring and Ensuring Safety During Clinical (2010) (0)
Analysis of medical costs as a secondary end-point in a clinical trial (1991) (0)
Robert McKinnon Califf, MD: a conversation with the editor. Interview by William Clifford Roberts. (1998) (0)
PCV65 CHANGE IN HEALTH-RELATED QUALITY OF LIFE FOLLOWING NON-FATAL CARDIOVASCULAR EVENTS IN POST-MYOCARDIAL INFARCTION PATIENTS (2008) (0)
P Biomarkers and Coronary Disease roponin-T and N-Terminal ProB-Type atriuretic Peptide Predict Mortality Benefit From oronary Revascularization in Acute Coronary Syndromes (2006) (0)
Mass Customization, Ubiquitous Information, and Improvements to Health Outcomes in the United States (2018) (0)
MuchDo We Gain by Redwing Time to Repdkhm Th41W@Bpy? (1996) (0)
Review: PCI has lower risk for procedural stroke but higher risks for angina and repeated revascularization than CABG. (2008) (0)
FREQUENCY, CLINICAL AND ANGIOGRAPHIC CHARACTERISTICS, AND OUTCOMES OF HIGH-RISK NON-ST-SEGMENT ELEVATION ACUTE CORONARY SYNDROMES PATIENTS WITH LEFT CIRCUMFLEX CULPRIT LESIONS (2012) (0)
Abstract 17137: Renal Dysfunction is a Potent Predictor of Stroke and Systemic Embolism Among Individuals with Atrial Fibrillation: Results from the ROCKET AF Trial (2011) (0)
A computerized method for the application of coronary artery disease risk classification models to a large patient population (1992) (0)
C-REACTIVE PROTEIN IN ACUTE DECOMPENSATED HEART FAILURE: INSIGHTS FROM ASCEND-HF (2013) (0)

This paper list is powered by the following services:

Other Resources About Robert Califf

en.wikipedia.org

What Schools Are Affiliated With Robert Califf?

Robert Califf is affiliated with the following schools:

Robert Califf's Academic­Influence.com Rankings